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IDENTIFICATION OF NOVEL INTERACTION  PARTNERS OF NUCLEAR 
FACTOR I B 
SUMMARY 
Nuclear factor I (NFI) family of transcriptional factors has four members (Nfia, Nfib, 
Nfic, and Nfix) and is a highly conserved gene family, which plays a key role in 
central nervous system development. These proteins are required for glial and 
neuronal cell differentiation and proper development of neuronal and glial 
populations in developing brain. By post-transcriptional processing many different 
splice variants can be produced from a single NFI gene and this creates additional 
heterogenity in NFI proteins. 
The typical NFI protein is composed of an N-terminal DNA-binding/dimerization 
domain and a C-terminal transcriptional activation and/or repression domain. The N-
terminal domain is around 200 amino acids and responsible for DNA-binding 
activity, dimerization and the stimulation of adenovirus DNA replication. The C-
terminal domain is referred to as a proline-rich activation domain and it is mostly 
responsible for regulation of gene expressions. NFI proteins bind to duplex DNA 
with TTGGC(N5)GCCAA palindromic motif. NFI proteins form either heterodimers 
or homodimers and bind DNA with similar affinity. 
During embryogenesis, NFI genes are expressed in distinct, overlapping patterns 
with high levels of expression of Nfia, Nfib, and Nfix in the developing central 
nervous system in ventricular zones. At late embryonic and early postnatal ages, 
expression is particularly high in the cerebral cortex, hippocampus, basilar pontine 
nuclei, cerebellum, and spinal cord. While NFI-A and NFI-B are expressed during 
early gliogenesis, NFI-X and NFI-C are expressed later during differentiation of 
astrocytes  and control the expression of late astrocyte markers. NFI proteins also 
regulate the cell migration and terminal differentiation in the cerebellum and glia 
mediated cell migration in the hippocampus. NFI family members are also involved 
in neurological diseases and cancer. 
The yeast two-hybrid system is a genetic system wherein the interaction between two 
proteins of interest is detected via the reconstitution of a transcription factor and the 
subsequent activation of reporter genes under the control of this transcription factor.  
Since interacting partners of NFIB in developing brain have not been well studied we 
aimed at identifying NFIB binding proteins by screening a human fetal brain cDNA 
library with the yeast two hybrid technique. As a result, we identified 12 potential 





























































NÜKLEER FAKTÖR I B’NİN  ETKİLEŞİM PARTNERLERİNİN 
TANIMLANMASI 
ÖZET 
Nükleer faktör I (NFI) transkripsiyon faktörleri ailesi barındırdığı 4 üyesi ile birlikte 
yüksek oranda korunumlu ve merkezi sinir sistemi gelişiminde anahtar rol oynayan 
bir ailedir. Bir diğer ismi de CTF ya da CCAAT-bağlanma transkripsiyon faktörleri 
olan NFI ailesinin, tek hücreli organizmaların genomunda yer almamasından dolayı 
metazoalara spesifik olduğu söylenebilir. 
NFI ailesi temelde 4 gen (Nfia, Nfib, Nfic, ve Nfix) ile temsil edilmesine rağmen tek 
bir genden post-transkripsiyonel modifikasyon ile 9 adet ürün üretilebilmektedir. NFI 
ailesi üyelerinden üretilen tüm proteinler N-uçlu DNA-bağlanma/dimerleşme 
domeyni ve C-uçlu transkripsiyonel aktivasyon ya da represyon domeyni olmak 
üzere iki temel domain içermektedir.   
N-uçlu DNA-bağlanma/dimerleşme domeyni 200 aa uzunluğundadır. Yapısal olarak 
kendine hastır ve yalnızca SMAD proteinlerinin MH1 (Mad Homoloji) domeyni ile 
sekans homolojisi taşımaktadır. İnsan, fare ve tavuk NFI genleri arasında yüksek 
oranda korunmuş olmakla birlikte DNA’ya bağlanma, dimerleşme ve adenovirüs 
DNA’sını replikasyonu stimüle etme gibi görevleri mevcuttur.  
C-uçlu domeyn, yaklaşık yüzde yirmibeşinin prolin rezidülerinden ibaret olmasından 
ötürü prolince zengin domeyn olarak adlandırılır ve çoğunlukla NFI aracılı gen 
ekspresyonlarından sorumludur. N-uçlu domeynin tersine, C-uçlu domeyn NFI 
proteinleri arasında belirgin farklılıklar göstermektedir ve bu farklılıkların C-uçlu 
domeynin transkripsiyonel  fonksiyonlarını belirlediği düşünülmektedir. 
Transfeksiyon çalışmalarıyla NFI-A ve NFI-X C-uçlu domeynlerinin transkripsiyonu 
baskıladığı görülmüştür. Ayrıca NFI proteinlerinin pek çok promotoru negatif olarak 
regüle ettiği görülmüştür. NFI proteinlerinin bu şekilde hem transkripsiyonu 
baskılama hem de aktifleştirme rolünün olmasından ötürü, bu proteinlerin 
aktifleştirme/baskılama mekanizmasının eksprese edildikleri hücre tipine ve 
bağlandıkları promotora bağlı olduğu düşünülmektedir. 
NFI proteinleri çift iplik DNA üzerinde TTGGC(N5)GCCAA dizisine bağlanmakta 
ve  NFI proteinlerinin insan genomik DNA’sı üzerinde toplamda 75.000 bölgeye 
bağlandığı tahmin edilmektedir.  
NFI transkripsiyonel faktörleri ailesinin ilk olarak Adenovirus DNA’sının 
replikasyonundan sorumlu olduğu ve fare memeli tümör virüsünün 
transkripsiyonunda rol aldığı gösterilmiş, daha sonraları ise pek çok hücresel genin 
transkripsiyonunda ve ekspresyonunda görev aldığı anlaşılmıştır. NFI proteinlerinin 
ayrıca histon H1 ve H3 ile de etkileştiği gösterilmiştir. 
NFI mRNA’larının vücuttaki pek çok organda örtüşen şablonlarla eksprese 
edilmeleri bu proteinlerin fonksiyonel analizlerini karmaşık hale getirmektedir. 
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NFI ailesi üyelerinden Nfib, akciğer epitelyumundaki genlerin ekspresyonu regüle 
etmesinden ötürü akciğer gelişiminde özel bir öneme sahiptir. NFI ailesinin bir diğer 
üyesi olan Nfia kalp, karaciğer, akciğer, yumurtalık, iskelet kası, böbrek, testis, 
pankreas, dalak, fetal karaciğer ve beyin gibi pek çok organda eksprese edilmektedir. 
Nfic ise özellikle diş kökü oluşumunda rol almaktadır.  
Gelişmekte olan beyinde önce nörogenez daha sonra gliogenez meydana 
gelmektedir. Nöral gelişimin bu sıralı yapısı dışsal sinyaller, farklı transkripsiyon 
ailesi faktörleri ve histon ile DNA’nın modifikasyonu tarafından kontrol 
edilmektedir. NFI transkripsiyon faktörleri ailesi de merkezi sinir sistemi gelişiminde 
glial ve nöronal hücre faklılaşmasına rehberlik eden önemli bir aktör konumundadır.  
Merkezi sinir sisteminin gelişimi sırasında meydana gelen nöron-glia geçişi tam 
anlaşılmış bir proses olmamakla birlikte Notch sinyalizasyon yolağının temel bir rol 
üstlendiği bilinmektedir. Ancak Notch yolağının aktif hale gelmesi nöral progenitör 
hücrelerinde Nfia ekspresyonuna bağlıdır. Nfia’nın bir diğer rolü de gliogenezin 
koordinasyonu için Sox9 proteini ile birlikte nörogenezi sabitlemesidir. Nfia, 
gliogenez ve oligodentrosit faklılaşmasını modüle etme görevini sadece beyinde 
değil gelişmekte olan omurilikte de yürütmektedir. Nfib-/- farede yapılan çalışmalar 
gelişmekte olan neokorteks ve hipokampüste glial gelişimde gecikme olduğunu 
göstermiştir. Bu da beyindeki glial gelişim sırasında Nfib’nin de görev aldığını 
ortaya koymaktadır.  
Anatomik açıdan bakıldığında, Nfia, Nfib, ve Nfix başlangıçta ventriküler bölgelerde 
ifade edilirken, geç embriyonik ve postnatal dönemlerde ise serebral korteks, 
hipokampus, beyincik, ve omurilik da ekspresyon yüksek olmaktadır. NFI proteinleri 
ayrıca beynin gelişim sürecindeki hücre göçünü de düzenlemektedirler. 
NFI ailesi üyeleri ayrıca kanser ve nörolojik hastalıklarla da ilişkilidir.  
NFI proteinlerinin tavuk embriyosu fibroblast hücrelerinde aşırı ekspresyonu 
yapıldığında fibroblast hücrelerini onkogenlerin transformasyonuna daha dirençli 
hale getirdiği görülmüştür. Spesifik olarak NFI-A geninin farklı kronik kötü huylu 
miyeloid hastalıklarıyla ilişkili olduğu ve NFIB’nin Adenoid kistik kanserindeki rolü 
gösterilmiştir. 
Meme kanserli dokularda NFIB proteininin ekspresyon sıklığı çalışılmış ve NFIB 
mRNA düzeyinin triple negatif meme kanserinde belirgin miktarda olduğu 
gözlenmiştir. Diğer taraftan NFIB geninin susturulmasının hücre çoğalmasında 
azalma ve apoptotik sinyal yolağında artışa yol açtığı gösterilmiştir. 
NFI ailesinin nörolojik hastalıklardaki rolüne bakıldığında Nfia geninin homozigot 
delesyonunun hayvanlarda %95 ölüme yol açtığı ve sağ kalanların da ciddi nörolojik 
kusurları olduğu gösterilmiştir. Yine Nfib-/- farede beyincik içerisinde gelişim 
defektleri tespit edilmiştir. Nfix geninin susturulduğu farelerde ise perinatal ölüm 
hidrosefalus, korpus kallosumun oluşum bozukluğu, beyin kütlesinde artış ve 
anormal hipokampüs oluşumu rapor edilmiştir. 
Bu tez çalışmasında Maya 2 Hibrid (M2H) tekniği kullanılarak insan fetal beyin 
kütüphanesinde Nfib3 proteininin bağlanma partnerleri araştırılmıştır. M2H 
sisteminde iki protein arasındaki etkileşim, bir transkripsiyon faktörünün yeniden 
inşa edilmesi ve devamında bu transkripsiyon faktörünün kontrolü altındaki haberci 
genlerin aktivasyonu ile tespit edilir. NFIB ile etkileşecek proteinlerin tespit 
edilesinde M2H tekniğinin seçilmiş olmasında tekniğin görece ucuz ve basit olması, 
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aynı zamanda maya sistemlerinin yüksek ökaryotlarda rastlanan posttranslasyonel 
modifikasyonlara imkan tanıması rol oynamıştır. 
Bu tez projesinde “Matchmaker” M2H sistemi kullanılmıştır. Bu sistemde AUR1-C, 
HIS3, ADE2, MEL1 olmak üzere 4 adet haberci gen bulunmakta ve protein 
etkileşimlerini tespit etmek için sırasıyla Aureobasidin A antibiyotiğine dirençlilik, 
histidin amino asiti yoksunluğunun giderilmesi, adenin amino asiti yoksunluğunun 
giderilmesi ve X-α-Gal substratının parçalanarak mavi renk açığa çıkartılması 
esaslarından faydalanılmıştır. 
Bu projede öncelikle Nfib3 cDNA’sı ve Nfib3’ün kısaltılmış versiyonu olan NFIBΔ, 
pGBKT7 ekspresyon plazmidine klonlanmıştır. Sonrasında Nfib proteininin eksprese 
edildiği, Nfib fragmentlerinin mayaya toksik etki göstermediği ve ilgili haberci 
genleri otoaktive etmediği gibi bir dizi kontrol deneyi yapılmıştır. Bu kontrol 
deneyleri sırasında kısaltılmış versiyonun otoaktivasyon gösterdiği tespit edilmiş ve 
esas maya 2 hibrit taramalarına yalnızca Nfib3 tam fragmenti ile devam edilmiştir. 
Maya 2 hibrit taramaları için insan fetal cDNA kütüphanesi taşıyan ‘av’ maya suşu, 
Nfib3 cDNA’sı taşıyan ‘yem’ maya suşu ile 1 gün boyunca eşleştirilmiş ve elde 
edilen diploid mayalar petrilere ekilerek ilk seleksiyon AUR1-C ve MEL1 haberci 
genleri üzerinden gerçekleştirilmiştir. Sonrasında HIS3 ve ADE2 haberci genlerinin 
de katıldığı seleksiyon ve bunu takiben maya koloni PCR, restriksiyon kesimi, ve 
segregasyon analizi ile ‘gerçek etkileşim’lerin ortaya çıkartılması hedeflenmiştir. Son 
olarak, bulunan ekileşimlerin teyit edilmesi amacıyla bir eşleştirme çalışması daha 
yapılmıştır. Bu son deney ile elde edilen klonlar dizi analizine gönderilerek NFIB 
proteini ile etkileşen proteinlerin cDNA’sı tespit edilmiş ve veritabanlarıyla 








1.1.   Background Information 
1.1.1.  NFI family of transcription factors 
The nuclear factor I (NFI) family of transcription factors is composed of four 
members, Nfia, Nfib, Nfic, and Nfix which are highly conserved among vertebrates. 
These transcription factors are specific to metazoans as no members of this family is 
present in the genome of a unicellular organism. NFI family members have also been 
referred to as the CTF or CCAAT-binding transcription factors. 
Up to now, NFI proteins have been found to have binding sites on and to regulate 
many genes (Gronostajski et al., 2011) and NFI proteins are estimated to bind to 
≈75.000 sites in total on human genomic DNA (Gronostajski et al., 1985). DNA-
binding assays (Hennighausen et al., 1985; Leegwater et al., 1985; Nowock et al., 
1985) and isolation of NFI binding sites (Gronostajski et al., 1985) revealed that NFI 
proteins bind to a palindromic motif with five or six nucleotides spacing between two 
pentameric half-sites (TTGGC(N5)GCCAA sequence) on duplex DNA. However it 
was also shown (Gounari et al., 1990; Wuarin et al., 1990) that individual half-sites 
(TTGGC or GCCAA) are sufficient for promoter binding and transcriptional 
activation. The binding affinity of NFI proteins for half sites (Kd ~ 10
−9 M) is 
remarkably reduced compared to that of the dyad symmetric site (Kd ~ 10
−11 M) 
(Meisterernst et al., 1988). NFI proteins form either heterodimers or homodimers 
(Kruse and Sippel, 1994b; Chaudhry et al., 1998). The binding affinity of 
heterodimers and homodimers of NFI proteins to DNA were investigated for all four 
NFI genes and no significant difference was detected (Kruse and Sippel, 1994b). It 
was also shown that transcriptional activation potentials of NFI heterodimers are at 
intermediate level when compared with NFI homodimers and it was proposed that 
this could be a potential mechanism by which different NFI proteins can regulate 




1.1.2  Structural properties of NFI family members 
While NFI proteins are encoded by four genes, as many as 9 different splice variants 
are produced from a single gene by post-transcriptional processing and this creates 
additional heterogeneity in NFI proteins (Altmann et al., 1994; Chaudhry et al., 
1997; Kruse et al., 1991; Kruse and Sippel, 1994a; Santoro et al., 1988; Paonessa et 
al., 1988). 
The proteins expressed from all members of NFI family contain two distinct 
components: (1) an N-terminal DNA-binding/dimerization domain and (2) a C-
terminal transcriptional activation and/or repression domain. 
The N-terminal domain is responsible for DNA-binding activity, dimerization and 
the stimulation of adenovirus DNA replication (Mermod et al., 1989; Gounari et al., 
1990). Deletion studies (Mermod et al., 1989; Gounari et al., 1990) showed that this 
DNA binding/dimerization domain is around 200 amino acids in length and is highly 
conserved  between human, mouse and chicken NFI genes. 
 
Figure 1.1 Domains and alternative splicing of vertebrate NFI genes. The  top line 
shows general structure of NFI genes. The angle brackets below each gene represent 
alternatively spliced isoforms of individual family members. The boxes or lines 
connected to the second exon show alternative first exons. The second exon includes 
four conserved cysteine residues (labeled C) which are required for DNA-binding 
and redox regulation of binding. Approximate residue numbers and exon numbers 
are shown above and below the line, respectively. The C-terminal regions of each 
protein correspond to specialized domains (labeled Transactivation and repression) 
including the proline-rich transactivation domain (labeled Proline-rich) (Adapted 
from Gronostajski, 2000). 
NFI DNA-binding domain has sequence homology to MH1 (Mad Homology) 
domain of SMAD proteins which implies that there may be a structural similarity as 
well (Sadreyev and Grishin, 2003).  No other sequence homology has been reported 
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and NFI protein structure has not been elucidated. It was shown (Bandyopadhyay 
and Gronostajski, 1994) that the four cysteine residues of NFI DNA-binding domain 
are conserved between NFI family members and 3 of these 4 residues are needed for 
providing DNA-binding activity.  
The C-terminal domain contains a proline-rich activation domain as approximately 
25 percent of this domain consists of proline residues (Figure 1.1, Proline rich). In 
contrast to the DNA-binding domain, significant variations are seen within the C-
terminal transactivation domains among NFI proteins and this variation of  C-
terminal domain structure affects transcriptional modulatory functions of NFI 
proteins (Santoro et al., 1988; Kruse and Sippel, 1994b). The 100 residues on the C-
terminal domain corresponding to residues between 399-499, were shown to be 
necessary for maximal transcriptional activation of an NFI-site containing promoter 
in Drosophila Schneider cells (Mermod et al., 1989).  
While the N-terminal domain is responsible for DNA-binding and replication 
activities of NFI proteins, C-terminal domain is mostly responsible for regulation of 
gene expression. With transient or stable transfection assays, the C-terminal domain 
of both NFI-A and NFI-X has also been shown to repress transcription (Nebl and 
Cato, 1995; Monaci et al., 1995; Osada et al., 1997a,b). Additionally, NFI binding 
sites have been shown to act as negative regulatory elements in several promoters 
(Adams et al., 1995; Macleod and Plumb, 1991; Osada, 1997a; Rajas et al., 1998; 
Gao et al., 1996; Szabo et al., 1995; Cooke and Lane, 1999).  
1.1.3 Functional properties of NFI family members 
The NFI family of transcriptional factors plays extensive roles in animal 
development and pathology. NFI protein was first shown to be responsible for the 
replication of Adenovirus DNA (Nagata et al., 1982) and was also reported to have 
an important role in transcription of mouse mammary tumor virus (Cato et al., 1988). 
Later it was understood that NFI family is involved in the transcription and 
expression of cellular genes as well (Jones et al.,1987; Jackson et al., 1993; Grewal 
et al., 1992).  NFI proteins may activate or repress transcription depending on the 
specific isoform present in a particular cell type regulating different promoters, with 
their binding partners (Gronostajski, 2000).  
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The four NFI genes were shown to be expressed in overlapping patterns in several 
organs throughout the body complicating functional analysis of their protein products 
(Chaudhry et al., 1997). While all NFI family members are expressed in the lung 
(Chaudhry et al., 1997), Nfib has a particular importance in lung development 
(Mason et al., 2009; Steele-Perkins et al., 2005) and can directly regulate expression 
of epithelial cell specific genes in the lung (Bachurski et al., 2003). Phenotypes 
exhibited by Nfic -/- mice (Steele-Perkins et al., 2003; Park et al.,2007) indicate that 
Nfic is particularly important in tooth root formation. Nfic may also have a role in the 
regeneration and tissue growth processes of skin, hair follicles, and teeth (Plasari et 
al., 2010). While Nfic regulates hair growth cycle, Nfib was recently found to control 
hair follicle stem cell behavior (Chang et al, 2013). 
A dual reporter gene assay has revealed that Nfic can protect a gene from silencing 
when its DNA-binding sites are inserted between the gene and the telomeric ends 
(Esnault et al., 2009). Ferrari et al. (2004) reported that Nfic may bind  histone H3 
and act as a barrier between telomeres and downstream gene. 
The role of NFI proteins in adipogenesis has been shown as NFI-binding sites have 
been identified in an adipocyte-specific enhancer (Graves et al., 1991) and an 
adipocyte-specific promoter (Singh and Ntambi, 1998). Also, NFIA and NFIB were 
shown (Waki et al., 2011) to have physiological roles in adipocyte differentiation as 
siRNA knockdown of either NFIA or NFIB led to the suppression of induction of the 
expression of the adipogenic transcription factors PPARc and C/EBPa and also to 
reduction of lipid accumulation in adipogenic cell lines. 
1.1.4  Roles of NFI family in CNS development 
In vertebrates, the central nervous system (CNS) is consists of two main cell types: 
neurons and glia. The glial cells are further divided into subcategories as 
oligodendrocytes, astrocytes and microglia.  
While the main functions of oligodendrocytes in CNS are forming myelin sheaths 
that insulate axons and promoting the saltatory conduction of electric signals, 
astrocytes are responsible for structural integrity of the brain, providing metabolic 
support to neurons, maintaining water and ionic balance and modulating synaptic 
transmission (Guillemot, 2007b). 
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The numerous subtypes of neurons as well as oligodendrocytes and astrocytes arise  
from multipotent progenitors, a single layer of neural stem cells in the early embryo, 
located in the walls of the embryonic neural tube. (reviewed in Guillemot, 2007b and 
Corbin et al., 2008). This is achieved by first neurogenesis followed by gliogenesis 
(Miller and Gauthier, 2007).  These sequential phases of neural development are 
controlled by extrinsic signals, different families of transcription factors and 
modifications of histones and DNA (reviewed by Rowitch, 2004; Guillemot, 2007a). 
                        
Figure 1.2 Cell types and differentiation in CNS (Adapted from Guillemot, 2007b) 
The generation of a particular class of neuron or glial cell from a multipotent 
progenitor consists of sequential steps (Guillemot,  2007b). The whole process starts 
with the spatial patterning of the neural primordium in which progenitor cells acquire 
unique positional identities. In the second step, called cell type selection or 
commitment, daughter progenitor cells are produced from multipotent progenitors. 
This newly produced progenitor cells can only give rise to a single neural cell type 
which may be neurons, oligodendrocytes or astrocytes. In the next step of subtype 
specification, the committed neuronal progenitors become restricted to produce 
particular kinds of neurons such as motor neurons or interneurons. Once these 
particular neurons are produced, the neuronal progenitors become postmitotic and 
start to migrate to more differentiated areas of the neural tube to terminally 
differentiate. Oligodendrocytes, astrocytes and some types of neurons begin to 
migrate and differentiate while they are still dividing.  
During neuronal differentiation, ventricular zone progenitors transit from neurogenic 
to gliogenic divisions, and this process is known as the gliogenic switch. While the 
molecular mechanisms that control this switch are not very well understood, the 
Notch signaling pathway seems to play a fundamental role by maintaining 
telencephalic progenitors in an undifferentiated state (Mizutani and Saito, 2005).  
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Besides Notch signalling pathway, JAK-STAT signaling in neural precursors was 
also shown to be effective in triggering gliogenesis (Barnabe-Heider et al., 2005; 
Ochiai et al., 2001).  
NFI proteins role in neural development is underlined by their expression pattern.  
During embryogenesis, NFI genes are expressed in distinct, overlapping patterns 
with high levels of expression of Nfia, Nfib, and Nfix in the developing neocortex 
(Chaudhry et al., 1997). Initially, Nfia, Nfib, and Nfix are highly expressed in 
ventricular zones (Chaudhry et al., 1997; Deneen et al., 2006; Plachez et al., 2008).  
At late embryonic and early postnatal ages, expression is particularly high in the 
cerebral cortex, hippocampus, basilar pontine nuclei, cerebellum, and spinal cord 
(Chaudhry et al., 1997; Gesemann et al., 2001; Shu et al., 2003; Deneen et al., 2006; 
Wang et al., 2007; Plachez et al., 2008).  
The role of NFI proteins in gliogenesis has been well established in several regions 
of the CNS (Namihira et al., 2009; Deneen et al., 2006; Piper et al., 2010; Kang et 
al., 2012). Previous loss of function studies (das Neves et al., 1999; Shu et al., 2003; 
Steele-Perkins et al., 2005; Deneen et al., 2006; Driller et al., 2007; Wang et al., 
2007; Campbell et al., 2008) show that in order for the neuronal and glial populations 
to properly develop in cerebral cortex, hippocampus, cerebellum, and spinal cord, 
NFI proteins are required.  
Nfia acts downstream from Notch to facilitate expression of astrocyte specific genes, 
such as GFAP and astrocyte differentiation in cortical cultures as the astrocytic gene 
promoters were protected from DNMT1 (DNA (Cytosine-5-)-Methyltransferase 1) 
via the binding of NFIA to these promoters (Namihira et al., 2009). However, in the 
embryonic spinal cord, Notch signaling during the gliogenic switch did not result in 
the induction of NFIA or gliogenesis (Deneen et al., 2006). Nfia also downregulates 
the activity of the Notch signaling pathway via repression of the key Notch effector 
Hes1 (Piper et al., 2010). 
Another role of Nfia in gliogenesis is that it interacts with Sox9 to arrest 
neurogenesis and regulate genes associated with gliogenesis (Kang et al., 2012). Nfia 
and Nfib also modulates gliogenesis and oligodendrocyte differentiation within the 
developing spinal cord (Deneen et al., 2006) and hippocampus (Piper et al., 2010).  
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The lack of midline glia and the abnormalities in protein expression lead to agenesis 
of corpus collosum (Shu et al., 2003; das Neves et al., 1999). Moreover, Nfib 
regulates expression of guidance molecules such as Slit1 and neuropilin leading to 
defects in midline crossing of commissural axons and agenesis of corpus collosum 
(Piper et al., 2009). Nfib-/- mice exhibits delayed glial differentiation and maturation 
within the developing neocortex and hippocampus (Barry et al., 2008; Piper et al., 
2009), supporting Nfib’s role in regulation of glial development in the CNS.  
These in vivo data are complemented by in vitro studies on human embryonic stem 
cells which show that while NFI-A and NFI-B are expressed during early 
gliogenesis, NFI-X and NFI-C are expressed later in the differentiation of astrocytes 
and control the expression of late astrocyte markers including GFAP and SPARCL1 
(Wilczynska et al., 2009).  
Interestingly, while they regulate gliogenesis in the developing neocortex, 
hippocampus, and spinal cord, NFI proteins also regulate cell migration and terminal 
differentiation in the cerebellum and glia mediated cell migration in the hippocampus 
(Barry et al., 2008; Wang et al., 2007). 
1.1.5 Roles of NFI family in cancer and neurodegenerative diseases 
NFI family members are not only involved in developmental processes but also in 
neurological diseases and cancer.  
According to Lu et al. (Lu et al., 2007), NFIA haploinsufficiency resulted in central 
nervous system malformation such as tethered spinal cord, Chiari type I 
malformation, seizures, hypoplastic or absent corpus callosum, and hydrocephalus. 
Additionally, Koehler et al. (2010) reported that deletion of a 4.9 Mb part of NFIA 
gene resulted in hypoplasia of the corpus callosum, ventriculomegaly, and 
dysmorphic features. Also, NFIB has been shown to mediate the function of a 
transcriptional activator that is associated with Autism Spectrum Disorder (Choi et 
al., 2011).  
In addition to NFIA and NFIB’s involvement in human neurological conditions, they 
have also been implicated in cancer. Using genomic hybridization and DNA 
sequencing NFI-A gene was shown to be associated with different chronic malignant 
myeloid diseases with structural alterations of the NFI-A gene (Bernard et al., 2009). 
Similarly, NFIB’s has been shown to translocate with  high-mobility group 
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(nonhistone chromosomal) protein isoform I-C (HMGIC) in pleomorphic adenomas 
has been shown (Geurts et al., 1998).  
Conversely, when NFI proteins were overexpressed in chick embryo fibroblasts 
cells, they cause fibroblasts cells to become more resistant to transformation by a 
several nuclear oncogenes, including fos, jun and qin (Schuur et al., 1995). In a 
recent study (Moon et al., 2011), the expression frequency of NFIB protein in human 
breast cancer tissues and its clinical implications were investigated and significant 
level of NFIB transcripts were seen in triple negative breast cancer. Additionally, 
silencing the NFIB gene lead to significant reduction in cell proliferation and 
increase in apoptotic signaling pathway. 
Another study implicating NFIB in cancer showed that the fusion of MYB oncogene 
and NFIB is common in Adenoid cystic carcinoma (ACC) (Persson et al., 2009)  
leading to the overexpression of MYB in the salivary gland (Mitani et al., 2010). 
Interestingly, Fujita et al. (2008) predicted and confirmed that the NFIB mRNA is a 
target of miR-21, a key microRNA which is known to be highly expressed in various 
cancers (Selcuklu et al., 2009). 
1.2 Experimental Background 
1.2.1 Screening technologies for protein-protein interactions 
All cellular processes involve protein-protein interactions. For analyzing protein-
protein interactions, several methods have been developed so far (reviewed in 
Brückner et al., 2009). Some of these are copurification, affinity purification or 
coimmunoprecipitation of protein complexes. These techniques test for interactions 
in vitro. Mass Spectrometry (MS) coupled to affinity purification techniques can be 
used to identify interacting partners of a specific protein. Although this approach is 
straightforward, it is costly and time-consuming.  
Phage display or yeast two-hybrid (Y2H) techniques can also be good candidates to 
screen for potential binding partners of particular proteins. These techniques make 
use of cDNA-expression libraries. The cDNA library is expressed in bacteriophage 
with the bacteriophage coat protein on the surface of the viral particle which is then 
allowed to bind to bait protein immobilized on a solid surface. Attached phages can 
then be isolated and characterized. 
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Y2H and affinity purification coupled to MS (AP/MS) are preferred methods for 
automated screening of interactions (Brückner et al., 2009). In the case of MS, mass-
to-charge ratio of ionized molecules are determined to identify proteolytic fragments 
of proteins or even entire proteins and protein complexes. However, MS requires 
expensive and large equipment. This is a disadvantage when compared to Y2H. 
Consistently, it is estimated that half of the interaction data available on databases 
such as IntAct and MINT arise from Y2H assays (Brückner et al., 2009). 
1.2.1.1 Yeast two hybrid system 
Originally created by Fields and Song (Fields and Song, 1989), yeast two-hybrid 
technique has been used extensively to search for interacting proteins. In the Y2H 
system, the interaction between two proteins of interest is detected via the 
reconstitution of a transcription factor and the subsequent activation of reporter genes 
under the control of this transcription factor (Auerbach et al., 2005). 
To analyze interactions between two proteins, GAL-4 DNA binding domain (GAL4-
DBD) and GAL-4 activation domain (GAL4-AD) are used to make fusion protein 
constructs. For constructing bait, the protein of interest is fused to N-terminal part of 
GAL4-DBD and for constructing prey, the interactor protein is fused to the C-
terminal part of GAL4-AD. When these constructs are transformed into yeast and 
fusion proteins are expressed, the two separate polypeptides reconstitute Gal4 
transcription factor,  subsequent recruitment of RNA polymerase II by Gal4 leads to 
transcription of a GAL1-lacZ fusion gene. Since this reporter gene encodes the beta-
galactosidase enzyme, the interaction can be checked with a colorimetric assay.  
Figure 1.3 The yeast two-hybrid system. 
(A) A bait is expressed as a fusion to a 
DNA binding domain (DBD). The DBD–
bait binds to the operator sequences present 
in the promoter region upstream of the 
reporter gene but does not activate its 
transcription since the DBD–bait does not 
contain an activation domain. (B) A prey is 
expressed as a fusion to an activation 
domain (AD). The AD–prey fusion has the 
capability to activate transcription in yeast 
but because it is not actively targeted to the 
promoter it does not activate transcription 
of the reporter gene. (C) The interaction 
between bait and prey targets the AD–prey 
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fusion protein to the promoter, thereby reconstituting an active transcription factor. 
The hybrid transcription factor is bound to the promoter upstream of the reporter 
gene and therefore activates transcription (Auerbach et al., 2005). 
In the Matchmaker GAL4-based two-hybrid assay, a bait protein is fused to the Gal4 
DNA-binding domain (DNA-BD), while libraries of prey proteins are fused to the 
Gal4 activation domain (AD). In the Matchmaker Gold Yeast Two-Hybrid System, 
when bait and library (prey) fusion proteins interact, the DNA-BD and AD are 
brought into proximity to activate transcription of four independent reporter genes 
(AUR1-C, ADE2, HIS3, and MEL1). 
There are four integrated reporter genes under the control of three distinct Gal4-
responsive promoters (Figure 1.4) in Clontech’s Y2HGold Yeast Strain, which are 
used to detect two-hybrid interactions: 
AUR1-C. The reporter gene AUR1-C encodes the enzyme inositol phosphoryl 
ceramide synthase. This gene is expressed in Saccharomyces cerevisiae as a result of 
protein-protein interaction. The enzyme expressed by AUR1-C then confers 
resistance to the toxic drug Aureobasidin A. 
HIS3. Y2HGold strain is unable to grow on media that lack of histidine, as it is 
unable to synthesize this amino acid. When an interaction occurs between bait and 
prey proteins, this reporter gene is expressed and allows cell to biosynthesize 
histidine and to grow on minimal medium which lacks of histidine. 
ADE2. Y2HGold strain is unable to grow on media that lack of adenine, as it is 
unable to synthesize this amino acid. When an interaction occurs between bait and 
prey proteins, this reporter gene is expressed and allows cell to biosynthesize adenine 
and to grow on minimal medium which lacks of adenine. 
MEL1. This reporter gene encodes the enzyme α-galactosidase. When a two-hybrid 
interaction occurs between two proteins, α-galactosidase is expressed and digests 







Y2HGold (Mating Partner) reporter gene constructs 
 
Y187 (Library Host Strain) reporter gene constructs 
 
Figure 1.4 Reporters of Y2HGold and Y187 strains (Clontech, PT4084-1 
(PR033493) Published 30 March 2010). 
1.3  NFI Binding Proteins 
NFI proteins have been shown to interact with several proteins and in many cases, 
this interaction was identified by yeast two hybrid technique. Some of these protein 
interaction based studies are described below.  
Yeast two hybrid technique was used for identifying proteins that may interact with 
proline-rich transactivation sequence of Nfic which contains a TGF-β responsive 
domain (TRD) (Alevizopoulos et al., 1995). The interacting protein was shown to be 
histone H3, point mutations which were made in the TRD reduced TGF-β induction 
and Nfic binding to histone H3. These interactions may act downstream and regulate 
chromatin structure in response to TGF-β signaling.  
Another study (Ferrari et al., 2004) showed that Nfic interacts with histone H3 to 
mediate the boundary effect that protects genes near the telomeres from silencing. A 
deletion mutagenesis localized the barrier activity to the Nfic histone-binding domain 
and identified several amino acids that were involved in the boundary and histone 
binding activities.  
A mammalian two hybrid study (Bachurski et al., 2003) concerning Surfactant 
protein C(SP-C) and Thyroid transcription factor 1 (TTF-1) was performed. The 
proximal promotor region of SP-C, contains a binding site for NFI and TTF-1. To 
understand whether or not NFI isoforms regulate SP-C transcription by interacting 
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with TTF-1, NFI family members and TTF-1 cotransfected into JEG-3 cells. A 
synergistic activation was seen on SP-C promoter. By doing coimmunoprecipitation 
and mammalian two hybrid assays, it was shown that TTF-1 directly interacts with 
conserved DNA binding and dimerization domains of all NFI family members. 
Interaction between these proteins activates SP-C transcription. 
NFI proteins may negatively regulate transcription of phosphoenolpyruvate 
carboxykinase (GTP) (PEPCK) by competing with cAMP regulatory element-
binding protein (CREB) for the CREB binding site on CBP (CREB binding protein) 
(Leahy et al., 1999). To demonstrate direct interaction between the transactivation 
domain of NFI-C (220–499)  and the CREB binding domain of the CREB-binding 
protein (CBP) a mammalian two-hybrid system was used.  
Tanese et al. (1991) showed that a Gal4 fusion protein that carries the proline rich 
activation domain of NFIC (carboxy-terminal 100 amino acids) can interact with 
purified coactivator proteins to initiate transcription in vitro. 
A yeast model system was utilized to study the functional interaction between the 
human estrogen receptor (hER) and NFIC (Tsai-Pflugfelder et al., 1998). Using 
chimeric proteins of NFIC and GAL4 to measure activation of an ER- and CTF1-
dependent reporter plasmids, they showed that proline-rich transactivation domain of 
NFIC is responsible for this interaction. 
Xiao et al. (1994) found that the proline-rich transcriptional activation domain of the 
NFIC contains a sequence with striking similarity to the heptapeptide repeats of the 
CTD and this CTD-like motif is essential for the transcriptional activator function of 
the proline-rich domain of NFIC. Additionally, the proline-rich activation domain of 
NFIC interacts directly with the TATA-box-binding protein (TBP), and a mutation in 
the CTD-like motif that abolished transcriptional activation reduces the affinity of 
the proline-rich domain for TBP which was shown by protein affinity 
chromatography.  
Through a Y2H screen, NFIX was shown (Singh et al., 2009) to interact with high 
mobility group protein (HMGN1) and the CGG triplet repeat binding protein 1 
(CGGBP1) and these interactions are impotant in regulation of HSF1 (a heat shock-
related transcription factor) expression.  In this Y2H experiment, CTF1 domain of 
NFIX was selected as bait and a fetal human brain cDNA library was screened. Upon 
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a heat shock, the transcription of HSF1 is inhibited by a protein complex contaning 
NFIX, CGGBP1 and HMGN1. This requires CGG repeat in HSF1 promoter and 
HSF1 binding site in NFIX promoter. 
1.4  Aim of the Study 
NFI family of transcriptional factors has four members: Nfia, Nfib, Nfic, and Nfix. 
These genes are expressed in specific overlapping patterns during fetal development 
resulting in more than 9 isoforms due to alternative splicing. The typical NFI protein 
is composed of an N-terminal DNA-binding/dimerization domain and C-terminal 
transcriptional activation and/or repression domains (Altmann et al., 1994; Chaudhry 
et al., 1997; Kruse et al., 1991; Kruse and Sippel, 1994a; Santoro et al., 1988; 
Paonessa et al., 1988). 
NFI proteins act as cellular transcription/replication factors and play a key role in 
central nervous system development, including cell migration, terminal 
differentiation as well as neurogenesis and gliogenesis. These proteins are required 
for proper development of neuronal and glial populations in the cerebral cortex, 
hippocampus, cerebellum, and spinal cord (Barry et al., 2008; Wang et al., 2007). 
The members of NFI family regulate different developmental processes and genes in 
different parts of the brain. For example, in cerebellum, their roles are directed 
towards migration and terminal differentiation, wheras in forebrain, they are mostly 
involved in neurogenesis and gliogenesis, and in spinal cord, they regulate 
gliogenesis and astrocyte differentiation (Deneen et al., 2006; Piper et al., 2010). 
Since the DNA-Binding domains of NFI proteins are highly conserved and their 
affinities for consensus DNA binding sites are very similar, the variation between 
their roles in transcriptional regulation can be explained by “combinatorial control”. 
Combination of several transcription factors and chromatin modifying proteins lead 
to the final readout of gene expression. Thus, if NFI proteins interact with different 
proteins in different CNS regions and cell types during development, they will have 
different effects on the transcriptional regulation and as a result, they will play 
different roles in forebrain, neocortex, hippocampus and cerebellum. 
The fact that knockout of NFI genes that are expressed in the same brain region can 
have different phenotypes and NFI proteins can regulate different processes and 
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genes in different brain regions suggests that some of the interaction partners of NFI 
proteins in CNS still need to be identified to better understand their roles in 
transcriptional regulation and in brain diseases.  
In this study, we performed a Yeast Two-Hybrid Screen to search for interactors of 
NFIB from human fetal brain cDNA library. Although the role of NFI family 
members, in particular NFIB protein, in the developing CNS has been studied 
extensively, there is no report of a screen for interacting partners of NFIB during 
neural development. 
Since NFIB is a transcription factor, it could autoactivate related reporters used  
during two hybrid screening. To avoid such false positive interactions, in addition to 
full NFIB protein, we also made a prey construct of truncated NFIB where its DNA-
binding domain is missing.  The findings of this study will reveal unidentified 









2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1. Equipment 
The equipment that was used in this thesis project is listed below: 
Table 2.1 Equipment. 
Equipment Brand & Supplier Company 
DNA Sequencer Applied Biosystems 
Gel Electrophoresis System Bio-Rad 
Microcentrifuge ScanSpeed 
pH Meter WTW 
Precision Weigher Precisa 
Shaker Sartorius 
Rocking platform shaker Heidolph 
Vortex LMS Group 
Water Bath Memmert 
Thermal Cycler Applied Biosystems 
Nucleic acid Spectrometer NanoDrop/Thermoscientific 
Tabletop Centrifuge Beckman Coulter 
2.1.2 Chemicals 
The chemicals that were used in this thesis project are shown below: 
Table 2.2 Chemicals. 
Chemical Supplier Company 
Agar, Bacteriological Acumedia 
Low Electroendosmosis Agarose Lonza 
Yeast Nitrogen Base Clontech 
-Leu/-Trp Drop Out Amino Acid Mixture Clontech 
-Leu Drop Out Amino Acid Mixture Clontech 
-Trp Drop Out Amino Acid Mixture Clontech 
-Ade/-His/-Leu/-Trp/ Drop Out Amino Acid Mixture Clontech 
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Table 2.2 (continued) : Chemicals. 
Chemical Supplier Company 
Isopropanol J.T.Baker 
Ethanol, absolute Carlo Erba 
Methanol,analytical grade Fisher Scientific 
Acetic Acid J.T.Baker 




Peptone G Acumedia 
Glycine Fischer Scientific 
Tryptone Lab M 
Yeast Extract Lab M 
Tris Base Fischer Scientific 
EDTA Carlo Erba 
Adenine hemisulfate salt Sigma 
PronaSafe Nucleic Acid Staining Dye Conda Lab 
Ethidium Bromide Fischer Scientific 
X-α-Gal Clontech 
2.1.3 Reagents 
The reagents including primers, enzymes and buffers that were used in this thesis 
project are listed below; 
Table 2.3 Reagents. 
Reagent Brand & Supplier Company 
1 kb DNA Ladder Fermentas 
6X DNA Loading Dye Fermentas 
10 mM dNTP Mix Fermentas 
OneTaq® DNA Polymerase New England Biolabs 
5X OneTaq Standard Reaction Buffer New England Biolabs 
XmaI Restriction Enzyme New England Biolabs 
Sal I Restriction Enzyme New England Biolabs 
Hae III Restriction Enzyme Thermo Scientific 
10X Fast Digest Buffer Thermo Scientific 
NEBuffer New England Biolabs 
Lyticase from Anthrobacter luteus Sigma Aldrich 
50X Advantage 2 polymerase mix Clontech 
10X Advantage 2 PCR Buffer Clontech 
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    Table 2.3 (continued) : Reagents. 
Reagent Brand & Supplier Company 
α-NFI primary antibody Santa Cruz Biotechnology 
α-myc primary antibody Clontech 
GAL4 DNA-BD monoclonal antibody Clontech 
Goat anti-mouse seconder antibody Thermo Scientific 
Goat anti-rabbit seconder antibody Thermo Scientific 
2.1.4 Commercial kits 
The commercial kits that were used in this thesis project are shown below: 
Table 2.4 Commercial kits. 
Kit Brand & Supplier Company 
High Pure Plasmid Purification Kit Roche Applied Science 
Agarose Gel DNA Extraction Kit Roche Applied Science 
Yeastmaker Yeast Transformation System 2 Clontech 
Pretransformed Human Fetal Brain cDNA 
Library 
Clontech 
MatchMaker Gold Yeast Two-Hybrid System Clontech 
In Fusion HD Cloning Kit Clontech 
 
2.1.5 Buffers and solutions 
The buffers and solutions that were used in this thesis project are shown below: 
Table 2.5 Buffers and solutions. 
Buffer/Solution Content 
TAE Buffer (50X) 40mM Tris, 20 mM Acetic Acid, 1 mM EDTA(pH:8.0), dH2O 
1.1X TE/LiAc 1.1X LiAc, 1.1X TE, dH2O 
PEG/LiAc 40% (w/v) PEG 3350, 1X TE buffer, 1X LiAC 
0.9% NaCl 0.9 g NaCl, 100 ml dH2O 
 
2.1.6 Microorganism strains 
2.1.6.1 Bacterial strains 
Escherichia coli (E.coli) XL1-Blue strain endA1 gyrA96(nalR) thi-1 recA1 relA1 lac 




2.1.6.2 Yeast strains 
 Saccharomyces cerevisiae Y2HGold strain (Clontech): 
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2 : : GAL1UAS–
Gal1TATA–His3, GAL2UAS–Gal2TATA–Ade2URA3 : : MEL1UAS–Mel1TATA AUR1-C 
MEL1 
 Saccharomyces cerevisiae Y187 strain (Clontech): 
MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4Δ, gal80Δ, met–, 
URA3 : : GAL1UAS–Gal1TATA–LacZ, MEL1 
2.1.7 Culture media 
LB Medium: 10 g tryptone, 5 g yeast extract, and 10 g NaCl were dissolved in 
ultrapure water and the volume was adjusted to 1 L. For sterilization, the media was 
autoclaved at 121 oC for 15 minutes. For preparing LB agar plates, 15 g agar was 
added to 1 L LB medium before sterilization. For preparing selective medium, the 
medium was allowed to cool to 55 oC following sterilization, and then the relevant 
antibiotics were added. The stock and working concentrations of antibiotics used in 
this thesis are listed in Table 2.6. 
Table 2.6 Antibiotics and their concentrations. 
Antibiotic Stock Solution Concentraion Working Solution Concentraion 
Kanamycin 10 mg/L in ultrapure water 50 µg/L in medium 
Ampicillin 10 mg/L in ultrapure water 100 µg/L in medium 
 
SOB Medium: 2 g tryptone, 0.5 g yeast extract, 0.058 g NaCl, 0.0186 g KCl were 
dissolved in 100 ml ultrapure water and autoclaved at 121 oC for 15 minutes.  
SOC Medium: SOC medium was prepared by adding 0.095 g MgCl2, and 0.24 g 
MgSO4, and 0.36 g glucose into SOB medium followed by filter sterilization (0.22 
µm). 
HTB Solution: 10 mM HEPES, 15 mM CaCl2, 250 mM KCl were dissolved in 
dH2O. pH of the solution was adjusted to 6.7 with 1 M KOH. MnCl2 was added to a 
final concentration of 55 mM and volume was brought to 200 ml. The solution was 
filter sterilized (0.45µM).  
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YPD medium: 20 g Peptone G, 10 g Yeast Extract, and 2 g Dextrose were dissolved 
in 1 L ultrapure water followed by autoclaving at 121 oC for 15 minutes. For 
preparing YPD agar plates, agar was added to YPD medium at 20 g/L before 
sterilization. 
YPDA medium: YPDA medium is adenine supplemented version of YPD medium,  
Adenine hemisulfate was added to YPD medium after sterilization at a working 
concentration of 120 mg/L. 
SD Medium:  20 g dextrose and 6.7 g yeast nitrogen base without amino acids, were 
dissolved in 1 L ultrapure water to prepare SD base medium. The appropriate amount 
of drop-out amino acid mixture shown in Table 2.7 was then added to this SD base 
and the resulting solution was autoclaved at 121 oC for 15 minutes. For SD agar 
plates, agar was added to a final concentration of 20 g/L. The drop-out amino acid 
mixtures with their final concentrations are listed below: 
Table 2.7 Concentrations of drop-out (DO) nutrients. 
Nutrient Final Concentration 
-Trp DO Supplement 0.74 g/L 
-Leu DO Supplement 0.69 g/L 
-Leu/-Trp DO Supplement 0.64 g/L 
-Ade/-His/-Leu/-Trp DO Supplement 0.60 g/L 
 
2.1.8 Vectors 
2.1.8.1 pGBKT7, DNA binding domain vector 
The proteins that are expressed from pGBKT7 vector are fused to amino acids 1–147 
of the GAL4 DNA binding domain (DNA-BD). The pGBKT7 vector also contains 
the following main elements: a constitutive ADH1 promoter (PADH1) from which 
fusion proteins are expressed at high levels; T7 and ADH1 termination signals (TT7 & 
ADH1) which terminates transcription; a T7 promoter; a c-Myc epitope tag; a MCS;  
pUC and 2 μ ori from which pGBKT7 replicates autonomously in both E. coli and S. 
cerevisiae,  respectively; kanamycin resistance gene (Kanr) for selection in E. Coli; 
TRP1 nutritional marker for selection in yeast; 
The restriction map and the multiple cloning site (MCS) of pGBKT7 along with 




Figure 2.1 Map of pGBKT7 Vector 
 
 
Figure 2.2 Restriction site of pGBKT7 vector 
2.1.8.2 pGADT7,  activation domain vector 
The proteins that are expressed from pGADT7 vector are fused to amino acids 768–
881 of the GAL4 activation domain (AD). The pGADT7 vector also contains the 
following main elements: a constitutive ADH1 promoter (PADH1) from which fusion 
proteins are expressed at high levels; T7 and ADH1 termination signals (TT7 & ADH1) 
which terminates transcription; the SV40 nuclear localization sequences (added to 
the activation domain sequence) by which the fusion protein is targeted to the yeast 
nucleus; a T7 promoter; an HA epitope tag; a MCS;  pUC and 2 μ ori from which 
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pGBKT7 replicates autonomously in both E. coli and S. Cerevisiae,  respectively;  an 
ampisillin resistance gene (Ampr) for selection in E. Coli; LEU2 nutritional marker 
for selection in yeast. 
The restriction map and the multiple cloning site (MCS) of pGADT7 along with 
other  important elements on vector are shown in Figure 2.3 and 2.4. 
 
Figure 2.3 Map of pGADT7 vector 
 
Figure 2.4 Restriction site of pGADT7 vector 
2.1.8.3 pCHNFI-B2,  insert vector 
Nfib3 cDNA is cloned in pCHNFI-B2 vector. This construct was kindly provided by 
Richard Gronostajski (University at Buffalo, New York, USA).  
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This vector contains 2238 bp long mouse Nfib3 cDNA which codes for a 435 aa 
protein fused to a N-terminal hemagglutinin epitope tag. The construction of 
pCHNFI-B2 plasmid has been described previously (Chaudhry et al.,1997). 
2.1.9 Primers 
The primers used in this thesis were as follows; 
Table 2.8 Primers 















TTTTCGTTTTAAAACCTAAGAGTC Alpha DNA 










2.2.1 Construction of bait plasmid 
Mouse NFIB2 cDNA and truncated version of NFIB2 cDNA (NFIB2Δ) was cloned 
into pGBKT7 expression vector by PCR amplifying it from pCHNFI-B2 construct 
using the following primer pairings: mNFIB2_Xma_IF5,-mNFIB2_Sal_IFR and 
mNFIB2_Xma_IF6- mNFIB2_Sal_IFR. 
2.2.1.1 Restriction digestion of pGBKT7 expression vector 
For cloning NFIB2 inserts into pGBKT7 vector, pGBKT7 was restriction digested 




Figure 2.5 Digestion patterns of restriction enzymes 
XmaI 
5’-  C/CCGGG  -3’ 
3’-  GGGCC/C  -5’ 
SalI 
5’-  G/TCGAC -3’ 
3’-  CAGCT/G -5’ 
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Partial sequence of the multiple cloning site of pGBKT7 after restriction digestion is 
shown below. The shaded bases show recognition sites of restriction enzymes.  
5’…CATATGGCCATGGAGGCCGAATTC    -3’   CCGGGGATCCG      5’- T CGA CCTGCAGCGGCCGCATAA…3’ 
3’…GTATACCGGTACCTCCGGCTTAAG GGC C -5’    CCTAGGCAGCT   3’-      GGACGTCGCCGGCGTATT…5’ 
Figure 2.6 Multiple cloning site of pGBKT7 vector 
The restriction was carried out at 37oC, overnight. At the end of the restriction 
reaction, a heat shock was applied at 65 oC for 20 minutes in a water bath. The 
reaction components were indicated in Table 2.9. 
Table 2.9 Components of restriction reaction. 
Reaction Components Amounts / Volumes 
dH2O 40.3 µl 
NEB4 5 µl 
pGBKT7 Vector 3.25 µl : 5 µg 
SalI 0.5 µl 
XmaI 0.5 µl 
TOTAL 50 µl 
 
2.2.1.2 Primers for amplification of pCHNFI-B2 vector 
To amplify NFIB2 cDNA and NFIB2Δ cDNA from pCHNFI-B2 vector, primers 
were designed according to the instructions in the Clontech’s InFusion Cloning 
System. 
First, the primers contained 15 bases of homology (Figure 2.6;  underlined bases) 
with the ends of the linearized vector. The 5’ overhangs generated on the linearized 
pGBKT7 vector through restriction digestion were included in this 15 bp sequence. 
Secondly, one additional nucleotide was added to each primer in order to reconstruct 
XmaI and SalI restriction sites. These additional nucleotides were not part of the 15 
bases of sequence homology. Thirdly, appropriate number of bases were selected on 
extreme sequences of NFIB2 and NFIB2Δ for implementing general primer design 
rules. Lastly, an extra base was added adjacent to the reconstructed restriction sites in 
the primer for ‘in frame’ cloning.  





5’-   V15     +   RS   +      IF    +      Nn     -3’ 
Figure 2.7 A representation of the primers used (V15: Sequence specific to pGBKT7 
Vector (15 bases), RS: Additional base for reconstructing Restriction Sites, IF: 
Additional base for ‘In Frame’ cloning, NN: n bases specific to NFIB2 cDNA) 
In the figures below, representative sequences of NFIB2 and NFIB2Δ are shown; 
5’- ATGATGTATTCTCCCATCTGTCTCACTCAGGATG……CTCAAACGAGCCAGTCCTGGTACCTGGGCTAG -3’ 
3’- TACTACATAAGAGGGTAGACAGAGTGAGTCCTAC……GAGTTTGCTCGGTCAGGACCATGGACCCGATC -5’ 
Figure 2.8a The extreme sequences of NFIB2 
5’- GAGGACAGCTTTGTAAAATCCGGAGTCTTCAATGTA……CAAACGAGCCAGTCCTGGTACCTGGGCTAG -3’ 
3’- CTCCTGTCGAAACATTTTAGGCCTCAGAAGTTACAT……GTTTGCTCGGTCAGGACCATGGACCCGATC -5’ 
Figure 2.8b The extreme sequences of NFIB2Δ 
In the figures above, the underlined bases are the ones that were included in primers. 
The sequence specific to the NFIB2 cDNA or NFIB2Δ cDNA must be 18–25 bases 
long, with %GC: 40-60, Tm: 58-65
oC,  Tm|G1-G2| ≤4oC. 
For designing primers, we also utilized Clontech’s online tool which can be accessed 
via the following link: http://bioinfo.clontech.com/infusion/ 
2.2.1.3 Amplification of NFIB2 inserts by PCR 
A PCR reaction was setup to amplify the NFIB2 and NFIB2Δ fragments using the 
primers described above. 
Below are the reaction components to carry out this PCR reaction;   
Table 2.10 Components in the PCR reaction for pCHNFIB2 vector. 
Components Volumes/Amounts 
dH2O 16.375 µl 
5X One Taq Standart Reaction Buffer 5 µl 
10 mM dNTPs 0.5 µl 
10 µm Forward Primer 0.5 µl 
10 µm Reverse Primer 0.5 µl 
One Taq DNA Polymrease 0.125 µl 
TOTAL 23 µl 
 
12.5 ng pCHNFI-B2 was added to the 23 µl master mix. The reactions were carried 
out in quintuplicate. At the end of amplification, the PCR products were combined 




94 oC : 1 minutes 
o 94 oC : 30 seconds 
o 54 oC : 30 seconds   
o 68 oC : 90 seconds 
68 oC : 5 minutes 
Figure 2.9 PCR cycling protocol for amplification of NFIB2 inserts 
2.2.1.4 Purification of NFIB2 insert 
The PCR products were resolved on agarose gel and resulting bands were purified by 
Agarose Gel DNA Extraction Kit, Roche according to the manufacturer’s instruction. 
Briefly; 
 300 µl Binding Buffer per 100 mg gel was added in a sterile microcentrifuge 
tube and the tube was vortexed for 15-30 seconds. 
 The suspension was incubated for 10 minutes at 56 oC by vortexing in every 
2-3 minutes. 
 150 µl isopropanol per 100 mg gel was added and vortexed. 
 Filter tube was placed in a collection tube and the suspension was transferred 
into filter tube. 
 The suspension was centrifuged for 30-60 seconds at maximum speed. 
 The flow-through was discarded and the filter tube was placed in the same 
collection tube. 
 500 µl wash buffer was added and the tube was centrifuged for 1 minutes at 
maximum speed. 
 The flow-through was discarded and the filter tube was placed in the same 
collection tube. 
 200 µl wash buffer was added and the tube was centrifuged for 1 minutes at 
maximum speed. 
 The flow-through and the collection tube were discarded. The filter tube was 
placed in a steril microcentrifuge tube. 
 50-100 µl elution buffer was added. 
 The tube was centrifuged for 1 minutes at maximum speed. 




 Without touching the base of the tube, the supernatant was transferred to a 
seperate tube. The purified DNA was in this supernatant.  
 DNA concentration of purified DNA was measured by NanoDrop instrument. 
2.2.1.5  Cloning NFIB2 cDNAs into pGBKT7 vector 
For insertion of NFIB2 and NFIB2Δ amplicons into pGBKT7 vector separately, we 
used Clontech InFusion system. The reaction components of InFusion system and 
their amounts are shown below: 
Table 2.11 Components in the InFusion reaction. 
Reaction Components 
Amounts / Volumes 
NFIB2 NFIB2Δ 
5X InFusion HD Enzyme Premix 2 µl 2 µl 
Linearized Vector 100 ng: 1.85 µl 100 ng: 1.85 µl 
Purified PCR Fragment 100 ng: 0.98 µl 100 ng: 2.14 µl 
dH2O 5.17 µl 4.01 µl 
Total 10 µl 10 µl 
The InFusion reaction was caried out at 50oC for 15 minutes. 
2.2.1.6 Transformation of InFusion cloning reaction 
Following InFusion reaction, we transformed the resulting reaction mixtures into 
competent XL-1 Blue Escherichia coli cells. To prepare competent XL-1 Blue E.coli 
cells, we used competent cell protocol based on CaCl2 treatment of E.coli cells. The 
competent cell protocol that we used was as follows: 
 LB plate was streaked with cells from a frozen stock of XL-1 Blue. 
 10 fresh colonies were picked and transfered into 200 ml SOB liquid medium 
and incubated at room temperature until OD600 reached 0.45. 
 The culture was divided into four 50 ml falcon tubes and kept on ice for 10 
minutes. 
 Falcon tubes were centrifuged at 2500 g for 15 minutes and supernatants 
were discarded. 
 Cells were resuspended with 16ml HTB solution and kept on ice for 10 
minutes. 




 Cells were resuspended with 4ml HTB solution and tubes were combined. 
 1.2 ml DMSO was added and the tubes were gently mixed. 
 The suspension was immediately aliquoted into microcentrifuges tubes each 
of which contained 200 µl cell suspension. 
 Tubes were frozen rapidly using dry ice and placed in -80oC. 
Subsequent to preparing competent E.coli cells, we transformed them. The following 
protocol was applied for this: 
 One fourth of InFusion reaction mixture (2.5 µl) was combined with 50 µl of 
competent cells in a sterile pre-chilled microcentrifuge tube. 
 1 µl of 40% DMSO was added to the tube and mixed. 
 The tube was placed on ice bath for 30 minutes. 
 A heat shock was applied at 42oC for 45 seconds in a water bath. 
 The tube was incubated on an ice bath for 2 minutes. 
 SOC medium was added to the tube to a final volume of 500 µl.  
 The transformation reaction was diluted 1/10 in 100 µl SOC medium and 
spread on a separate LB plate containing 50 µg/ml Kanamycin. 
 The remainder of each transformation reaction was centrifuged at 6000 rpm 
for 5 min. Supernatant was discarded. 
 Each pellet was resuspended in 100 μl fresh SOC medium. Each sample was 
spread on a separate LB plate containing 50 µg/ml Kanamycin. 
 All of the plates were incubated overnight at 37°C. 
2.2.1.7 Isolation of bait vectors  
For isolating bait vectors, pGBKT7-NFIB2 and pGBKT7-NFIB2Δ constructs, we 
used Roche Plasmid Isolation Miniprep Kit. 
The procedure of this kit is not much different from conventional plasmid 
purification kits. It starts with an alkaline lysis step which allows plasmid DNA to 
free from the cell. After centrifugation of cell suspension, choromosomal DNA is 
trapped in the cell debris and the supernatant is applied to the spin filter tube. The 
plasmid DNA is specifically adsorbed by the surface of glass fibers. A washing step 
ensures removal of the salts, proteins, and other cellular impurities from plasmid 
DNA. At the end, plasmid DNA is recovered with low salt elution buffer. 
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The procedure is given below; 
 One colony was transferred into 3 ml of LB medium, with a yellow pipet tip 
in a 15 ml falcon tube and left for incubation at 37oC overnight with 250 rpm 
shaking. 
 Next day, culture was centrifuged at 3000 g for 5 minutes and supernatant 
was completely discarded.  
 The pellet was suspended in 250 µl suspension buffer [50 mM Tris-HCl, 10 
mM EDTA; pH: 8.0 at 25 oC] by pipetting. 
 250 µl lysis buffer [0.2 M NaOH, 1% SDS] was added to the tube and the 
suspension was mixed with inverting the tube 6 times. 
 The suspension was incubated at room temperature for 5 minutes. 
 350 µl chilled binding buffer [4 M guanidine hydrochloride, 0.5 M potassium 
acetate; pH:4.2] was added and suspension was mixed with inverting the tube 
6 times. 
 The solution was incubated on ice for 5 minutes followed by centrifugation 
for 10 minutes at 13500 rpm. 
 A filter tube was placed in a collection tube and supernatant was transferred 
into filter tube. 
 The mixture was centrifuged for 1 minutes at maximum speed and flow-
through was discarded. 
 Filter tube was placed in the same collection tube and 500 µl Wash Buffer I  
[final concentrations after addition of ethanol: 5 M guanidine hydrochloride, 
20 mM Tris-HCl, pH: 6.6 at 25 oC] was added to filter tube followed by 1 
minute centrifugation at maximum speed.  
 Filter tube was placed in the same collection tube and 700 µl Wash Buffer II  
[final concentrations after addition of ethanol: 20 mM NaCl, 2 mM Tris-HCl, 
pH: 7.5 at 25 oC] was added to filter tube followed by 1 minute centrifugation 
at maximum speed (13500 rpm). 
 Flow-through was discarded and an additional minute centrifuge was 
performed to dry filter tube. 
 Flow-through and collection tube were discarded and filter tube was placed in 
a fresh sterile microcentrifuge tube. 
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 100 µl elution buffer [10 mM Tris-HCl; pH: 8.5 at 25 oC] was added to filter 
tube followed by 1 minute incubation step at room temperature. 
 The tube was centrifuged for 1 minute at maximum speed and the 
concentration of plasmid DNA in the resulting eluate was calculated from 
A260 measurements with UV Spectroscopy. 
2.2.1.8 Analytical restriction digestion of purified plasmids 
To ascertain that purified plasmids contained the correct inserts, we digested the 
isolated plasmids with SalI which cuts pGBKT7, pGBKT7-NFIB2 and pGBKT7-
NFIB2Δ at an only single recognition site. The reaction components were as follows; 
Table 2.12 Components of restriction reaction. 
Components 
Amount  / Volume 
NFIB2 NFIB2Δ 
dH2O 19.63 µl 17.14 µl 
10 X NEB4 Buffer 2.5 µl 2.5 µl 
Plasmid DNA 2.37 µl : 500 ng 4.86 µl : 500 ng 
Sal I restriction enzyme 0.5 µl : 10 U 0.5 µl : 10 U 
TOTAL 25 µl 25 µl 
 
The reactions were terminated the following day by heat shock at 65oC for 20 
minutes in a water bath. Subsequent to restriction digestion, one fifth of the reaction 
volumes were analyzed on a 0.8 % agarose gel. 
2.2.1.9 Sequencing of pGBKT7-NFIB2 and pGBKT7-NFIB2Δ constructs 
Selected purified plasmid DNAs were sent to sequencing to verify that the correct 
fragments were cloned into pGBKT7. The sequencing was performed by IonTek, 
Turkey. 
The forward and reverse primers that were used for sequencing were chosen from 
upstream and downstream sites of NFIB2 and NFIB2Δ inserts. For this, 3' DNA-BD 
Sequencing Primer and T7 Sequencing Primer were used (indicated in Table 2.8). 
2.2.2 Yeast transformation 
After constructing the bait plasmids (pGBKT7-NFIB2 and pGBKT7-NFIB2Δ), we 
transformed them into the Y2HGold yeast strain to use in the subsequent mating 
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experiments. The following procedures, including competent cell preparation and 
transformation steps, were used in both bait strain transformation and in subsequent 
control experiments. 
2.2.2.1 Preparation of competent cells 
For competent cell preparation and subsequent transformation steps, Clontech 
Yeastmaker™ Yeast Transformation System 2 was used. This system is based on 
high-efficiency polyethylene glycol (PEG)/LiAc-based method for preparing and 
transforming competent yeast cells.  
The following protocol was used for preparing competent yeast cells: 
 A freshly prepared YPDA agar plate was streaked with yeast cells from a 
frozen yeast stock. The plate was incubated upside down at 30° C until 
colonies appear (3 days). 
 One colony (diameter 2–3 mm, < 4 weeks old) was inoculated into 3 ml 
YPDA medium in a sterile 15 ml culture tube. 
 The cell suspension was incubated at 30° C with shaking at 150 rpm for 10 
hours. 
 5 μl of the culture was transferred to 50 ml of YPDA in a 250 ml flask. 
 The culture was incubated with shaking at 150 rpm until the OD600 reaches 
0.22. 
 The cells were centrifuged at 700 g for 5 min at room temperature. The 
supernatant was discarded and the pellet was resuspended in 100 ml of fresh 
YPDA. 
 The culture was incubated at 30° C until the OD600 reaches 0.45. 
 50 ml of the culture was transferred to a sterile falcon tube and the cells were 
centrifuged at 700 g for 5 min at room temperature. The supernatant was 
discarded and pellet was resuspended in 30 ml sterile, deionized H20. 
 The cells were centrifuged at 700 g for 5 min at room temperature. The 
supernatant was discared and pellet was resuspended in 1.5 ml of 
1.1xTE/LiAc. 
 The cell suspension was transferred to a 1.5 ml microcentrifuge tube and 
centrifuged at 13500 rpm for 15 sec. 
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 The supernatant was discarded and the pellet was resuspended in 600 μl of 
1.1xTE/LiAc.  
2.2.2.2 Transformation into Yeast 
Once the competent cells were prepared, they were transformed with plasmid DNA.  
The following protocol was applied for transformation: 
 The Yeastmaker Carrier DNA (10 μg/μl) was denatured by heating to 95–
100°C for 5 min, then cooled rapidly in an ice bath.  
 100 ng plasmid DNA and 10 μl carrier DNA were combined in a pre-chilled, 
sterile 1.5 ml tube. 
 50 μl of competent cells were added and the tube was gently mixed. 
 500 μl of PEG/LiAc was added and the tube was gently mixed. 
 The suspension was incubated for 30 minutes at 30° C mixing cells every 10 
minutes by tapping. 
 20 μl of DMSO was added and the tube was mixed. 
 The tube was placed in a 42° C water bath for 15 minutes. 
 Cells were mixed every 5 min by gently vortexing. 
 The yeast cells were centrifuged at 13500 rpm for 15 seconds to obtain cell 
pellet. 
 The supernatant was removed and the cells were resuspended in 1 ml YPD 
Plus Medium. 
 Cells were incubated at 30° C for 1 hour with shaking. 
 The yeast cells were centrifuged at 13500 rpm for 15 seconds to obtain cell 
pellet. 
 The supernatant was discarded and cells were resuspended in 1 ml 0.9 % 
(w/v) NaCl Solution. 
 100 μl of 1/10 and 1/100 dilution was spread onto 100 mm plates containing 
the appropriate drop-out selection medium and X-α-Gal substrate.  






2.2.3 Control experiments 
Control experiments were performed before mating experiments. The control 
experiments consisted of four experiments: control for bait expression, control for 
bait toxicity, control for bait autoactivation, and control for mating. 
2.2.3.1 Control for protein expression of bait vector 
The bait vector must express NFIB protein in order for yeast two-hybrid screen to 
work. To look for yeast clones that express NFIB protein well, first we transformed 
pGBKT7-NFIB2 and pGBKT7-NFIB2Δ plasmids into Y2HGold competent cells, 
grew transformants on selection medium, extracted proteins from individual 
colonies, and subjected the extracts to Western Blot analysis. 
Protein extraction from yeast 
After preparing competent yeast cells and transforming them with the appropriate 
plasmids (pGBKT7-NFIB2 and pGBKT7-NFIB2Δ constructs), we grew transformed 
Y2HGold cells on selective medium and then extracted whole cell proteins by lysis. 
A number of colonies on selective plates were compared according their western 
bands in terms of their ability to express NFIB2 fusion protein. 
The following protocol was used for growing the cultures and protein extraction: 
 One colony (2-3 mm in diameter) was picked and transferred into 3ml SD/-
Trp liquid drop-out medium in a 15 ml falcon tube and incubated at 30oC 
overnight with shaking at 150 rpm. 
 Next day, 5 ml fresh SD/-Trp medium was inoculated with the overnight 
culture to obtain a new culture with the initial OD600 value of 0.15. 
 This new culture was incubated at 30oC with shaking at 150 rpm until its 
OD600 reached 0.4-0.6. 
 The cells were centrifuged at 4100 rpm for 15 minutes. The supernatant was 
discarded and cell pellet was suspended in 50 µl 1X sample buffer [0.0625M 
Tris-HCl: pH: 6.8, 10% (v/v) Glycerol, 2% SDS].  
 This suspension was transferred to a clean microcentrifuge tube containing 
≈50 µl glass beads, and mixed by pipetting. 
 The resulting suspension was vortexed for 30 seconds and immediately 
placed on ice for 30 seconds. This was repeated 3 times. 
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 The resulting cell lysate was centrifuged at 16000 rpm for 5 minutes at 4oC. 
The supernatant was transferred to a clean microcentrifuge tube. 
 The tube was placed on a block heater and incubated at 95oC for 5 minutes. 
 The tube was centrifuged at 16000 rpm for 5 minutes at 4oC and supernatant 
was transfered to a clean microcentrifuge tube. 
 25-40 µl of this protein extract was used in SDS-PAGE experiments. 
SDS-PAGE electrophoresis and western blotting of protein extracts 
Once the cell protein extracts were obtained, 30-40 µl of protein extracts were 
resolved on SDS-PAGE at 100 V for about 1.5 hours. 
Following SDS-PAGE, the proteins were transferred from gel to the nitrocellulose 
membrane overnight at 15 V.  
 The membrane was removed from transfer system and stained with Ponceau 
S solution.  
 The presence of protein bands were confirmed visually, lanes and direction of 
blot were marked with a pencil.  
 The membrane was soaked in 3% dry milk in TBST [50 mM Tris-HCl; pH:  
7.5, 150 mM NaCl, 0.1% Tween 20] in a plastic bag and incubated for at least 
30 minutes in room temperature with gentle agitation. 
 Primary antibodies were diluted and the membrane was incubated with 
primary antibody solutions overnight at 4oC with gentle agitation (2 hour at 
room temperature for Gal4-DNA-BD antibody). Dilution ratios and type of 
solutions shown in Table 2.13. 
 The membrane was washed 4 times with TBST for 15 minutes at room 
temperature  
 The secondary antibody was diluted and the membrane was incubated for 1 
hour at room temperature with gentle agitation. Dilution rates and type of 
solutions are shown in Table 2.13. 
 The membrane was washed 3 times with TBST and once with TBS [20 mM 
Tris-HCl; pH: 7.5, 140 mM NaCl] for 10 minutes at room temperature.  
For western blotting and imaging of proteins, following protocol was used; 
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 The substrate solution [250 µl LumiGLO® Reagent A, 250 µl Peroxide 
Reagent B and 4.5 ml dH2O] was prepared. 
 The membrane was placed on a square piece of parafilm. Substrate reagent 
was applied onto it and incubated for 1 minute.  
 After the membrane was removed from parafilm and cleaned from excess 
substrate solution, it was sandwiched in a piece of two layer stretch film, and 
then placed in a X-ray film cassette.  
 One blue light sensitive autoradiography film was placed onto membrane and 
the cover of cassette was closed.  
 The membrane was exposed to film for 1 minute.  If required, a second piece 
of film was exposed for longer time periods (e.g. 5 minues). The film was 
removed from cassette and placed in autoradiography instrument. 
Table 2.13 Dilution rates & solutions of antibodies. 
Primary Antibody & dilution Secondary Antibody & dilution 
α-myc 1/1000 in 3% dry 
milk 
anti-mouse 1/500 in 3% dry milk 
α-NFI 1/1000 in 3% dry 
milk 
anti-rabbit 1/500 in 3% dry milk 
Gal4-DNA-BD 0.5 ng/µl in TBST anti-mouse 1/500 in TBST 
2.2.3.2 Control for toxicity of bait vector 
In order for the bait construct to be successfully used in the yeast two hybrid screen, 
the bait protein must not be toxic to yeast cells.  
According to the instructions in the Clontech MatchmakerTM Yeast Two Hybrid 
System, if the colonies containing bait vector are significantly smaller than colonies 
containing the empty pGBKT7 vector, the expression of bait vector is considered to 
be toxic to the cells. Additionally, the cells containing toxic bait protein would grow 
on plates slower than the cells containing non-toxic bait protein.  
The number and size of colonies resulting from transformation with either bait 
vectors or empty vector were compared. 
2.2.3.3 Control for autoactivation of bait  
The aim of autoactivation test is to confirm that the bait protein does not 
autonomously activate the reporter genes in Y2HGold, in the absence of a prey 
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protein. For this test, fresh 2-3mm colonies were streaked onto SD/Trp, SD/Trp/X-α-
Gal, and SD/Trp/X-α-Gal/AbA plates. At the end of 3 days, the color of colonies 
were scored as blue, pale blue, or white.  
2.2.3.4 Control for mating 
Before doing actual mating and library screening experiments, a mating control was 
performed. 
As a positive control, pGBKT7-53 that encodes the Gal4 DNA-BD fused to murine 
p53 was mated with pGADT7-T that encodes the Gal4 AD fused to SV40 large T-
antigen. Since p53 and large T-antigen are known to interact in a yeast two-hybrid 
assay, mating Y2HGold [pGBKT7-53] with Y187 [pGADT7-T] will result in diploid 
cells containing both plasmids that can activate all four reporters. 
A negative control was performed using pGBKT7-Lam (which encodes the Gal4 BD 
fused to lamin) and pGADT7-T. Diploid yeast containing pGBKT7-Lam and 
pGADT7-T should grow on SD/–Leu, SD/–Trp and SD/–Leu/–Trp (DDO) minimal 
media, but no colonies should grow on DDO + AbA plates. 
For both positive and negative control matings the following protocol was used; 
 Using the Yeast Transformation Protocol (small-scale) in the section 2.2.2, 
the following three transformations were done separately and plated on 
appropriate selective media: pGBKT7-53 and pGBKT7-Lam into Y2HGold 
plated on SD/-Trp, pGADT7-T into Y187 plated on SD/-Leu. 
 Plates were incubated at 30oC for 3 days and one 2–3 mm colony of each type 
was picked for use with the following small-scale mating procedure: 
o Positive Control Mating: Y2HGold [pGBKT7-53] and Y187 
[pGADT7-T]. 
o Negative Control Mating: Y2HGold [pGBKT7-Lam] and Y187 
[pGADT7-T]. 
 Both colonies were placed in a single 1.5 ml centrifuge tube containing 500 
μl of 2X YPDA and vortexed to mix. 
 Cultures were incubated with shaking at 200 rpm at 30°C overnight. 
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 From the mated culture (0.5 ml), 100 μl of 1/10, 1/100, and 1/1,000 dilutions 
were spread on each of the following agar plates. Plates were incubated 
(colony side facing downward) at 30°C for 3–5 days. 
o SD/–Trp 
o SD/–Leu 
o SD/–Leu/–Trp (=DDO) 
o SD/–Leu/–Trp/X-α-Gal/AbA (=DDO/X/A) 
 From DDO plates, 2 mm healthy colonies were picked and restreaked onto 
fresh DDO plates, and incubated at 30°C for 4 days for possible further use. 
2.2.4 Yeast two hybrid mating and screening 
For mating, Saccharomyces cerevisiae Y2HGold and Y187 strains were used.  
In the mating step, a concentrated bait culture was prepared and this bait culture was 
then combined with a 1 ml Human Fetal Brain cDNA library (Normalized 
Mate&PlateTM Library, Clontech) aliquot. After 22 hours incubation, the mated 
culture was plated. We used following procedure; 
 One fresh, large (2–3 mm) colony of bait strain (NFIB-α3) was inoculated 
into 50 ml of SD/–Trp liquid medium. 
 The culture was incubated shaking (250–270 rpm) at 30°C until the OD600 
reaches 0.8 (16–20 hr). 
 The culture was centrifuged to pellet the cells (1,000 g for 5 min), and 
supernatant was discarded. 
 The pellet was resuspended to a cell density of 2.9x108 cells per ml in SD/–
Trp (5 ml). Cells were counted using a hemocytometer. 
 A 1 ml aliquot of human fetal brain cDNA library was thawed in a room 
temperature water bath. 10 μl of aliquot was removed for titering on 100 mm 
SD/–Leu agar plates. 
 1 ml of our Mate & Plate Library was combined with 5 ml bait culture in a 
sterile 2 L flask. 
 45 ml of 2xYPDA liquid medium (with 50 μg/ml kanamycin) was added. 
 Cells from the library vial was rinsed twice with 1 ml 2xYPDA and added to 
the 2 L flask. 
 Culture was incubated at 30°C for 20–24 hr, slowly shaking (30–50 rpm). 
37 
 
 After 20 hours, a drop of the culture was checked under a phase contrast 
microscope (40X) to see whether or not zygotes were present, then continued 
incubation for additional 4 hours. 
 The culture was centrifuged to pellet the cells (1,000 g for 10 min). 
 The 2L flask was rinsed twice with 50 ml 0.5X YPDA (with 50 μg/ml 
kanamycin), the rinses were combined, and used this to resuspend the 
pelleted cells. 
 The suspension was centrifuged to pellet the cells (1,000 g for 10 min) and 
the supernatant was discarded. 
 All pelleteted cells were resuspended in 10 ml of 0.5X YPDA/Kan liquid 
medium. The total volume of cells + medium was measured. 
 To calculate the number of clones screened, 100 μl of 1/10, 1/100, 1/1,000, 
and 1/10,000 dilutions of the mated culture were spread on each of the 
following 100 mm agar plates and incubated at 30°C for 3–5 days: 
o SD/–Trp 
o SD/–Leu 
o SD/–Leu/–Trp (DDO) 
 The remainder of the culture was plated, 200 μl per 150 mm on DDO/X/A 
(54 plates) and incubated at 30°C for 3–5 days. 
 The number of screened clones (diploids) was calculated by counting the 
colonies on the DDO plates after 3 days of growth and using the following 
formula: 
o Number of Screened Clones = cfu/ml of diploids x resuspension 
volume (ml) 
 The mating efficiency was determined as percentage of diploids by first 
determining the limiting partner of the mated yeast strains and then using the 
following formula: 
partner limiting of cfu/ml of No.
Diploids % = 100 x diploids of cfu/ml of No.
 
 We measured the following viability values of the strains (bait or prey) and 
then the strain (prey or bait) with the lower viability was chosen as limiting 
partner. 
o No. of cfu/ml on SD/–Leu  (viability of the Prey Library) 
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o No. of cfu/ml on SD/–Trp  (viability of Bait) 
o No. of cfu/ml on SD/–Leu/–Trp (viability of diploids) 
2.2.5 Revealing positive interactions  
The QDO/X/A colonies were further analyzed to identify duplicates and to verify 
positive interactions. To do this, higher stringency screening, yeast colony PCR, 
restriction digestion, and multiple streaking experiments were performed. 
2.2.5.1 Higher stringency screening 
All the blue colonies that grew on DDO/X/A were streaked onto higher stringency 
QDO/A agar plates using a yellow pipette tip. The resulting colonies were then 
streaked onto QDO/X/A plates. 
2.2.5.2 Yeast colony PCR  
Yeast Colony PCR was conducted for revealing colonies that contained more than 
one prey vector. The primers were complementary to upstream (MATCHMAKER 5' 
AD LD-Insert Screening Amplimer) and downstream (MATCHMAKER 3' AD LD-
Insert Screening Amplimer) regions from the prey inserts (referred to as 5-AD-LD-
ISA and 3-AD-LD-ISA, respectively).   
The following protocol was used for Yeast Colony PCR; 
 100 µl of sterile, ultrapure water was added to a microcentrifuge tube and a 
small colony was suspended in this tube by vortexing. 
 PCR reaction mix was prepared in advance as seen in Table 2.14 and 8 µl of 
the colony suspension was transferred to the PCR mix. 
Table 2.14 Components of yeast colony PCR. 
Components Volume / Amount 
dH2O 10 µl 
10X Advantage II PCR Buffer 2.5 µl 
50 X dNTP Mix 0.5 µl 
10 µM Forward Primer 0.5 µl 
10 µM Reverse Primer 0.5 µl 
10 X Melting Solution 2.5 µl 
50 X Advantage II Polymerase Mix 0.5 µl 
Template DNA 8 µl 




The following protocol was used for colony PCR; 
   94 oC : 10 minutes 
    98 oC : 10 seconds 
    59 oC : 30 seconds   
    68 oC :   3 minutes 
   68 oC : 5 minutes 
Figure 2.10 Colony PCR cycling protocol 
After Colony PCR, 10 µl of PCR product was run on 1% agarose gel stained with 1X 
electrophoresis dye (PronaSafe) and the colonies that gave more than one PCR 
product were noted. 
2.2.5.3 Restriction digestion of colony PCR products 
Once Yeast Colony PCR was completed and potential duplicate clones were 
determined, PCR products of similar length were subjected to restriction digest. To 
do this, a frequent cutter enzyme, HaeIII was used. HaeIII is a four-cutter restriction 
enzyme with the following recognition pattern.  
5’… GG/CC …3’ 
3’… CC/GG …5’ 
Figure 2.11 Restriction pattern of HaeIII enzyme 
The reactions were set-up as indicated below and incubated for 5 minutes at 37oC in 
a water bath. 
Table 2.15 Components in the restriction digestion. 
Components Volume / Amount 
dH2O, Nuclease-free 17 µl 
10X Fast Digest Green Buffer 2 µl 
HaeIII Fast Digest Restriction Enzyme 1 µl 
Colony PCR Product 10 µl 
TOTAL 30 µl 
10 µl of the restriction digest was run on 2%  agarose gel stained with PronaSafe dye 
to identify PCR products with similar rstriction digest patterns. When more than one 
PCR product showed the same restriction pattern, the colonies were deemed to be 






2.2.5.4 Multiple streaking 
Yeast cells may take up more than one version of a plasmid following 
transformation. This means that a yeast cell can contain a prey vector whose protein 
product is able interact with the bait and activate reporters, as well as multiple prey 
vectors whose protein products are noninteracting. 
If the DNA of such a yeast clone is tried to be rescued directly via E.coli 
transformation without an intermediate plasmid segregation step, one may select a 
random E.coli colony which contains the wrong plasmid whose protein is not able to 
interact bait protein. In order to avoid isolation of noninteracting plasmids, one needs 
to perform segregation steps to increase the chance of selecting positive prey 
plasmid. 
We have streaked blue colonies twice on DDO/X (no Aureobasidin A), each time 
picking a single blue colony for restreaking. After the first streak, a mixture of blue 
and white colonies were obtained, indicating segregation of positive interactors 
(blue) from non-interactors (white). At the end of 2 streaks, most of the colonies 
appeared in blue color and we continued with them in the next step. The clones none 
of whose colonies appeared in blue color were eliminated. 
We also picked blue colonies from DDO/X plates and streaked them on QDO/A 
plates twice to make sure that the colonies retained their ability to activate AUR1-C, 
HIS3 and ADE2 reporters. Only then we proceeded with plasmid rescue from each 
one of these clones.  
2.2.6 Distinguishing genuine interactions 
Once the duplicate clones were eliminated by colony PCR, and the non-interacting 
prey plasmids by library plasmid segregation, we then proceeded with final yeast 
mating experiments to distinguish genuine interactions from false positives. 
2.2.6.1 Final yeast mating 
To distinguish genuine interactions from false positives, we have performed a final 
yeast mating experiment. First, we isolated plasmids, then we transformed them into  
E.coli cells and eventually we performed yeast mating. For this mating step, we have 
followed the same protocol as we did in the control mating experiments. 
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Plasmid Isolation from yeast 
Before performing final yeast mating experiments, we isolated the library plasmids 
from colonies isolated after multiple streaking. Since yeast has thick cell walls and 
their plasmids are inside their spheroplasts, one must apply sequential steps to isolate 
yeast plasmid DNA. A combination of plasmid isolation protocols was performed. 
The yeast plasmid isolation procedure is given below; 
 One blue colony was picked from QDO/X/A plate and suspended in 1.5 ml 
DDO medium. 
 The suspension was incubated at 30oC overnight shaking at 150 rpm. 
 The culture was transfererd to a microcentrifuge tube and centrifuged at 
13.500 rpm for 5 minutes. 
 The supernatant was poured off and residual medium was removed with a 
pipette.  
 The pellet was resuspended in 50 μl Potassium Phosphate [67 mM KH2PO4; 
pH: 7.5]. 
 2 μl of lyticase solution (25 U/µl) diluted in 8 μl TE buffer and added to the 
tube. The solution was pipetted up and down repeatedly to thoroughly 
resuspend the pellet. 
 The suspension was incubated at 37°C for 60 minutes. 
 20 μl of 10% SDS was added to each tube and vortexed vigorously for 1 min. 
 Samples were put through one freeze/thaw cycle (–20°C) and vortexed again 
before use. 
 We proceeded with Roche Plasmid Isolation Protocol described in section 2. 
starting from suspension step by adding 250 µl suspension buffer. 
 At the end, samples were eluted in of 30 μl of elution buffer. 
E.coli transformation  
E.coli was transformed with isolated yeast plasmids according to the following 
procedure; 
 20 μl of isolated plasmid and 50 µl competent cells were combined and 
mixed in a microcentrifuge tube. 
 1 µl of 40% DMSO was added to the tube and mixed. 
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 The tube was placed on ice bath for 30 minutes. 
 A heat shock was applied at 42oC for 90 seconds in a water bath. 
 The tube was incubated on an ice bath for 2 minutes. 
 400 µl SOC medium was added to the tube and the tube was incubated with 
shaking for 45 minutes at 37oC. 
 100 µl of suspension was transferred on an LB plate which contained 100 
µg/ml ampicillin and incubated overnight. 
 Next day, 3 ml of LB/Amp liquid medium was inoculated with one colony  
and incubated at 37oC overnight with shaking at 180 rpm. 
 The culture was then centrifuged and prey plasmid was isolated according to 
the miniprep plasmid isolation protocol described in section 2.2.1.7. 
Final mating of yeast strains 
Since two-hybrid screen can detect false positives, it is important to confirm that the 
interactions are genuine. If prey activates the Gal4-responsive reporters in the 
absence of bait, then the interaction is considered to be a false positive. If both bait 
and prey are required to activate the Gal4-responsive reporters then the interaction is 
a genuine positive. 
The following protocol was used for final yeast mating to distinguish genuine 
positives from false positives; 
 100 ng of each prey vector was transformed into Y187 Competent Cells using 
the small scale yeast transformation procedure described in section 2.2.2 and 
plates were incubated at 30oC until colonies become 3 mm in diameter. 
 One fresh bait colony from a SD/-Trp plate was mixed with one Y187 colony 
transformed with a prey vector in a microcentrifuge tube containing 500 µl 
2X YPDA. 
 The same procedure was performed by combining prey colonies with a Y2H 
Gold colony containing empty pGBKT7. 
 The microcentrifuge tubes were incubated at 30oC for 24 hours shaking at 
150 rpm. 
 The mated cultures were diluted 1/10 in 0.9% NaCl solution and 100 μl of 




At the end of 3 days, prey clones that resulted in colonies when mated with NFIB2 
expressing bait clone, and no colony when mated a clone transformed with empty 
vector were considered to be genuine interactors. 
2.2.7 Sequence analysis 
Once the genuine positive clones were identified by yeast mating, the prey plasmids 
isolated from these clones were sequenced to identify these interactors. Sequencing 
analysis was performed with T7 Sequencing Primer by IonTek, Turkey. The 


























3.1 Construction of Bait Plasmid 
We cloned mouse Nfib3 cDNA and Nfib3 transcription modulation domain (aa 209-
420) as they are cloned in pCHNFI-B2 vector, in this thesis they will referred to as 
NFIB2 and NFIB2Δ, into pGBKT7 vector by PCR amplifying them from pCHNFI-
B2 vector. First, we restriction digested pGBKT7 vector with SalI and XmaI 
restriction enzymes, then we amplified NFIB2 and NFIB2Δ cDNA fragments from 
pCHNFI-B2 vector, and eventually, we cloned them to linearized pGBKT7 vector 
with Clontech InFusion Cloning System. 
 
Figure 3.1 Gel image of PCR amplified NFIB2 insert (Lane 1: NFIB2 cDNA PCR-
amplified from pCHNFI-B2 Vector, Lane 2: Fermentas GeneRulerTM 1 kb DNA 
Ladder, Lane 3: NFIB2Δ cDNA PCR-amplified from pCHNFI-B2 Vector). 
Once the InFusion cloning reaction was complete, a fraction of the reaction mix was 
transformed into E.coli. Only 3 colonies were obtained for pGBKT7-NFIB2 cloning 
reaction and 2 colonies for pGBKT7-NFIB2Δ (none for negative control). Plasmid 
DNA was purified from these colonies and checked for presence of insert by 




Figure 3.2 Gel image of cloned NFIB2 insert (Lane 1: Fermentas GeneRulerTM 1 kb 
DNA Ladder, Lane 2: Linearized pGBKT7 with NFIB2 Insert, Lane 3: Linearized 
pGBKT7, Lane 4: Linearized pGBKT7 with NFIB2Δ Insert).  
All 5 colonies were deemed to contain inserts and were subjected to DNA 
sequencing analysis to check if NFIB2 and NFIB2Δ were cloned into pGBKT7 
expression vector correctly and if their sequence were the same as its original 
sequence in pCHNFI-B2 vector. Seeing that the sequences of cloned fragments 
corresponded to the expected NFIB2 and NFIB2Δ sequences and were cloned in 
frame, we proceeded with the control experiments. The sequence data for pGBKT7-
NFIB2 and pGBKT7-NFIB2Δ are shown in Appendix A. 
3.2 Control Experiments 
Before performing the yeast two hybrid screen, we conducted a series of contol 
experiments. These experiments comprised control for bait expression, control for 
bait toxicity, control for bait autoactivation, and control for mating. 
The bait vector must express GAL4-DNA-BD-NFIB2 fusion protein in order to 
detect interactions with prey proteins. We verified that Y2HGold colonies 
transformed with pGBKT7-NFIB2 expressed NFIB2 fusion protein by Western Blot 
analysis using GAL4-DNA-BD and α-NFI antibodies as shown in Figure 3.3. 
However, we could not detect a protein product of NFIB2 fusion protein with anti-
myc antibody (see section 4 for discussion). Additionally, the truncated version of 
fusion protein (NFIB2Δ) could not be detected with the α-NFI antibody as this 
antibody recognizes the N terminal domain. 
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Several colonies were tested for their ability to express NFIB2 fusion protein and the 
highest expressing clone (NFIB2-α3) was selected for library screening. The 
appearent molecular weights of the protein bands, which were determined by their 
relative mobility in SDS-PAGE with respect to protein molecular weight markers, 
were in accordance with the expected sizes of the bands as depicted in the Figure 
below. 
        a          b               c      d            e          f        
  
  GAL4-DNA-BD        α-NFI 
Figure 3.3 Control test for protein expression (a-b:Proteins labeled with GAL4-
DNA-BD antibody; c-f: Proteins labeled with α-NFI antibody; a,c,d,e,f: NFIB 
Protein fused to GAL4 DNA Binding Domain: 63 kDa; b:Murine p53 Protein: 57 
kDa) 
To check whether bait vectors are toxic to the cell we performed the following test. 
Y2HGold competent cells were transformed with pGBKT7-NFIB2, pGBKT7-
NFIB2Δ constructs or the pGBKT7 vector and grown on SD/-Trp plates. After 4 
days, the number of resulting colonies were counted and diameters of colonies 
transformed with different vectors were compared. According to the results as shown 
in Table 3.1, there was no evidence of toxicity as the colonies of fusion proteins were 
similar to colonies of no fusion protein in number and in diameter. 
Table 3.1 Results of toxicity test 






pGBKT7 1/10 SD/-Trp 69 2mm 6,9×104 
pGBKT7-NFIB2 1/10 SD/-Trp 77 2mm 7,7×104 
pGBKT7- NFIB2Δ 1/10 SD/-Trp 50 2mm 5,0×104 
 
pGBKT7 1/100 SD/-Trp 10 2mm 1,0×105 
pGBKT7-NFIB2 1/100 SD/-Trp 12 2mm 1,2×105 
pGBKT7- NFIB2Δ 1/100 SD/-Trp 14 2mm 1,4×105 
  
In the autoactivation test, we tested if bait protein autonomously activates the 
reporter genes in Y2HGold in the absence of a prey protein. According to the results 
given in Table 3.2., NFIB2 did not autoactivate, however, there was a significant 
autoactivation by the NFIB2Δ fusion protein as SD/-Trp/X-α-Gal/AbA plate gave 
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blue colonies. Therefore, following control tests, we performed mating experiments 
only with NFIB2 fusion protein. 
Table 3.2 Results of autoactivation test 
Vector Medium Color of Cells 
pGBKT7-NFIB2 
 
SD/-Trp White cells 
SD/-Trp/X A mix of blue and pale blue cells 




SD/-Trp White cells 
SD/-Trp/X Blue cells 
SD/-Trp/X/A Blue cells 
 
Finally, a mating control was conducted to optimize the procedures of the two-hybrid 
screen. For positive mating, pGBKT7-53 that encodes the Gal4 DNA-BD fused to 
murine p53 and pGADT7-T that encodes the Gal4 AD fused with SV40 large T-
antigen were mated.  We also performed a negative control using pGBKT7-Lam 
(which encodes the Gal4 BD fused with lamin) and pGADT7-T. The following 
results were obtained from mating control: 
Table 3.3 Results of mating control 
Vector 1 Vector 2 Dilution Medium 
Colony 
Number 
pGBKT7-53 pGADT7-T 1/100 SD/-Leu /-Trp/X-α-gal-AbA 10 
pGBKT7-53 pGADT7-T 1/100 SD/-Leu /-Trp 18 
pGBKT7-53 pGADT7-T 1/100 SD/-Leu >1000 
pGBKT7-53 pGADT7-T 1/100 SD/-Trp >1000 
     
pGBKT7-53 pGADT7-T 1/10 SD/-Leu /-Trp/X-α-gal-AbA 96 
pGBKT7-53 pGADT7-T 1/10 SD/-Leu /-Trp 176 
pGBKT7-53 pGADT7-T 1/10 SD/-Leu >2000 
pGBKT7-53 pGADT7-T 1/10 SD/-Trp >2000 
 
According to the results, the colonies were mated properly. 
3.3 Yeast Two Hybrid Mating and Screening 
To screen for NFIB binding proteins, a concentrated bait culture of NFIB2-α3 was 
prepared and the library aliquot was thawed.  
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After number of cells in bait and prey cultures were counted, cultures were combined 
in a sterile 2L flask. At this stage, the concentrations of bait culture and prey aliquot 
were 2.9 × 108 cell/ml and 1.39 ×109 cell/ml, respectively. 
The process of mating was first checked at 20-hours. Since only small number of 
diploids were seen under microscope, we waited an additional 2 hours and then 
harvested the cells. Finally, we resuspended cells in 10 ml 0.5X YPDA/Kan liquid 
medium resulting in a total suspension volume of 13.5 ml. This suspension was 
spread on 54 × 150 mm DDO agar plates and incubated at 30°C for 3 days. 
3.3.1 Calculating mating efficiency 
A mating efficiency between 2–5% is reported to indicate succesful mating.  In order 
to calculate the mating efficiency, one needs to first determine the limiting partner 
among prey and bait cultures. The limiting partner is the one its number of cfu/ml 
value is less than the other partner. The formula to calculate number of cfu/ml is 
given below; 
Number of cfu/ml = [Number of cfu × 1000 µl/ml] / [Volume Plated (µl) × Dilution 
factor] 
According to our results, the limiting parner is the prey library. Since less diluted 
plates resulted in too many colonies to count, we only focused on 1/10,000 dilution 
plates. Our results were as follows; 
1/10,000 SD/-Leu/-Trp → 24 (for diploids) 
1/10,000 SD/-Leu → 224 (for prey) 
1/10,000 SD/-Trp → 2000 (for bait) 
Applying the formula above, we found the following Number of cfu/ml values; 
Number of cfu/ml for SD/-Leu/-Trp → 2.4 × 106 
Number of cfu/ml for SD/-Leu → 2.24 × 107 
Number of cfu/ml for SD/-Trp → 2 × 108 
Since mating efficiency is expressed as the ratio of number of dipoid cells to the 
number of cells of limiting partner, our mating efficiency was as follows; 






3.3.2 Counting the number of clones screened 
The number of screened clones (diploids) was calculated by counting the colonies 
from the DDO plates (24 colonies on 1/10,000 dilution plates) after 4 days and 
applying following formula; 
Number of Screened Clones = cfu/ml of diploids × resuspension volume (ml) 
According to this formula, the number of clones we screened was as follows: 
Number of Screened Clones = 2.4 × 106 × 13.5 = 32.4 million 
3.4 Confirmation of positive interactions 
To confirm positive interactions, we performed higher stringency streaking, yeast 
colony PCR, restriction digestion, and multiple streaking experiments. 
3.4.1 Plating on higher stringency medium  
470 blue colonies from 150 mm plates were streaked on higher stringency agar 
plates, QDO/A. At the end of 3 days, 258 grew and gave blue colonies. When these 
were streaked on QDO/X/A plates, 57 blue colonies were obtained. These 57 
colonies were further analyzed by yeast colony PCR. 
3.4.2 Yeast colony PCR 
Using Matchmaker™ AD LD-Insert Screening Amplimers, we performed colony 
PCR to screen for colonies that contained more than one prey vector. PCR products 
were analyzed by agarose gel electrophoresis (Figure 3.4).  
 
Figure 3.4a Gel image of yeast colony PCR (10 µl of Colony PCR product was run 




Figure 3.4b Gel image of yeast colony PCR (10 µl of Colony PCR product was run 
on 1% agarose gel) 
 
Figure 3.4c Gel image of yeast colony PCR (10 µl of Colony PCR product was run 
on 1% agarose gel) 
As seen in the images, most of the bands are in the 1000 bp-2000 bp range. 
3.4.3 Restriction digestion of colony PCR products 
Restriction digestion analysis of yeast colony PCR products was performed with 
HaeIII. Following restriction reaction, the digested samples were analyzed by 




Figure 3.5a Gel image of restricted fragments with HaeIII (10 µl of restriction 
product was run on 2%  agarose gel)  
 
Figure 3.5b Gel image of restricted fragments with HaeIII (10 µl of restriction 
product was run on 2%  agarose gel) 
 
 
Figure 3.5c Gel image of restricted fragments with HaeIII (10 µl of restriction 
product was run on 2%  agarose gel) 
Based on the information obtained from restriction digestion as seen in the Figure 
3.5a and 3.5b and 3.5c, some of clones were thought to be the identical in length and 
these were then run on agarose gel again. The ultimate comparison of these clones 
are shown in Figure 3.6a and 3.6b. 
5 of the total number of colonies (39-3, 7-1, 6-5 and 1-4, 26-11) were determined to 




Figure 3.6a Gel Image of restriction fragments of similar length (10 µl of restriction 
product was run on 2%  agarose gel stained with PronaSafe dye) 
 
Figure 3.6b Gel image of restriction fragments of similar length (10 µl of restriction 
product was run on 2%  agarose gel stained with PronaSafe dye) 
3.4.4 Multiple streaking 
Multiple streaks were performed to increase the chance of rescuing the positive prey 
plasmid. For this, blue colonies from QDO/X/A plates were restreaked on DDO/X, 
each time picking a single blue colony for restreaking. At the end of 2 streaks, the 
total number of colonies decreased to 49 as 5 colonies were white only. Next, these 
clones were tested for their ability to activate AUR1-C, HIS3 and ADE2 reporters. 
To do this, we picked blue colonies from DDO/X plates and streaked them on 
QDO/A plates. The number of surviving clones decreased to 40. Then, we proceeded 
with plasmid rescue from each one of these clones. 
3.5 Distinguishing Genuine Interactions 





3.5.1 Yeast mating 
In order to reveal genuine interactions between bait and potential prey canditates, we 
performed final yeast mating experiments. For this, we used bait colonies of NFIB2-
α3 and prey colonies of Y187 into which we previously transformed prey vectors.  
The number of prey clones that we investigated in this final mating procedure was 40 
and 24 of these clones which were mated with NFIB2-α3 gave colonies on QDO/A 
plates but no colonies on QDO/A plates when mated with empty vector (outlined in 
Table 3.4, underlined numbers correspond to clones which were considered as 
positive). The number of colonies were greater than 1000 on all DDO plates. We 
then sent the plasmid DNAs of these positive clones to sequencing. 
Table 3.4 Plate results of final yeast mating  
3.6 Sequence Analysis  
Out of 40 prey clones identified with yeast two hybrid screening, 24 were sent to 
sequencing. 4 clones were detected to code for the same protein, 4 clones 
corresponded to noncoding genomic sequences, 3 clones were not in frame with Gal4 
Colony 
Number 




Control Plate ↔  
NFIB2-α3 Plate 
34-10 0 ↔ >100 24-4 78 ↔ 30 
16-11 0 ↔ 4 20-11 134 ↔ >400 
1-4 0 ↔ >100 48-6 28 ↔ 162 
54-7 0 ↔ >100 9-2 >100 ↔ >100 
49-2 0 ↔ >100 7-1 >100 ↔ >100 
21-2 0 ↔ 26 35-8 0 ↔ 13 
28-9 2 ↔ 26 54-6 0 ↔ 24 
31-10 8 ↔ 41 26-10 >100↔ >200 
31-7 >1000↔ >1000 53-8 >1000 ↔ >1000 
27-3 0 ↔ 0 22-2 0 ↔ >100 
53-9 0 ↔ 0 48-5 0 ↔ >100 
25-13 0 ↔ 36 51-4 0 ↔ >100 
50-5 0 ↔ 52 13-4 17 ↔ >200 
38-1 0 ↔ 38 24-1 16 ↔ >100  
20-9 0 ↔ >100 49-3 0 ↔ >100 
23-3 0 ↔ >100 5-8 0 ↔ >100 
16-9 0 ↔ >100 16-1 0 ↔ >100 
14-1 0 ↔ 28 14-3 0 ↔ >100 
4-4 1 ↔ 218 11-7 >1000 ↔ >100 
43-3 >1000 ↔ 179 32-2 0 ↔ >100 
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activation domain and one clone corresponded to 3’UTR of a protein and they were 
eliminated. Consequently, 12 were found to code for a full or a partial protein. These 
proteins are listed below:  
Homo sapiens LIM domain only 4 (LMO4), mRNA 
LMO4 gene encodes a cysteine-rich protein that contains two LIM domains but lacks 
a DNA-binding homeodomain. It is a transcription factor and it shows its 
transcription modulation activity by interacting selectively and non-covalently with a 
specific DNA sequence, with a transcription factor, with an enhancer, or with zinc 
(Zn) ions.  
LMO4 plays essential roles in the developing brain. The loss of LMO4 in the cortex 
results in neurogenesis defects whereas its expression facilitates differentiation of 
cortical neurons (Asprer et al., 2011). Its function has been shown in neural tube 
closure (Hahm et al.,2004; Lee et al., 2005) and development of the neural tube in 
mice (Tse et al., 2004). It was proposed to have role in the diversity of motor cortex 
projection neuron subpopulations (Cederquist et al., 2013) and in the balanced 
generation of inhibitory and excitatory neurons in the ventral spinal cord (Joshi et al., 
2009). 
The effects of LMO4 in neurodegenerative diseases were also investigated. Its high 
level of expression in the entorhinal cortex (EC) and in the CA1 hippocampal region 
was seen in healthy brains whereas a consistent decrease in the expression of LMO4 
was observed in AD brains (Leuba et al., 2004). In protecting neurons from ischemic 
injury after stroke requires LMO4 (Schock et al., 2008).  
LMO4 was found to interact with several proteins such as CREB in calcium-
dependent gene expression (Kashani et al.2006), nuclear LIM interactor (NLI) in 
mediating nuclear retention of LMO proteins in the early embryo (Kenny et al., 
1998), basic Helix-Loop-Helix protein (HEN1) in modulating transcriptional activity 
of HEN1 in neuronal cells (Manetopoulos et al., 2003), peroxisome proliferator-
activated receptor gamma (PPARγ) in PPARgamma signaling to protect cortical 
neurons from ischemic injury (Schock et al., 2008) and Neogenin in repulsive axon 
guidance in human neuronal cells and in rat primary neurons (Schaffar et al., 2008). 
The expression of LMO4 was detected in many tissues throughout human body but 
particularly high expression was seen in fetal brain and prefrontal cortex (Url-1). The 
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localization of LMO4 at sub-cellular level was detected primarily in the nucleus with 
a substantial amount also detected in the cytoplasm (HPRD: 09122). 
Homo sapiens prosaposin (PSAP), transcript variant 3, mRNA   
This gene encodes a highly conserved glycoprotein which is a precursor for 4 
cleavage products: saposins A, B, C, and D. They localize primarily to the lysosomal 
compartment where they facilitate the catabolism of glycosphingolipids with short 
oligosaccharide groups. It exists both as a secretory protein and as an integral 
membrane protein. Its greatest expression in the brain was seen in hypothalamus, 
thalamus and prefrontal cortex.  
PSAP is suggested to be an essential neurotrophic factor and vital for the survival of 
cortical neurons as its deﬁciency resulted in massive neuronal loss (Sikora et al., 
2007). PSAP-/- mice was shown to have a short life span (30 days) and central 
nervous system (CNS) neuronal degeneration (Chu et al., 2005). One of four 
glycoproteins (saposin C) encoded by PSAP was suggested to play a role in axonal 
membrane homeostasis, as disruption of saposin C resulted in neurodegeneration in 
lysosomal storage disease (Yoneshige et al., 2010). It was proposed that neural 
progenitor cells secrete PSAP to defend neighboring mature neurons from apoptosis 
upon injury (Li et al., 2010). 
By performing yeast two-hybrid screen using human fetal brain cDNA, PSAP was 
found to ineract with TFPI-2 (tissue factor pathway inhibitor-2) and this interaction 
inhibits PSAP, leading to the inhibited abilities of invasion, migration and even 
metastasis of malignant tumour cells (Xu et al., 2012). Another yeast two-hybrid 
screen revealed that PSAP interacts with Rhox5 and this interaction was hypotesized 
to regulate the development of male reproductive organs dynamically (Guo et al., 
2007). 
Mutations in this gene have been associated with Gaucher disease, Tay-Sachs 
disease, and metachromatic leukodystrophy. 
Homo sapiens peptidylprolyl cis/trans isomerase, NIMA-interacting 1 (PIN1), 
transcript variant 1, mRNA 
PIN1 gene encodes one of the PPIases (Peptidyl-prolyl cis/trans isomerases) that 
specifically binds to phosphorylated ser/thr-pro motifs to catalytically regulate the 
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post-phosphorylation conformation of its substrates via cis/trans isomerization of 
peptidyl-prolyl peptide bonds.  
Pin1 was shown to be highly expressed in NPCs at the late developmental stage and 
has a major impact on their neuronal differentiation (Nakamura et al., 2010). In 
differentiating neurons an interaction between BNIP-H and Pin1 was identified 
which may provide a post-translational regulation on the cellular activity of BNIP-H 
during neuronal differentiation (Buschdorf et al., 2008). β-catenin was identified as 
an interactor of Pin1 in neural progenitor cells and upon interaction, Pin1 stabilizes 
β-catenin by inducing conformational changes after phosphorylation (Nakamura et 
al., 2010). 
Pin1 was also shown to be involved in neurodegenerative disorders. Pin1 was 
proposed to play a role in Parkinson disease (PD) by mediating Lewy body 
formations which is an indication of PD (Ryo et al., 2006). PIN1 was shown to 
interact with tau in Alzheimer's disease (AD) brain and this interaction is thought to 
restore the ability of tau to bind microtubules and promote microtubule stability 
(Dakson et al., 2011). Pin1 dysregulation has been proposed to affect the progression 
of neurodegenerative pathology as Pin1 inhibition was shown to up-regulate cyclin 
D1 and caspase 3 producing apoptosis in cultured rat hippocampal neurons (Atabay 
and Karabay, 2012). 
While its expression was detected in liver, kidney, blood, heart, expression of PIN1 
in the brain is higher than that of in other organs (Url-2). At the sub-cellular level, 
PIN1 protein is mainly localized in nucleus as well as the cytoplasm (HPRD:03031).  
Homo sapiens microtubule-associated protein 1B (MAP1B), mRNA 
MAP1B encodes a protein that belongs to the microtubule-associated protein family. 
The proteins of this family are thought to be involved in microtubule assembly, 
which is an essential step in neurogenesis.  
MAP1B was found to interact with metabotropic glutamate receptor 4 (mGluR4), a 
G-protein-coupled receptor that mediates inhibition of neurotransmitter release. 
Since MAP1B and mGluR4 colocalize at excitatory synapses in cultured 
hippocampal neurons, it was proposed that MAP1B might be implicated in the 
synaptic trafficking and/or regulation of mGluR4 (Moritz et al.,2009). By two-hybrid 
and pull-down assays, α-, β-, and βIII-tubulins were found to interact with MAP1B 
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1-126 and since overexpression of MAP1B 1-126 induced both neurite extension and 
neuronal death it was proposed that MAP1B 1-126 could be involved in neuronal 
degeneration (Gomi and Uchida, 2012). A possible interaction between MAP1B and 
tubulin tyrosine ligase was shown and it was suggested that this interaction may be 
important for general processes involved in nervous system development such as 
axonal guidance and neuronal migration (Utreras et al., 2008). Fujiwara et al. found 
that neuronal Hu proteins directly interact with the light chain of microtubule-
associated proteins MAP1B (LC1) and suggested that Hu proteins are involved in 
microtubule-mediated regulation of mRNA expression within neuronal processes 
(Fujiwara et al.,2011). 
At the sub-cellular level, it is primarly localized at cytoplasm and cytoskeleton and 
alternatively in nucleus and on plasma membrane and its expression is high in 
cerebellum, cerebrum, fetus and neuron during development (HPRD: 01139). 
Homo sapiens ataxin 3 (ATXN3), transcript variant o, mRNA 
ATXN3 has deubiquitinase activity and appears to be a component of the ubiquitin 
proteasome system. It may also have roles in transcriptional regulation and 
neuroprotection (reviewed by Haacke et al., 2006). 
The protein encoded by ATXN3 contains (CAG)n repeats in the coding region, and 
the expansion of these repeats from the normal 13-36 to 68-79 is one of the causes of 
Machado-Joseph disease(also known as spinocerebellar ataxia-3), an autosomal 
dominant neurologic disorder (Bettencourt e al., 2012). 
By performing yeast two hybrid and GST pull-down assays, it was demonstrated that 
ATXN3 is able to establish a direct interaction with NEDD8, through its Josephin 
domain (JD) and it was proposed that this interaction may add a new perspective to 
the possible physiological role of ATXN3 modulating the activity of the ubiquitin–
proteasome system (Ferro et al., 2007). Other identified interactors of ATXN3 are 
proteasome-binding factors Rad23 and valosin-containing protein (VCP/p97) (Doss-
Pepe et al., 2003), HHR23A and HHR23B (Wang et al., 2000). 
The expression of ATXN3 in CNS is mainly in caudate nucleus, cerebellum, frontal 
cortex, pons. While in neurons, ATXN3 was shown to predominantly localize in 
cytoplasm (Paulson et al.,1997), ATXN3 becomes concentrated in the nucleus of 
neurons during disease (Bettencourt and Lima, 2011). 
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SGIP1 SH3-domain GRB2-like (endophilin) interacting protein 1 (SGIP1): SGIP1 is 
an endocytic protein that affects signaling by receptors in neuronal systems involved 
in energy homeostasis via its interaction with endophilins (Trevaskis et al., 2005; 
Uezu et al., 2007). The processes that SGIP1 is involved are endocytosis, positive 
regulation of energy homeostasis, positive regulation of feeding behavior, positive 
regulation of receptor-mediated endocytosis and response to dietary excess. It 
interacts with SH3 domains (Src homology 3) of proteins. Trevaskis et al. (2005) 
showed that SGIP1 interacts with endophilin-3 and endophilin-1 via the SGIP1 
central proline-rich region. Other interactors of SGIP1 are AMPH, Eps15, ITSN1, 
REPS1. Its expression was detected in many tissues throughout human body such as 
adipose, blood, breast, colon, kidney, lung, ovary, prostate, skeletal muscle. 
However, its expression was also seen in brain regions such as cerebellum, frontal 
cortex and frontal lobe. Trevaskis et al. (2005) performed RT-PCR of P. obesus 
tissues and detected strong expression in brain, particularly in cerebellum, cortex, 
and midbrain. At sub-cellular level, SGIP1 protein is localized in the plasma 
membrane, clathrin-coated pits and in the cytoplasm. 
Homo sapiens 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) (HMGCS1), 
transcript variant 1, mRNA 
HMGCS1 is an enzyme that condenses acetyl-CoA with acetoacetyl-CoA to form 
HMG-CoA, which is the substrate for HMG-CoA reductase. The processes in which 
HMGCS1 involves are cellular lipid metabolic process, cellular response to 
cholesterol and hormone stimulus, response to acid and drug, liver and brain 
development. The expression of this protein in fetal brain is high.  At the sub-cellular 
level, HMGCS1 protein is localized in the cytoplasm. 
Homo sapiens nitrogen permease regulator-like 2 (S. cerevisiae) (NPRL2), mRNA 
NPRL2 suppresses Src-dependent tyrosine phosphorylation and activation of PDPK1 
and its downstream signaling. Its main functions are negative regulation of kinase 
activity and protein phosphorylation. It is also known as tumor suppressor candidate 
4. The expression of a NPRL2 transcript was found to be most abundant in skeletal 
muscle, followed by brain, liver, and pancreas. At the sub-cellular level, it is 




Homo sapiens complement component 1, q subcomponent, A chain (C1QA), mRNA 
C1QA encodes a major constituent of the human complement subcomponent C1q. 
C1q associates with C1r and C1s in order to yield the first component of the serum 
complement system. Deficiency of C1q has been associated with lupus 
erythematosus and glomerulonephritis. The processes in which C1QA is involved are 
cell-cell signaling, complement activation, innate immune response. Stevens et al. 
(2007) found that expression of mouse C1q by postnatal neurons is induced by 
immature astrocytes and C1q protein localized to synapses throughout the postnatal 
central nervous system (CNS) and retina. C1QA is an extracellularly localized 
protein. 
Homo sapiens MAD2 mitotic arrest deficient-like 2 (yeast) (MAD2L2), transcript 
variant 1, mRNA 
MAD2L2 is a component of the mitotic spindle assembly checkpoint that prevents 
the onset of anaphase until all chromosomes are properly aligned at the metaphase 
plate. In S. cerevisiae, members of the MAD (mitotic arrest deficient) encode 
proteins that play a role in the mitotic spindle checkpoint, its defects have been 
implicated in the aneuploidy observed in human cancer cells. The processes in which 
MAD2L2 is involved are DNA repair, mitotic spindle assembly checkpoint, actin 
filament organization. At the sub-cellular level, it is primarily localized in the 
nucleus and alternatively in the cytoplasm. 
Homo sapiens syndecan binding protein (syntenin) (SDCBP), transcript variant 1, 
mRNA 
SDCBP was initially identified as a molecule linking syndecan-mediated signaling to 
the cytoskeleton. The syntenin protein contains tandemly repeated PDZ domains that 
bind the cytoplasmic, C-terminal domains of a variety of transmembrane proteins. 
This protein may also affect cytoskeletal-membrane organization, cell adhesion, 
protein trafficking, and the activation of transcription factors. The syntenin-1 protein 
associates with Neurofascin, which stimulates neurite outgrowth in chicken tectal 
neurons (PMID: 10662501, PMID: 19356150). This protein is primarily localized to 
membrane-associated adherens junctions and focal adhesions but is also found at the 
endoplasmic reticulum and nucleus.  
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Homo sapiens SEC31 homolog A (S. cerevisiae) (SEC31A), transcript variant 6, 
mRNA 
SEC31A protein is similar to yeast Sec31 protein, a component of the COPII protein 
complex that is responsible for vesicle budding from endoplasmic reticulum (ER). 
The main processes in which MAD2L2 is involved are ER to Golgi vesicle-mediated 
transport, cellular membrane organization, COPII vesicle coating. This protein is 
primarily localized to the endoplasmic reticulum as well as the cytoplasm, golgi 






















4.1 Potential NFIB Interacting Proteins 
The yeast two hybrid stystem revealed 12 genuine interactions. While most of them 
seem to less likely to interact with NFIB, 5 of them (ATXN3, MAP1B, PIN1, PSAP, 
LMO4) are strong candidates to be potential NFIB interactors. 
LMO4 modulates trancription by binding other transcription factors. Its expression in 
fetal brain is high and it plays roles in spinal cord and in intermediate neuron 
differentiation. At sub-cellular level, it localizes in nucleus. So, it seems to be an 
important canditate in terms of interacting with NFIB. 
PIN1 protein codes for one of PPIases (Peptidylprolyl cis-trans isomerases), and 
regulates the conformation of substrates following phosphorylation. Besides its 
functions in cell growth, immune and stress response, pluripotent germ cell 
maintenance and induction, it also plays role in neuron differentation and 
maintenance. It is also known that this protein is involved in Alzheimer and 
neurodegenerative disorders. That it is localized in nucleus increases the its 
possibility to interact with NFIB. 
MAP1B protein is primarly localized in cytoplasm, not in nucleus. However since it 
is involved in microtubule formation, a main process in neurogenesis, it draws 
attention. Additionally, it is important that this protein was shown to play role in 
neural development through gene deletion studies and that its expression is high in 
cerebellum, cerebrum during development. 
ATXN3 protein is thought to play role in proteasome system due to its 
deubiquitinase activity. Interestingly, it is involved in Machado-Joseph disease, an 
autosomal dominant neurologic disorder. Additionally, it plays role in transcriptional 
regulation and neuroprotection. It has strong expression in central nervous system 




PSAP is a protein which is involved in processes such as blood coagulation and lipid 
metabolism. It can function both as a secretary protein and as an integral protein. 
Altough it does not seem to be involved in processes associated with NFIB, it can 
show neurotrophic activity, and it is involved in maintenance of neurons and because 
of these, it may interact with NFIB in nucleus.  
SGIP1 plays roles in the endocytosis related processes. It generally bind to 
membrane associated proteins via its SH3 domain. Altough its expression are seen in 
cerebellum, cortex, and midbrain, it is localized in membrane and in clathrin coated 
vesicles. Since NFIB protein is localized in nucleus, the probability that NFIB and 
SGIP1 interact wih each other is low.  
HMGCS1 is basically involved in lipid metabolism, cholesterol and hormonal 
stimulus. At sub-cellular level, it is located in cytoplasm. Altough it was not proven 
experimentally, the algorithms in electronic databases reveal that it may play a role 
in brain development. 
NPRL2 is a protein which is involved in protein phosphorylation and regulation of 
kinase activity. Since it is primarly expressed in skeletal muscle and it was not 
detected to play a role in neurological processes, it is not expected for this protein to 
interact with NFIB. 
C1QA protein codes for some members of serum complement system which plays 
role in autoimmune reaction development in humans. It has functions in cell 
signaling, in activation of complement system, and in immun response. Since C1QA 
protein plays roles in postnatal neurons, and is subcellularly localized in cytoplasm, 
not in nucleus, it seems to be a low possibility that this protein interacts with NFIB in 
developing brain. 
MAD2L2 protein plays role in controlling that chromosomes are aligned correctly 
before anaphase stage in cell cycle as a component of mitotic spindle assembly 
checkpoint. It is primarly localized in nucleus but no relation of this protein with 
neurological processes was detected so there is no clue that MAD2L2 may interact 
with NFIB. 
SDCBP protein binds to C-terminal domains of transmembran proteins and is 
involved in syndecan mediated signaling to cytoskeleton. Beside its role in protein 
trafficking, cell adhesion, cytoskeletal-membrane organization processes, it is 
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interesting that this protein  is associated with Neurofascin protein which stimulates 
neurite outgrowth. 
SEC31A protein is involved in processes such as transport between endoplasmic 
reticulum (ER) and Golgi apparatus, vesicle coating and membrane organization. 
Since it is primarily localized in ER and it was not detected to be involved in 
neurological processes, it is unlikely that SEC31A protein interacts wih NFIB.  
4.2 Technical Issues 
4.2.1 Final mating procedure 
To prove genuine interactions of prey and bait proteins, we tried to co-transform bait 
and prey vectors first into competent Y2HGold yeast cells. However, after growing 
transformed cells on QDO/A medium for 3 days, we had difficulty achieving 
sufficient transformation efficieny. The number of colonies on DDO plates were very 
low, and the number of colonies on QDO/A plates were zero indicating that a 
significant amount yeast cells did not take in the two different plasmids, hindering 
detection of interactions. 
The probability of transforming the same yeast cell with multiple vectors is very low. 
Therefore, Y2HGold cells that expressed bait protein (NFIB2-α3) were transformed 
with prey expressing vectors (sequential transformation). While these experiments 
performed better than simultaneous transformation, the efficiency was still low. 
Finally genuine interactors were determined by mating experiments as described for 
control mating procedures. This “final mating experiments” circumvented the 
problem and we obtained sufficient number of colonies on QDO/A plates and 
distinguished genuine interactions. 
4.2.2 Autoactivation control 
In the autoactivation experiment, we did not see any autoactivation with the plasmid 
containing NFIB2 cDNA. However, the truncated version of NFIB2 spanning the 
transcription modulation domain (NFIB2Δ) autoactivated reporters. This construct 
was then discarded. 
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It appears that NFIB activation domain (209-420 aa)  has the capability to auto-
activate these reporters in yeast and that the DNA-Binding Domain of NFIB prevents 
complete protein from auto-activating reporters.  
4.2.3 Control for protein expression of bait vector  
Additionally, eventhough both pGBKT7-53 and pGBKT7-NFIB2 constructs contain 
the same sequence specific to anti-c-myc antibody, we detected pGBKT7-53 cDNA 
expression with anti-c-myc antibody, while we could not detect the expression of 
NFIB2 or NFIB2Δ. It is possible that  GAL4-DNA-BD- NFIB2 fusion protein folds 
in such a way that the myc epitope is not exposed. The fact that the NFI antibody 
detected a protein of expected size and anti GAL4-DBD antibody also detected the 
same protein indicated that the NFIB2 fusion protein was expressed as expected. 
When we tested protein expression of NFIB2Δ fusion protein with α-NFI antibody, 
we could not detect a band for this protein. The reason for this is that the NFI  
antibody (H-300) is a rabbit polyclonal IgG its epitope corresponds to amino acids 1-
300 mapping at the N-terminus of NFI proteins of human origin. However, the 
NFIB2Δ fusion protein comprised only the C-terminus of NFIB2 protein. 
4.2.4 Yeast two hybrid technique 
Y2H is a very powerful technique that is extensively used in protein-protein 
interaction studies. It is superior to bacterial expression systems as it embodies an in 
vivo technique using the yeast host cell. 
In this thesis project, although we have identified novel interaction partners of NFIB, 
we could not detect the proteins that were previously found to interact with NFIB. 
Additionally, NFI proteins are expected to interact with each other as they need to 
form dimers to be functional. 
One reason for this false negative interactions may be folding problems. We 
hypothesized that the presence of Gal4-DNA-BD in fusion protein may have 
negatively affected correct folding of NFIB. Another possibility is that Y2H screen 
could not detect transient interactions that normally occur in NFIB’s known 
interactions with other proteins. Lastly, the proteins may not have been cloned in 
correct reading frame. While in conventional Y2H screens, only one out of six fused 
cDNAs is in the correct reading frame (Criekinge and Beyaert, 1999), in this screen, 
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since we used a directional library, one out of three fused cDNAs are expected to be 






































5. CONCLUSION AND FUTURE DIRECTIONS 
In this study, we have isolated protential NFIB binding partners from Human Fetal 
Brain Library. We determined the identity of interacting proteins by sequencing their 
cDNAs and recovering the genes coding from these proteins by searching on the 
NCBI database. However, Yeast Two Hybrid technique does not exactly represent in 
vivo mammalian cell processes and these prey proteins may only interact with NFIB 
in an in vitro environment, rather than coming into proximity in vivo. Therefore, 
these interactions should be confirmed in mammalian cells. 
Coimmunoprecipitation may be a good start for further confirming the interactions of 
identified proteins. For this, we can incubate  mammalian cell or nuclear extracts 
with antibody coupled resin. After precipitating extracts and removing unbound 
proteins by washing, the elute can be analyzed in terms of containing interacted 
proteins. The interaction can then be resolved by SDS-PAGE and visualized by 
western blotting. 
GST-pulldown technique can be used to confirm coimmunoprecipitation results or 
can be directly applied to study instead of coimmunoprecipitation. In this technique 
we can tag one of our bait proteins with glutathione S-transferase (GST) and capture 
it on an immobilized affinity ligand specific for the tag. Subsequently, we can 
incubate this immobilized bait with cell extracts. After washing away unbound 
proteins, we can elute interaction complex and analyze it by SDS-PAGE and western 
blotting. 
A further step to prove interactions may be colocalization experiment. By applying 
fluorescence microscopy and via labelling two interacting proteins with fluorescent 
labels, we can observe the nearly localization of two proteins in the cell environment. 
Finally, the significance of these interactions can be investigated in vivo by setting 
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APPENDIX A  
1 ATGATGTATT CTCCCATCTG TCTCACTCAG GATGAATTCC ACCCATTTAT TGAGGCACTT 
61 CTTCCTCACG TCCGTGCAAT TGCCTATACT TGGTTCAACC TGCAGGCTCG AAAACGCAAG 
121 TACTTTAAAA AGCATGAGAA ACGAATGTCG AAGGATGAAG AAAGGGCAGT CAAAGACGAG 
181 CTGCTCAGTG AGAAGCCCGA AATCAAGCAG AAGTGGGCAT CCAGGCTCCT GGCCAAACTG 
241 CGCAAAGATA TCCGCCAGGA GTACCGGGAG GACTTTGTGC TTACCGTGAC TGGCAAGAAG 
301 CACCCGTGCT GTGTCTTATC CAATCCAGAC CAGAAGGGTA AGATTAGGAG GATCGACTGC 
361 CTGCGACAGG CAGACAAAGT CTGGCGTCTG GATCTAGTCA TGGTGATCCT GTTCAAAGGC 
421 ATCCCTTTGG AGAGTACGGA TGGAGAGCGA CTCATGAAGT CCCCGCACTG CACAAACCCA 
481 GCACTTTGTG TTCAGCCACA CCACATCACA GTATCAGTTA AGGAGCTTGA CTTGTTTTTG 
541 GCATACTACG TGCAGGAGCA AGATTCTGGA CAATCAGGAA GTCCAAGCCA CAGTGATCCT 
601 GCCAAGAATC CTCCAGGGTA CCTCGAGGAC AGCTTTGTAA AATCCGGAGT CTTCAATGTA 
661 TCAGAGCTTG TGAGAGTATC CAGAACACCC ATAACCCAGG GAACTGGAGT CAACTTCCCA 
721 ATCGGAGAAA TTCCCAGCCA ACCATACTAT CATGACATGA ACTCTGGTGT GAACCTGCAG 
781 AGGTCGCTGT CTTCTCCACC GAGCAGCAAA AGACCCAAAA CTATATCTAT AGATGAAAAT 
841 ATGGAGCCAA GTCCTACAGG AGACTTTTAC CCCTCTCCAA ATTCACCAGC TGCTGGAAGT 
901 CGAACATGGC ATGAACGAGA TCAAGATATG TCTTCTCCAA CTACAATGAA GAAGCCTGAG 
961 AAGCCACTGT TTAGCTCTAC ATCTCCACAG GATTCTTCCC CAAGATTGAG CACTTTCCCC 
1021 CAGCACCATC ATCCCGGAAT ACCTGGAGTC GCGCACAGTG TCATCTCAAC TCGAACTCCA 
1081 CCTCCGCCCT CACCGTTGCC ATTTCCGACG CAAGCTATCC TTCCTCCGGC ACCTTCCAGC 
1141 TACTTCTCTC ATCCAACAAT CAGATATCCT CCTCACCTGA ATCCTCAGGA TACTCTGAAG 
1201 AACTACGTAC CTTCTTATGA CCCATCCAGT CCTCAAACGA GCCAGTCCTG GTACCTGGGC 
1261 TAG 
Figure A.1 Sequence data for NFIB2 insert. 
 
 
1 GAGGACAGCT TTGTAAAATC CGGAGTCTTC AATGTATCAG AGCTTGTGAG AGTATCCAGA 
61 ACACCCATAA CCCAGGGAAC TGGAGTCAAC TTCCCAATCG GAGAAATTCC CAGCCAACCA 
121 TACTATCATG ACATGAACTC TGGTGTGAAC CTGCAGAGGT CGCTGTCTTC TCCACCGAGC 
181 AGCAAAAGAC CCAAAACTAT ATCTATAGAT GAAAATATGG AGCCAAGTCC TACAGGAGAC 
241 TTTTACCCCT CTCCAAATTC ACCAGCTGCT GGAAGTCGAA CATGGCATGA ACGAGATCAA 
301 GATATGTCTT CTCCAACTAC AATGAAGAAG CCTGAGAAGC CACTGTTTAG CTCTACATCT 
361 CCACAGGATT CTTCCCCAAG ATTGAGCACT TTCCCCCAGC ACCATCATCC CGGAATACCT 
421 GGAGTCGCGC ACAGTGTCAT CTCAACTCGA ACTCCACCTC CGCCCTCACC GTTGCCATTT 
481 CCGACGCAAG CTATCCTTCC TCCGGCACCT TCCAGCTACT TCTCTCATCC AACAATCAGA 
541 TATCCTCCTC ACCTGAATCC TCAGGATACT CTGAAGAACT ACGTACCTTC TTATGACCCA 
601 TCCAGTCCTC AAACGAGCCA GTCCTGGTAC CTGGGCTAG 















APPENDIX B  
Homo sapiens LIM domain only 4 (LMO4), mRNA 
Score = 1685 bits(912), Expect = 0.0, Identities = 21/925(99%) 
Gaps = 2/925(0%),Strand = Plus/Plus    
 
Query  102   GCGATTT-aaaaaaaaaaaaaaGCCGcccttagccccctcctcccctttcctgcttctgc  160 
             ||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   596   GCGATTTAAAAAAAAAAAAAAAGCCGCCCTTAGCCCCCTCCTCCCCTTTCCTGCTTCTGC  655 
 
Query  161   gagaactccctccctccctccagctccGCCAGCCCAGGCGCCCCTTCCCTGGAAGCCGAG  220 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   656   GAGAACTCCCTCCCTCCCTCCAGCTCCGCCAGCCCAGGCGCCCCTTCCCTGGAAGCCGAG  715 
 
Query  221   CGGCTTCGCTCGCATTTCACCGCCGCCGCCTCTCGCAATATTGCAATATAGGGGAAAAGC  280 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   716   CGGCTTCGCTCGCATTTCACCGCCGCCGCCTCTCGCAATATTGCAATATAGGGGAAAAGC  775 
 
Query  281   AGACCATGGTGAATCCGGGCAGCAGCTCGCAGCCGCCCCCGGTGACGGCCGGCTCCCTCT  340 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   776   AGACCATGGTGAATCCGGGCAGCAGCTCGCAGCCGCCCCCGGTGACGGCCGGCTCCCTCT  835 
 
Query  341   CCTGGAAGCGGTGCGCAGGCTGCGGGGGCAAGATTGCGGACCGCTTTCTGCTCTATGCCA  400 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   836   CCTGGAAGCGGTGCGCAGGCTGCGGGGGCAAGATTGCGGACCGCTTTCTGCTCTATGCCA  895 
 
Query  401   TGGACAGCTATTGGCACAGCCGGTGCCTCAAGTGCTCCTGCTGCCAGGCGCAGCTGGGCG  460 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   896   TGGACAGCTATTGGCACAGCCGGTGCCTCAAGTGCTCCTGCTGCCAGGCGCAGCTGGGCG  955 
 
Query  461   ACATCGGCACGTCCTGTTACACCAAAAGTGGCATGATCCTTTGCAGAAATGACTACATTA  520 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   956   ACATCGGCACGTCCTGTTACACCAAAAGTGGCATGATCCTTTGCAGAAATGACTACATTA  1015 
 
Query  521   GGTTATTTGGAAATAGCGGTGCTTGCAGCGCTTGCGGACAGTCGATTCCTGCGAGTGAAC  580 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   1016  GGTTATTTGGAAATAGCGGTGCTTGCAGCGCTTGCGGACAGTCGATTCCTGCGAGTGAAC  1075 
 
Query  581   TCGTCATGAGGGCGCAAGGCAATGTGTATCATCTTAAGTGTTTTACATGCTCTACCTGCC  640 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   1076  TCGTCATGAGGGCGCAAGGCAATGTGTATCATCTTAAGTGTTTTACATGCTCTACCTGCC  1135 
 
Query  641   GGAATCGCCTGGTCCCGGGAGATCGGTTTCACTACATCAATGGCAGTTTATTTTGTGAAC  700 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   1136  GGAATCGCCTGGTCCCGGGAGATCGGTTTCACTACATCAATGGCAGTTTATTTTGTGAAC  1195 
 
Query  701   ATGATAGACCTACAGCTCTCATCAATGGCCATTTGAATTCACTTCAGAGCAATCCACTAC  760 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   1196  ATGATAGACCTACAGCTCTCATCAATGGCCATTTGAATTCACTTCAGAGCAATCCACTAC  1255 
 
Query  761   TGCCAGACCAGAAGGTCCGCTAAAAGGTCAGAGTAATGCAGAATGCGTGCCTTCATCTCA  820 
             ||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||| 
LMO4   1256  TGCCAGACCAGAAGGTCTGCTAAAAGGTCAGAGTAATGCAGAATGCGTGCCTTCATCTCA  1315 
 
Query  821   GATTTGTTCATCACAGGTGGATCCCATGTGTCTTCAGTAGACAAGTCACCTTTGTAGCTA  880 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   1316  GATTTGTTCATCACAGGTGGATCCCATGTGTCTTCAGTAGACAAGTCACCTTTGTAGCTA  1375 
 
Query  881   GCACCAGTGCCAGCTCCATGCCATTGCACCTTCTTTAGTCTTGATTGCCCTTCCCGCATT  940 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   1376  GCACCAGTGCCAGCTCCATGCCATTGCACCTTCTTTAGTCTTGATTGCCCTTCCCGCATT  1435 
 
Query  941   TATTGGTGTATTAAAATGACTGAATATGAACATTAAGGACTCCATGAACCTGGGCTAATG  1000 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
LMO4   1436  TATTGGTGTATTAAAATGACTGAATATGAACATTAAGGACTCCATGAACCTGGGCTAATG  1495 
 
Query  1001  GGAGACTGTAGAGaaaaa-aaaaaa  1024 
             |||||||||||||||||  |||||| 
LMO4   1496  GGAGACTGTAGAGAAAATGAAAAAA  1520 
Figure B.1 Alignment data for LMO4 mRNA. 
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This insert sequence is homologous to nt 596-1520 of LIM domain only 4 (LMO4), 
mRNA. (NM_006769.3).. This partial cDNA sequence is fused in frame to the 
GAL4 DNA-BD and codes for the first 164 amino acids of 165 amino acid LMO4 
protein. 
Homo sapiens prosaposin (PSAP), transcript variant 3, mRNA   
Score = 1753 bits(949), Expect = 0.0,Identities = 969/977(99%) 
Gaps = 8/977(0%),Strand = Plus/Plus 
    
Query  105   AACCTGGAGAAAAACAGCACCAAGCAGGAGATCCTGGCTGCTCTTGAGAAAGGCTGCAGC  164 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1374  AACCTGGAGAAAAACAGCACCAAGCAGGAGATCCTGGCTGCTCTTGAGAAAGGCTGCAGC  1433 
 
Query  165   TTCCTGCCAGACCCTTACCAGAAGCAGTGTGATCAGTTTGTGGCAGAGTACGAGCCCGTG  224 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1434  TTCCTGCCAGACCCTTACCAGAAGCAGTGTGATCAGTTTGTGGCAGAGTACGAGCCCGTG  1493 
 
Query  225   CTGATCGAGATCCTGGTGGAGGTGATGGATCCTTCCTTCGTGTGCTTGAAAATTGGAGCC  284 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1494  CTGATCGAGATCCTGGTGGAGGTGATGGATCCTTCCTTCGTGTGCTTGAAAATTGGAGCC  1553 
 
Query  285   TGCCCCTCGGCCCATAAGCCCTTGTTGGGAACTGAGAAGTGTATATGGGGCCCAAGCTAC  344 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1554  TGCCCCTCGGCCCATAAGCCCTTGTTGGGAACTGAGAAGTGTATATGGGGCCCAAGCTAC  1613 
 
Query  345   TGGTGCCAGAACACAGAGACAGCAGCCCAGTGCAATGCTGTCGAGCATTGCAAACGCCAT  404 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1614  TGGTGCCAGAACACAGAGACAGCAGCCCAGTGCAATGCTGTCGAGCATTGCAAACGCCAT  1673 
 
Query  405   GTGTGGAACTAGGAGGAGGAATATTCCATCTTGGCAGAAACCACAGCATTGGtttttttC  464 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1674  GTGTGGAACTAGGAGGAGGAATATTCCATCTTGGCAGAAACCACAGCATTGGTTTTTTTC  1733 
 
Query  465   TACTTGTGTGTCTGGGGGAATGAACGCACAGATCTGTTTGACTTTGTTATAAAAATAGGG  524 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1734  TACTTGTGTGTCTGGGGGAATGAACGCACAGATCTGTTTGACTTTGTTATAAAAATAGGG  1793 
 
Query  525   CTCCCCCACCTCCCCCATTTCTGTGTCCTTTATTGTAGCATTGCTGTCTGCAAGGGAGCC  584 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1794  CTCCCCCACCTCCCCCATTTCTGTGTCCTTTATTGTAGCATTGCTGTCTGCAAGGGAGCC  1853 
 
Query  585   CCTAGCCCCTGGCAGACATAGCTGCTTCAGTGCCCCTTTTCTCTCTGCTAGATGGATGTT  644 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1854  CCTAGCCCCTGGCAGACATAGCTGCTTCAGTGCCCCTTTTCTCTCTGCTAGATGGATGTT  1913 
 
Query  645   GATGCACTGGAGGTCTTTTAGCCTGCCCTTGCATGGCGCCTGCTGGAGGAGGAGAGAGCT  704 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1914  GATGCACTGGAGGTCTTTTAGCCTGCCCTTGCATGGCGCCTGCTGGAGGAGGAGAGAGCT  1973 
 
Query  705   CTGCTGGCATGAGCCACAGTTTCTTGACTGGAGGCCATCAACCCTCTTGGTTGAGGCCTT  764 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   1974  CTGCTGGCATGAGCCACAGTTTCTTGACTGGAGGCCATCAACCCTCTTGGTTGAGGCCTT  2033 
 
Query  765   GTTCTGAGCCCTGACATGTGCTTGGGCACTGGTGGGCCTGGGCTTCTGAGGTGGCCTCCT  824 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   2034  GTTCTGAGCCCTGACATGTGCTTGGGCACTGGTGGGCCTGGGCTTCTGAGGTGGCCTCCT  2093 
 
Query  825   GCCCTGATCAGGGACCCTCCCCGCTTTCCTGGGCCTCTCAGTTGAACAAAGCAGCAAAAC  884 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   2094  GCCCTGATCAGGGACCCTCCCCGCTTTCCTGGGCCTCTCAGTTGAACAAAGCAGCAAAAC  2153 
 
Query  885   AAAGGCAGTTTTATATGAAAGATTAGAAGCCTGGAATAATCAGGCTTTTTAAATGATGTA  944 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   2154  AAAGGCAGTTTTATATGAAAGATTAGAAGCCTGGAATAATCAGGCTTTTTAAATGATGTA  2213 
 
Query  945   ATTCCCACTGTAATAGCATAGGGATTTTGGAAGCAGCTGCTGGTGGCTTGGGACATCAGT  1004 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PSAP   2214  ATTCCCACTGTAATAGCATAGGGATTTTGGAAGCAGCTGCTGGTGGCTTGGGACATCAGT  2273 
 
Query  1005  GGGGCCAAGG-TTCTCTGTCCCTGGT-CAACTGTGATT-GGCTTTCCCGTG-CTTTC-TG  1059 
             |||||||||| ||||||||||||||| ||||||||||| |||||||||||| ||||| || 
85 
 
PSAP   2274  GGGGCCAAGGGTTCTCTGTCCCTGGTTCAACTGTGATTTGGCTTTCCCGTGTCTTTCCTG  2333 
 
Query  1060  GTGA-GC-TTGTT-GGG  1073 
             |||| || ||||| ||| 
PSAP   2334  GTGATGCCTTGTTTGGG  2350 
Figure B.2 Alignment data for PSAP  mRNA. 
This insert sequence is homologous to nt 1374-2350 of Proactivator polypeptide 
isoform b preproprotein (PSAP) mRNA (NM_001042465.1). This partial cDNA 
sequence is fused in frame to the GAL4 DNA-BD and codes for the last 103 amino 
acids of 526 amino acid PSAP  protein. 
 
Homo sapiens ataxin 3 (ATXN3), transcript variant o, mRNA 
Score = 652 bits(353),Expect = 0.0,Identities = 353/353(100%), 
Gaps = 0/353(0%),Strand = Plus/Plus 
 
Query  107  ggCGTGGGGGCCGTTGGCTCCAGACAAATAAACATGGAGTCCATCTTCCACGAGAAACAA  166 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATXN3  37   GGCGTGGGGGCCGTTGGCTCCAGACAAATAAACATGGAGTCCATCTTCCACGAGAAACAA  96 
 
Query  167  GAAGGCTCACTTTGTGCTCAACATTGCCTGAATAACTTATTGCAAGGAGAATATTTTAGC  226 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATXN3  97   GAAGGCTCACTTTGTGCTCAACATTGCCTGAATAACTTATTGCAAGGAGAATATTTTAGC  156 
 
Query  227  CCTGTGGAATTATCCTCAATTGCACATCAGCTGGATGAGGAGGAGAGGATGAGAATGGCA  286 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATXN3  157  CCTGTGGAATTATCCTCAATTGCACATCAGCTGGATGAGGAGGAGAGGATGAGAATGGCA  216 
 
Query  287  GAAGGAGGAGTTACTAGTGAAGATTATCGCACGTTTTTACAGCAGCCTTCTGGAAATATG  346 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATXN3  217  GAAGGAGGAGTTACTAGTGAAGATTATCGCACGTTTTTACAGCAGCCTTCTGGAAATATG  276 
 
Query  347  GATGACAGTGGTTTTTTCTCTATTCAGGTTATAAGCAATGCCTTGAAAGTTTGGGGTTTA  406 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATXN3  277  GATGACAGTGGTTTTTTCTCTATTCAGGTTATAAGCAATGCCTTGAAAGTTTGGGGTTTA  336 
 
Query  407  GAACTAATCCTGTTCAACAGTCCAGAGTATCAGAGGCTCAGGATCGATCCTAT  459 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATXN3  337  GAACTAATCCTGTTCAACAGTCCAGAGTATCAGAGGCTCAGGATCGATCCTAT  389 
Figure B.3 Alignment data for ATXN3 mRNA. 
This insert sequence is homologous to nt 37-389 of Homo sapiens ataxin 3 
(ATXN3), transcript variant o (NM_001164778.1). This partial cDNA sequence is 
fused in frame to the GAL4 DNA-BD and codes for the first 107 amino acids of 154 
amino acid ATXN3 protein.  
 
Homo sapiens peptidylprolyl cis/trans isomerase, NIMA-interacting 1 (PIN1), 
transcript variant 1, mRNA 
Score = 1814 bits(982),Expect = 0.0,Identities  = 990/994(99%) 
Gaps = 1/994(0%), Strand = Plus/Plus 
    
Query  110   GGAGCAGGCGCTGCGGCAGGAGGGAAGATGGCGGACGAGGAGAAGCTGCCGCCCGGCTGG  169 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   112   GGAGCAGGCGCTGCGGCAGGAGGGAAGATGGCGGACGAGGAGAAGCTGCCGCCCGGCTGG  171 
 
Query  170   GAGAAGCGCATGAGCCGCAGCTCAGGCCGAGTGTACTACTTCAACCACATCACTAACGCC  229 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query  230   AGCCAGTGGGAGCGGCCCAGCGGCAACAGCAGCAGTGGTGGCAAAAACGGGCAGGGGGAG  289 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   232   AGCCAGTGGGAGCGGCCCAGCGGCAACAGCAGCAGTGGTGGCAAAAACGGGCAGGGGGAG  291 
 
Query  290   CCTGCCAGGGTCCGCTGCTCGCACCTGCTGGTGAAGCGCAGCCAGTCACGGCGGCCCTCG  349 
             ||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||| 
PIN1   292   CCTGCCAGGGTCCGCTGCTCGCACCTGCTGGTGAAGCACAGCCAGTCACGGCGGCCCTCG  351 
 
Query  350   TCCTGGCGGCAGGAGAAGATCACCCGGACCAAGGAGGAGGCCCTGGAGCTGATCAACGGC  409 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   352   TCCTGGCGGCAGGAGAAGATCACCCGGACCAAGGAGGAGGCCCTGGAGCTGATCAACGGC  411 
 
Query  410   TACATCCAGAAGATCAAGTCGGGAGAGGAGGACTTTGAGTCTCTGGCCCCACAGTTCAGC  469 
             |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
PIN1   412   TACATCCAGAAGATCAAGTCGGGAGAGGAGGACTTTGAGTCTCTGGCCTCACAGTTCAGC  471 
 
Query  470   GACTGCAGCTCAGCCAAGGCCAGGGGAGACCTGGGTGCCTTCAGCAGAGGTCAGATGCAG  529 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   472   GACTGCAGCTCAGCCAAGGCCAGGGGAGACCTGGGTGCCTTCAGCAGAGGTCAGATGCAG  531 
 
Query  530   AAGCCATTTGAAGACGCCTCGTTTGCGCTGCGGACGGGGGAGATGAGCGGGCCCGTGTTC  589 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   532   AAGCCATTTGAAGACGCCTCGTTTGCGCTGCGGACGGGGGAGATGAGCGGGCCCGTGTTC  591 
 
Query  590   ACGGATTCCGGCATCCACATCATCCTCCGCACTGAGTGAGGGTGGGGAGCCCAGGCCTGG  649 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   592   ACGGATTCCGGCATCCACATCATCCTCCGCACTGAGTGAGGGTGGGGAGCCCAGGCCTGG  651 
 
Query  650   CCTCGGGGCAGGGCAGGGCGGCTAGGCCGGCCAGCTCCCCCTTGCCCGCCAGCCAGTGGC  709 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   652   CCTCGGGGCAGGGCAGGGCGGCTAGGCCGGCCAGCTCCCCCTTGCCCGCCAGCCAGTGGC  711 
 
Query  710   CGAACCCCCCACTCCCTGCCACCGTCACACAGTATTTATTGTTCCCACAATGGCTGGGAG  769 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   712   CGAACCCCCCACTCCCTGCCACCGTCACACAGTATTTATTGTTCCCACAATGGCTGGGAG  771 
 
Query  770   GGGGCCCTTCCAGATTGGGGGCCCTGGGGTCCCCACTCCCTGTCCATCCCCAGTTGGGGC  829 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   772   GGGGCCCTTCCAGATTGGGGGCCCTGGGGTCCCCACTCCCTGTCCATCCCCAGTTGGGGC  831 
 
Query  830   TGCGACCGCCAGATTCTCCCTTAAGGAATTGACTTCAGCAGGGGTGGGAGGCTCCCAGAC  889 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   832   TGCGACCGCCAGATTCTCCCTTAAGGAATTGACTTCAGCAGGGGTGGGAGGCTCCCAGAC  891 
 
Query  890   CCAGGGCAGTGTGGTGGGGAGGGGTGTTCCAAAGAGAAGGCCTGGTCAGCAGAGCCGCCC  949 
             |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||| 
PIN1   892   CCAGGGCAGTGTGGTGGG-AGGGGTGTTCCAAAGAGAAGGCCTGGTCAGCAGAGCCGCCC  950 
 
Query  950   CGTGTCCCCCCAGGTGCTGGAGGCAGACTCGAGGGCCGAATTGTTTCTAGTTAGGCCACG  1009 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   951   CGTGTCCCCCCAGGTGCTGGAGGCAGACTCGAGGGCCGAATTGTTTCTAGTTAGGCCACG  1010 
 
Query  1010  CTCCTCTGTTCAGTCGCAAAGGTGAACACTCATGCGGCCCAGCCATGGGCCCTCTGAGCA  1069 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PIN1   1011  CTCCTCTGTTCAGTCGCAAAGGTGAACACTCATGCGGCCCAGCCATGGGCCCTCTGAGCA  1070 
 
Query  1070  ACTGTGCAGCACCCTTTCACCCNCAATTAAACCC  1103 
             |||||||||||||||||||||| ||||||||||| 
PIN1   1071  ACTGTGCAGCACCCTTTCACCCCCAATTAAACCC  1104 
Figure B.4 Alignment data for PIN1 mRNA. 
This insert sequence is homologous to nt 112-1104 of Homo sapiens peptidylprolyl 
cis/trans isomerase, NIMA-interacting 1 (PIN1), transcript variant 1, mRNA 
(NM_006221.3). This partial cDNA sequence is fused in frame to the GAL4 DNA-





Homo sapiens microtubule-associated protein 1B (MAP1B), mRNA 
 
Score = 2098 bits(1136), Expect = 0.0, Identities = 1156/1165(99%) 
Gaps = 3/1165(0%), Strand = Plus/Plus 
    
Query  108   CATCCCCACAGACAAAACTGTCACGTACAAACACATGGACCCACCTCCAGCTCCCGTGCA  167 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  6799  CATCCCCACAGACAAAACTGTCACGTACAAACACATGGACCCACCTCCAGCTCCCGTGCA  6858 
 
Query  168   AGACCGCAGCCCTTCGCCACGCCACCCTGATGTGTCCATGGTGGACCCAGAAGCCTTGGC  227 
             ||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||| 
MAP1B  6859  AGACCGCAGCCCTTCGCCACGCCACCCTGATGTGTCCATGGTGGACCCAGAGGCCTTGGC  6918 
 
Query  228   CATTGAGCAGAACCTGGGCAAAGCTCTAAAGAAAGATCTGAAAGAGAAGACCAAAACCAA  287 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  6919  CATTGAGCAGAACCTGGGCAAAGCTCTAAAGAAAGATCTGAAAGAGAAGACCAAAACCAA  6978 
 
Query  288   AAAGCCAGGTACAAAGACCAAGTCATCTTCACCTGTCAAAAAGAGTGATGGGAAGTCTAA  347 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  6979  AAAGCCAGGTACAAAGACCAAGTCATCTTCACCTGTCAAAAAGAGTGATGGGAAGTCTAA  7038 
 
Query  348   GCCCTTGGCAGCTTCACCAAAACCAGCGGGCTTGAAAGAATCCTCGGATAAAGTGTCCAG  407 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7039  GCCCTTGGCAGCTTCACCAAAACCAGCGGGCTTGAAAGAATCCTCGGATAAAGTGTCCAG  7098 
 
Query  408   GGTGGCTTCTCCTAAGAAGAAAGAATCTGTGGAAAAGGCAGCAAAACCCACCACCACTCC  467 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7099  GGTGGCTTCTCCTAAGAAGAAAGAATCTGTGGAAAAGGCAGCAAAACCCACCACCACTCC  7158 
 
Query  468   TGAGGTCAAAGCTGCACGTGGGGAAGAGAAAGACAAGGAGACCAAGAATGCTGCCAATGC  527 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7159  TGAGGTCAAAGCTGCACGTGGGGAAGAGAAAGACAAGGAGACCAAGAATGCTGCCAATGC  7218 
 
Query  528   CTCTGCATCCAAGTCGGCCAAGACCGCCACTGCAGGACCAGGAACTACCAAGACGACCAA  587 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7219  CTCTGCATCCAAGTCGGCCAAGACCGCCACTGCAGGACCAGGAACTACCAAGACGACCAA  7278 
 
Query  588   GTCATCTGCTGTGCCCCCAGGCCTCCCTGTGTATTTGGACCTGTGCTACATTCCTAACCA  647 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7279  GTCATCTGCTGTGCCCCCAGGCCTCCCTGTGTATTTGGACCTGTGCTACATTCCTAACCA  7338 
 
Query  648   CAGCAATAGTAAGAATGTTGATGTGGAATTTTTCAAGAGAGTGCGGTCTTCCTACTACGT  707 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7339  CAGCAATAGTAAGAATGTTGATGTGGAATTTTTCAAGAGAGTGCGGTCTTCCTACTACGT  7398 
 
Query  708   GGTGAGTGGGAATGACCCTGCTGCTGAGGAGCCCAGCCGGGCTGTCCTGGACGCTTTGTT  767 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7399  GGTGAGTGGGAATGACCCTGCTGCTGAGGAGCCCAGCCGGGCTGTCCTGGACGCTTTGTT  7458 
 
Query  768   GGAAGGAAAGGCTCAGTGGGGCAGCAACATGCAGGTGACACTGATCCCAACTCATGACTC  827 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7459  GGAAGGAAAGGCTCAGTGGGGCAGCAACATGCAGGTGACACTGATCCCAACTCATGACTC  7518 
 
Query  828   AGAAGTGATGAGGGAATGGTACCAGGAGACCCATGAGAAACAGCAAGATCTCAACATCAT  887 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7519  AGAAGTGATGAGGGAATGGTACCAGGAGACCCATGAGAAACAGCAAGATCTCAACATCAT  7578 
 
Query  888   GGTTTTAGCAAGCAGCAGCACAGTGGTTATGCAAGATGAATCCTTCCCTGCATGCAAGAT  947 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7579  GGTTTTAGCAAGCAGCAGCACAGTGGTTATGCAAGATGAATCCTTCCCTGCATGCAAGAT  7638 
 
Query  948   TGAACTGTAAAAACCAAGGCCAGCCACACCACAGGATCTGAACTTTGTTTCCAGAAATTC  1007 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7639  TGAACTGTAAAAACCAAGGCCAGCCACACCACAGGATCTGAACTTTGTTTCCAGAAATTC  7698 
 
Query  1008  TTCAATTTGAAATCACCTTTTCTAAAAAGTCAATTCATCTAGTTAAGTCGCTGAACAATT  1067 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7699  TTCAATTTGAAATCACCTTTTCTAAAAAGTCAATTCATCTAGTTAAGTCGCTGAACAATT  7758 
 
Query  1068  ACCTGCCAAATGCTATACTGTGTCATGGTGATGCAAGTCACTAAATTTCTCAGTTTTTGC  1127 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAP1B  7759  ACCTGCCAAATGCTATACTGTGTCATGGTGATGCAAGTCACTAAATTTCTCAGTTTTTGC  7818 
 
Query  1128  TGATTGCTAAGGGAAATAACAGTATTTCCACAATAGGGTTCAAATTCCTGCAAA-TTACC  1186 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
88 
 
MAP1B  7819  TGATTGCTAAGGGAAATAACAGTATTTCCACAATAGGGTTCAAATTCCTGCAAAATTACC  7878 
 
Query  1187  TACCCCAGTTCATCTCTGCTGAACATTTGGAAACCATGCCCTAGCCAACC-AACTGATTT  1245 
             ||||||||||||||||||||||||||||||||||||||| |||||||||| |||||| || 
MAP1B  7879  TACCCCAGTTCATCTCTGCTGAACATTTGGAAACCATGCACTAGCCAACCCAACTGACTT  7938 
 
Query  1246  CTGGTAGGTAAAGGT-TTTGTCTTa  1269 
             ||| |||||| |||  ||||||||| 
MAP1B  7939  CTGCTAGGTAGAGGCATTTGTCTTA  7963 
Figure B.5 Alignment data for MAP1B mRNA. 
This insert sequence is homologous to nt 6799-7963 of Homo sapiens microtubule-
associated protein 1B (MAP1B), mRNA (NM_005909.3). This partial cDNA 
sequence is fused in frame to the GAL4 DNA-BD and codes for the last 282 amino 
acids of 2468 amino acid MAP1B protein. 
Homo sapiens 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) (HMGCS1), 
transcript variant 1, mRNA 
Score = 1062 bits(575), Expect = 0.0,Identities = 575/575(100%) 
Gaps = 0/575(0%),Strand = Plus/Plus 
   
Query  106  GCGGACTGTCCTTTCGTGGCTCACTCCCTTTCCTCTGCTGCCGCTCGGTCACGCTTGTGC  165 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 101  GCGGACTGTCCTTTCGTGGCTCACTCCCTTTCCTCTGCTGCCGCTCGGTCACGCTTGTGC  160 
 
Query  166  CCGAAGGAGGAAACAGTGACAGACCTGGAGACTGCAGTTCTCTATCCTTCACACAGCTCT  225 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 161  CCGAAGGAGGAAACAGTGACAGACCTGGAGACTGCAGTTCTCTATCCTTCACACAGCTCT  220 
 
Query  226  TTCACCATGCCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTGGGA  285 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 221  TTCACCATGCCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTGGGA  280 
 
Query  286  ATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAAA  345 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 281  ATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAAA  340 
 
Query  346  TATGATGGTGTAGATGCTGGAAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTC  405 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 341  TATGATGGTGTAGATGCTGGAAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTC  400 
 
Query  406  TGCACAGATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAG  465 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 401  TGCACAGATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAG  460 
 
Query  466  AGAAATAACCTTTCCTATGATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATC  525 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 461  AGAAATAACCTTTCCTATGATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATC  520 
 
Query  526  GACAAATCAAAGTCTGTGAAGACTAATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACA  585 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 521  GACAAATCAAAGTCTGTGAAGACTAATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACA  580 
 
Query  586  GATATAGAAGGAATCGACACAACTAATGCATGCTATGGAGGCACAGCTGCTGTCTTCAAT  645 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HMGCS1 581  GATATAGAAGGAATCGACACAACTAATGCATGCTATGGAGGCACAGCTGCTGTCTTCAAT  640 
 
Query  646  GCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGG  680 
            ||||||||||||||||||||||||||||||||||| 
HMGCS1 641  GCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGG  675 
Figure B.6 Alignment data for HMGCS1 mRNA. 
This insert sequence is homologous to nt 101-675 of 3-hydroxy-3-methylglutaryl-
CoA synthase 1 soluble protein (HMGCS1) mRNA (NM_001098272.2). This partial 
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cDNA sequence is fused in frame to the GAL4 DNA-BD and codes for the first 150 
amino acids of 520 amino acid HMGCS1 protein. 
Homo sapiens SH3-domain GRB2-like (endophilin) interacting protein 1 
(SGIP1), mRNA  
Score = 1923 bits(1041),Expect = 0.0, Identities = 1162/1215(96%) 
Gaps = 31/1215(2%),Strand = Plus/Plus 
 
Query  106   GGCAGTGCTCCCACCAGCAGTCTGGAATGCTGAACAACAGAGAATATTGTGGAAGATTCC  165 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2428  GGCAGTGCTCCCACCAGCAGTCTGGAATGCTGAACAACAGAGAATATTGTGGAAGATTCC  2487 
 
Query  166   TGATATCTCTCAGAAGTCAGAAAATGGAGGGGTGGGTTCTTTGTTGGCAAGATTTCAGTT  225 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2488  TGATATCTCTCAGAAGTCAGAAAATGGAGGGGTGGGTTCTTTGTTGGCAAGATTTCAGTT  2547 
 
Query  226   ATCTGAAGGCCCAAGCAAACCTTCTCCATTGGTTGTGCAGTTCACAAGTGAAGGAAGCAC  285 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2548  ATCTGAAGGCCCAAGCAAACCTTCTCCATTGGTTGTGCAGTTCACAAGTGAAGGAAGCAC  2607 
 
Query  286   CCTTTCTGGCTGTGACATTGAACTTGTTGGAGCAGGGTATCGATTTTCACTCATCAAGAA  345 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2608  CCTTTCTGGCTGTGACATTGAACTTGTTGGAGCAGGGTATCGATTTTCACTCATCAAGAA  2667 
 
Query  346   AAGGTTTGCTGCAGGAAAATACTTGGCAGATAACTAATGAAATCTTATGCAAGGATTTGG  405 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2668  AAGGTTTGCTGCAGGAAAATACTTGGCAGATAACTAATGAAATCTTATGCAAGGATTTGG  2727 
 
Query  406   AGGATTCATATAATGGAGAACTGATGTATGAGAAACAGATTTTAATTTTGGTTTGATGAA  465 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2728  AGGATTCATATAATGGAGAACTGATGTATGAGAAACAGATTTTAATTTTGGTTTGATGAA  2787 
 
Query  466   AACAAACCAATATCTGCACTTGGGATATATCAGGTGGAAAGTCAATGACTTTCATCTGTG  525 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2788  AACAAACCAATATCTGCACTTGGGATATATCAGGTGGAAAGTCAATGACTTTCATCTGTG  2847 
 
Query  526   ATTTCCCTCACACACTACCATGATGACCAGTCCTACAGTATTTACTTCTAGGTGTAATAT  585 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2848  ATTTCCCTCACACACTACCATGATGACCAGTCCTACAGTATTTACTTCTAGGTGTAATAT  2907 
 
Query  586   TGTTAATGGTTTTAAAATGTAATTATTGTATTTGTAAATTGTACTCTCATTCCAGTAAGG  645 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2908  TGTTAATGGTTTTAAAATGTAATTATTGTATTTGTAAATTGTACTCTCATTCCAGTAAGG  2967 
 
Query  646   CAGTTAGACACTTGAGTTTTAGCATTTTACCATTCCTGAAATGGATGTAATTTAAACTGT  705 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  2968  CAGTTAGACACTTGAGTTTTAGCATTTTACCATTCCTGAAATGGATGTAATTTAAACTGT  3027 
 
Query  706   GGTATGTAAATTTAATAGTAGTATTGTTGAATGGCACAATGCTTACAGAGGTAGATTGCA  765 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  3028  GGTATGTAAATTTAATAGTAGTATTGTTGAATGGCACAATGCTTACAGAGGTAGATTGCA  3087 
 
Query  766   TTTTGTCAATATATAAAATTTAAATATAATATTGATAGCTGTCATAAAGGGGGTGCCACA  825 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  3088  TTTTGTCAATATATAAAATTTAAATATAATATTGATAGCTGTCATAAAGGGGGTGCCACA  3147 
 
Query  826   TATTAAAGAAACTTAAGTGGAACCAGAAGAAAAAGAAACAAACTTACTTTTCTTCAATGC  885 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  3148  TATTAAAGAAACTTAAGTGGAACCAGAAGAAAAAGAAACAAACTTACTTTTCTTCAATGC  3207 
 
Query  886   TTAGTATGTTTTACTCTAGTGCTAAATAAAAACTCTATCTTCAAATGTTTAGTGGGTTAA  945 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SGIP1  3208  TTAGTATGTTTTACTCTAGTGCTAAATAAAAACTCTATCTTCAAATGTTTAGTGGGTTAA  3267 
 
Query  946   ATTGAGAAACTATTTCAGAAAAAA-TTCTAAGGTTACAGCATATTCAAAGAAAAGCATTA  1004 
             |||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
SGIP1  3268  ATTGAGAAACTATTTCAGAAAAAAATTCTAAGGTTACAGCATATTCAAAGAAAAGCATTA  3327 
 
Query  1005  GTTACCACTTTTTAAAAAGCttttttttCAAACTGCAATTTTCATAAAA-TGCAAACTGT  1063 
             |||||||||||||||||||||||||||||||||||||| |||||||||| |||||||||| 
SGIP1  3328  GTTACCACTTTTTAAAAAGCTTTTTTTTCAAACTGCAAATTTCATAAAAATGCAAACTGT  3387 
 
Query  1064  GTAAACAGGGCCTCTTATTTT-ATAACTTGTGTAAAAAGGGAAAGCA-TTCTTATTTAAA  1121 
90 
 
             ||||||||||||||||||||| ||||||||||||||||||||||||| ||| |||||||| 
SGIP1  3388  GTAAACAGGGCCTCTTATTTTTATAACTTGTGTAAAAAGGGAAAGCAATTCATATTTAAA  3447 
 
Query  1122  GTT-AAGT-TATTTAATTTTA-TCAAAAGTAA-GAAAAAGTTGAAG-CTTA-CTACTTGC  1175 
             ||| |||| |||| |||| || |||| ||||| ||| | ||||||| |||| |||||||| 
SGIP1  3448  GTTTAAGTATATTAAATTATAATCAAGAGTAAAGAAGATGTTGAAGTCTTAACTACTTGC  3507 
 
Query  1176  CCCCCT-TA-AGTTCC-CAAATG-GGGGATGG-TNAA-AATCCTCCA-A-TAAA-CCAAA  1226 
             ||| || || |||| | |||||| |||||| | | || ||||   || | |||| ||||| 
SGIP1  3508  CCCTCTCTACAGTTTCGCAAATGTGGGGATTGCTGAATAATCAGTCAGACTAAAACCAAA  3567 
 
Query  1227  TTTG-G-TTTTAA-ATT-CAAAA-TTTCGG-A-TTGAAAGGGTAAA-AATTTT-GCT-A-  1275 
              ||| | |||||| ||| ||| | |||| | | |||||  ||| || |||||| ||| |  
SGIP1  3568  ATTGTGATTTTAAGATTTCAAGACTTTCCGTAGTTGAACTGGTTAAGAATTTTTGCTTAG  3627 
 
Query  1276  T-ACTCGGAAAAGAT  1289 
             | |||| ||| |||| 
SGIP1  3628  TTACTCTGAATAGAT  3642 
Figure B.7 Alignment data for SGIP1 mRNA. 
This insert sequence is homologous to nt 2428-3642 of SH3-domain GRB2-like 
(endophilin) interacting protein 1 (SGIP1) mRNA (NM_032291.2). This partial 
cDNA sequence is fused in frame to the GAL4 DNA-BD and codes for the last 91 
amino acids of 828 amino acid SGIP1 protein. 
Homo sapiens nitrogen permease regulator-like 2 (S. cerevisiae) (NPRL2), mRNA 
Score = 2041 bits(1105), Expect = 0.0,Identities = 1175/1209(97%) 
Gaps = 8/1209(0%),Strand = Plus/Plus 
 
Query  109   GAGGCTGTCTCTGACAAGTGTTCACAGGAGGTGGGGACGCCTCTGCGCGAGGAACGAGGA  168 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  317   GAGGCTGTCTCTGACAAGTGTTCACAGGAGGTGGGGACGCCTCTGCGCGAGGAACGAGGA  376 
 
Query  169   GCTACGGGCCTGGGCCCGGTTATTGTCATGGGCAGCGGCTGCCGCATCGAATGCATATTC  228 
             ||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||| 
NPRL2  377   GCTACGGGCCTGGGCCCGGTTATTGCCATGGGCAGCGGCTGCCGCATCGAATGCATATTC  436 
 
Query  229   TTCAGCGAGTTCCACCCCACGCTGGGACCCAAGATCACCTATCAGGTCCCTGAAGACTTC  288 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  437   TTCAGCGAGTTCCACCCCACGCTGGGACCCAAGATCACCTATCAGGTCCCTGAAGACTTC  496 
 
Query  289   ATCTCCCGAGAGCTGTTTGACACAGTCCAAGTGTACATCATCACCAAGCCAGAGCTGCAG  348 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  497   ATCTCCCGAGAGCTGTTTGACACAGTCCAAGTGTACATCATCACCAAGCCAGAGCTGCAG  556 
 
Query  349   AACAAGCTTATCACTGTCACAGCTATGGAAAAGAAGCTGATCGGCTGTCCTGTGTGCATC  408 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  557   AACAAGCTTATCACTGTCACAGCTATGGAAAAGAAGCTGATCGGCTGTCCTGTGTGCATC  616 
 
Query  409   GAACACAAGAAGTACAGCCGCAATGCTCTCCTCTTCAACCTGGGCTTCGTGTGTGATGCC  468 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  617   GAACACAAGAAGTACAGCCGCAATGCTCTCCTCTTCAACCTGGGCTTCGTGTGTGATGCC  676 
 
Query  469   CAGGCCAAGACCTGCGCCCTCGAGCCCATTGTTAAAAAGCTGGCTGGCTATCTGACCACA  528 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  677   CAGGCCAAGACCTGCGCCCTCGAGCCCATTGTTAAAAAGCTGGCTGGCTATCTGACCACA  736 
 
Query  529   CTAGAGCTAGAGAGCAGCTTCGTGTCCATGGAGGAGAGCAAGCAGAAGTTGGTGCCCATC  588 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  737   CTAGAGCTAGAGAGCAGCTTCGTGTCCATGGAGGAGAGCAAGCAGAAGTTGGTGCCCATC  796 
 
Query  589   ATGACCATCTTGCTGGAGGAGCTAAATGCCTCAGGCCGGTGCACTCTGCCCATTGATGAG  648 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  797   ATGACCATCTTGCTGGAGGAGCTAAATGCCTCAGGCCGGTGCACTCTGCCCATTGATGAG  856 
 
Query  649   TCCAACACCATCCACTTGAAGGTGATTGAGCAGCGGCCAGACCCTCCGGTGGCCCAGGAG  708 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query  709   TATGATGTACCTGTCTTTACCAAAGACAAGGAGGATTTCTTCAACTCACAGTGGGACCTC  768 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  917   TATGATGTACCTGTCTTTACCAAAGACAAGGAGGATTTCTTCAACTCACAGTGGGACCTC  976 
 
Query  769   ACTACACAACAAATCCTGCCCTACATTGATGGGTTCCGCCACATCCAGAAGATTTCAGCA  828 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  977   ACTACACAACAAATCCTGCCCTACATTGATGGGTTCCGCCACATCCAGAAGATTTCAGCA  1036 
 
Query  829   GAGGCAGATGTGGAGCTCAACCTGGTGCGCATTGCTATCCAGAACCTGCTGTACTACGGC  888 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  1037  GAGGCAGATGTGGAGCTCAACCTGGTGCGCATTGCTATCCAGAACCTGCTGTACTACGGC  1096 
 
Query  889   GTTGTGACACTGGTGTCCATCCTCCAGTACCCCAATGTATACTGCCCAACGCCCAAGGTC  948 
             |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
NPRL2  1097  GTTGTGACACTGGTGTCCATCCTCCAGTACTCCAATGTATACTGCCCAACGCCCAAGGTC  1156 
 
Query  949   CAGGACCTGGTAGATGACAAGTCCCTGCAAGAGGCATGTCTATCCTACGTGACCAAGCAA  1008 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NPRL2  1157  CAGGACCTGGTAGATGACAAGTCCCTGCAAGAGGCATGTCTATCCTACGTGACCAAGCAA  1216 
 
Query  1009  GGGCACAAGAGGGCCAGTCTCCCGGGATGTGTTCCAGCTATACTGCAGCCTGAGCCCTGG  1068 
             |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
NPRL2  1217  GGGCACAAGAGGGCCAGTCTCC-GGGATGTGTTCCAGCTATACTGCAGCCTGAGCCCTGG  1275 
 
Query  1069  CACTACCGTGCGAGACCTCATTGGCCGcc-cccccAGCAGCTGCAGCATGTTGATGAACG  1127 
             ||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||| 
NPRL2  1276  CACTACCGTGCGAGACCTCATTGGCCGCCACCCCCAGCAGCTGCAGCATGTTGATGAACG  1335 
 
Query  1128  GAAGCTGATCCAGTTCGGGCTTATGAAGA-CCTCATCAGGCGACTACAGAATTATCCTGG  1186 
             ||||||||||||||||||||||||||||| ||||||||||||||||||||| |||||||  
NPRL2  1336  GAAGCTGATCCAGTTCGGGCTTATGAAGAACCTCATCAGGCGACTACAGAAGTATCCTGT  1395 
 
Query  1187  GCGGGTGACTCGGGAAAAACAGA-CCACCCTGCCCGG-TTTATACAGGCTGCCNAAGCTT  1244 
             |||||||||||||||| | |||| ||||||||||||| |||||||||||||||  ||||  
NPRL2  1396  GCGGGTGACTCGGGAAGAGCAGAGCCACCCTGCCCGGCTTTATACAGGCTGCCACAGCTA  1455 
 
Query  1245  TGACAAATTTTGTTGAAAAA-AGGCTTG-GCTCCCATGAACTTGAATAACGGGTTGAAAT  1302 
             |||| |  | || || || | |||| || ||| |||||| || ||  | ||| ||||||  
NPRL2  1456  TGACGAGATCTGCTGCAAGACAGGCATGAGCTACCATGAGCTGGATGAGCGGCTTGAAAA  1515 
 
Query  1303  NG-CCCCAA  1310 
              | |||||| 
NPRL2     1516  TGACCCCAA  1524 
Figure B.8 Alignment data for NPRL2 mRNA. 
This insert sequence is homologous to nt 317-1524 of Homo sapiens nitrogen 
permease regulator-like 2 (S. cerevisiae) (NPRL2), mRNA (NM_006545.4). This 
partial cDNA sequence is fused in frame to the GAL4 DNA-BD and codes for the 
first 278 amino acids of 380 amino acid NPRL2 protein. 
Homo sapiens complement component 1, q subcomponent, A chain (C1QA), mRNA 
Score = 1626 bits(880),Expect = 0.0, Identities = 880/880(100%) 
Gaps = 0/880(0%), Strand = Plus/Plus 
     
Query  105   GGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGG  164 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   145   GGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGG  204 
 
Query  165   CAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCG  224 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   205   CAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCG  264 
 
Query  225   GACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGG  284 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   265   GACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGG  324 
 
Query  285   CAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAA  344 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query  345   AGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCAT  404 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   385   AGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCAT  444 
 
Query  405   TCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCA  464 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   445   TCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCA  504 
 
Query  465   GGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTA  524 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   505   GGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTA  564 
 
Query  525   CTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAG  584 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   565   CTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAG  624 
 
Query  585   GGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGT  644 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   625   GGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGT  684 
 
Query  645   GGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGA  704 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   685   GGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGA  744 
 
Query  705   CCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCT  764 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   745   CCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCT  804 
 
Query  765   CATCTTCCCATCTGCCTGAGCCAGGGAAGGACCCCCTCCCCCACCCACCTCTCTGGCTTC  824 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   805   CATCTTCCCATCTGCCTGAGCCAGGGAAGGACCCCCTCCCCCACCCACCTCTCTGGCTTC  864 
 
Query  825   CATGCTCCGCCTGTAAAATGGGGGCGCTATTGCTTCAGCTGCTGAAGGGAGGGGGCTGGC  884 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   865   CATGCTCCGCCTGTAAAATGGGGGCGCTATTGCTTCAGCTGCTGAAGGGAGGGGGCTGGC  924 
 
Query  885   TCTGAGAGCCCCAGGACTGGCTGCCCCGTGACACATGCTCTAAGAAGCTCGTTTCTTAGa  944 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
C1QA   925   TCTGAGAGCCCCAGGACTGGCTGCCCCGTGACACATGCTCTAAGAAGCTCGTTTCTTAGA  984 
 
Query  945   cctcttcctggaataaacatctgtgtctgtgtctgctgaa  984 
             |||||||||||||||||||||||||||||||||||||||| 
C1QA   985   CCTCTTCCTGGAATAAACATCTGTGTCTGTGTCTGCTGAA  1024 
Figure B.9 Alignment data for C1QA mRNA. 
This insert sequence is homologous to nt 145-1024 of Homo sapiens complement 
component 1, q subcomponent, A chain (C1QA), mRNA (NM_015991.2). This 
partial cDNA sequence is fused in frame to the GAL4 DNA-BD and codes for the 
last 225 amino acids of 245 amino acid C1QA protein. 
Homo sapiens MAD2 mitotic arrest deficient-like 2 (yeast) (MAD2L2), transcript 
variant 1, mRNA 
Score = 1663 bits(900),Expect = 0.0,Identities = 914/921(99%) 
Gaps = 3/921(0%), Strand = Plus/Plus 
    
Query  153   GTGGTGGCCGATGTGCTCTGCGAGTTCCTGGAGGTGGCTGTGCATCTCATCCTCTACGTG  212 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 261   GTGGTGGCCGATGTGCTCTGCGAGTTCCTGGAGGTGGCTGTGCATCTCATCCTCTACGTG  320 
 
Query  213   CGCGAGGTCTACCCCGTGGGCATCTTCCAGAAACGCAAGAAGTACAACGTGCCGGTCCAG  272 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 321   CGCGAGGTCTACCCCGTGGGCATCTTCCAGAAACGCAAGAAGTACAACGTGCCGGTCCAG  380 
 
Query  273   ATGTCCTGCCACCCGGAGCTGAATCAGTATATCCAGGACACGCTGCACTGCGTCAAGCCA  332 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 381   ATGTCCTGCCACCCGGAGCTGAATCAGTATATCCAGGACACGCTGCACTGCGTCAAGCCA  440 
 
Query  333   CTCCTGGAGAAGAATGATGTGGAGAAAGTGGTGGTGGTGATTTTGGATAAAGAGCACCGC  392 
93 
 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 441   CTCCTGGAGAAGAATGATGTGGAGAAAGTGGTGGTGGTGATTTTGGATAAAGAGCACCGC  500 
 
Query  393   CCAGTGGAGAAATTCGTCTTTGAGATCACCCAGCCTCCACTGCTGTCCATCAGCTCAGAC  452 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 501   CCAGTGGAGAAATTCGTCTTTGAGATCACCCAGCCTCCACTGCTGTCCATCAGCTCAGAC  560 
 
Query  453   TCGCTGTTGTCTCATGTGGAGCAGCTGCTCCGGGCCTTCATCCTGAAGATCAGCGTGTGC  512 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 561   TCGCTGTTGTCTCATGTGGAGCAGCTGCTCCGGGCCTTCATCCTGAAGATCAGCGTGTGC  620 
 
Query  513   GATGCCGTCCTGGACCACAACCCCCCAGGCTGTACCTTCACAGTCCTGGTGCACACGAGA  572 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 621   GATGCCGTCCTGGACCACAACCCCCCAGGCTGTACCTTCACAGTCCTGGTGCACACGAGA  680 
 
Query  573   GAAGCCGCCACTCGCAACATGGAGAAGATCCAGGTCATCAAGGATTTCCCCTGGATCCTG  632 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 681   GAAGCCGCCACTCGCAACATGGAGAAGATCCAGGTCATCAAGGATTTCCCCTGGATCCTG  740 
 
Query  633   GCGGATGAGCAGGATGTCCACATGCATGACCCCCGGCTGATACCACTAAAAACCATGACG  692 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 741   GCGGATGAGCAGGATGTCCACATGCATGACCCCCGGCTGATACCACTAAAAACCATGACG  800 
 
Query  693   TCGGACATTTTAAAGATGCAGCTTTGCGTGGAAGAGCGCGCTCATAAAGGCAGCTGAGGG  752 
             ||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||| 
MAD2L2 801   TCGGACATTTTAAAGATGCAGCTTTACGTGGAAGAGCGCGCTCATAAAGGCAGCTGAGGG  860 
 
Query  753   GGCACCTGCCACCCCACTGATGCCCAAACTGTCAGACTTTGGGGGATCCCCGCCTAGGGC  812 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 861   GGCACCTGCCACCCCACTGATGCCCAAACTGTCAGACTTTGGGGGATCCCCGCCTAGGGC  920 
 
Query  813   AGTGCTGCATGGCTGCCCTGATTCCAAGTGCTCTTATCGCCTCTGNTGTGTGGATCGCCC  872 
             ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
MAD2L2 921   AGTGCTGCATGGCTGCCCTGATTCCAAGTGCTCTTATCGCCTCTG-TGTGTGGATCGCCC  979 
 
Query  873   GCCCCAGCCCGGGGCCGCTCAGGTCTGCTTGGAGGATGCCTCCCCCAGGAGGGCAGTGAG  932 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 980   GCCCCAGCCCGGGGCCGCTCAGGTCTGCTTGGAGGATGCCTCCCCCAGGAGGGCAGTGAG  1039 
 
Query  933   GGATGCCGCAACCTCGACTTCTCAGCCTCCTGGGGTTCCGCCGGCCAACACTGTCTGTCT  992 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MAD2L2 1040  GGATGCCGCAACCTCGACTTCTCAGCCTCCTGGGGTTCCGCCGGCCAACACTGTCTGTCT  1099 
 
Query  993   CAA-TACTGTGGCTGTGAGTTGTTTCAATAAAGGGGCCCCAAGGGCTGGGCTGAGaaaaa  1051 
             ||| ||||||| |||||||||||||||||||||||||||||||||||||||||| ||||| 
MAD2L2 1100  CAAATACTGTG-CTGTGAGTTGTTTCAATAAAGGGGCCCCAAGGGCTGGGCTGAAAAAAA  1158 
 
Query  1052  aaaaaaaannaaaaaaaaaaa  1072 
             ||||||||  ||||||||||| 
MAD2L2 1159  AAAAAAAAAAAAAAAAAAAAA  1179 
Figure B.10 Alignment data for MAD2L2 mRNA. 
This insert sequence is homologous to nt 261-1179 of Homo sapiens MAD2L2 
mitotic arrest deficient-like 2 (yeast) (MAD2L2), transcript variant 1, mRNA 
(NM_001127325.1). This partial cDNA sequence is fused in frame to the GAL4 
DNA-BD and codes for the last 198 amino acids of 211 amino acid MAD2B protein, 
(protein product of MAD2L2). 
Homo sapiens syndecan binding protein (syntenin) (SDCBP), transcript variant 1, 
mRNA 
Score = 2045 bits(1107),Expect = 0.0, Identities = 1223/1281(95%) 
Gaps = 12/1281(0%),Strand = Plus/Plus 
 
Query  107   TACATGGGGCTGAGTTTAAATGAAGAAGAAATACGTGCAAATGTGGCCGTGGTTTCTGGT  166 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query  167   GCACCACTTCAGGGGCAGTTGGTAGCAAGACCTTCCAGTATAAACTATATGGTGGCTCCT  226 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  376   GCACCACTTCAGGGGCAGTTGGTAGCAAGACCTTCCAGTATAAACTATATGGTGGCTCCT  435 
 
Query  227   GTAACTGGTAATGATGTTGGAATTCGTAGAGCAGAAATTAAGCAAGGGATTCGTGAAGTC  286 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  436   GTAACTGGTAATGATGTTGGAATTCGTAGAGCAGAAATTAAGCAAGGGATTCGTGAAGTC  495 
 
Query  287   ATTTTGTGTAAGGATCAAGATGGAAAAATTGGACTCAGGCTTAAATCAATAGATAATGGT  346 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  496   ATTTTGTGTAAGGATCAAGATGGAAAAATTGGACTCAGGCTTAAATCAATAGATAATGGT  555 
 
Query  347   ATATTTGTTCAGCTAGTCCAGGCTAATTCTCCAGCCTCATTGGTTGGTCTGAGATTTGGG  406 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  556   ATATTTGTTCAGCTAGTCCAGGCTAATTCTCCAGCCTCATTGGTTGGTCTGAGATTTGGG  615 
 
Query  407   GACCAAGTACTTCAGATCAATGGTGAAAACTGTGCAGGATGGAGCTCTGATAAAGCGCAC  466 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  616   GACCAAGTACTTCAGATCAATGGTGAAAACTGTGCAGGATGGAGCTCTGATAAAGCGCAC  675 
 
Query  467   AAGGTGCTCAAACAGGCTTTTGGAGAGAAGATTACCATGACCATTCGTGACAGGCCCTTT  526 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  676   AAGGTGCTCAAACAGGCTTTTGGAGAGAAGATTACCATGACCATTCGTGACAGGCCCTTT  735 
 
Query  527   GAACGGACGATTACCATGCATAAGGATAGCACTGGACATGTTGGTTTTATCTTTAAAAAT  586 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  736   GAACGGACGATTACCATGCATAAGGATAGCACTGGACATGTTGGTTTTATCTTTAAAAAT  795 
 
Query  587   GGAAAAATAACATCCATAGTGAAAGATAGCTCTGCAGCCAGAAATGGTCTTCTCACGGAA  646 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  796   GGAAAAATAACATCCATAGTGAAAGATAGCTCTGCAGCCAGAAATGGTCTTCTCACGGAA  855 
 
Query  647   CATAACATCTGTGAAATCAATGGACAGAATGTCATTGGATTGAAGGACTCTCAAATTGCA  706 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  856   CATAACATCTGTGAAATCAATGGACAGAATGTCATTGGATTGAAGGACTCTCAAATTGCA  915 
 
Query  707   GACATACTGTCAACATCTGGGACTGTAGTTACTATTACAATCATGCCTGCTTTTATCTTT  766 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  916   GACATACTGTCAACATCTGGGACTGTAGTTACTATTACAATCATGCCTGCTTTTATCTTT  975 
 
Query  767   GAACATATTATTAAGCGGATGGCACCAAGCATTATGAAAAGCCTAATGGACCACACCATT  826 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  976   GAACATATTATTAAGCGGATGGCACCAAGCATTATGAAAAGCCTAATGGACCACACCATT  1035 
 
Query  827   CCTGAGGTTTAAAATTCACGGCACCATGGAAATGTAGCTGAACGTCTCCAGTTTCCTTCT  886 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  1036  CCTGAGGTTTAAAATTCACGGCACCATGGAAATGTAGCTGAACGTCTCCAGTTTCCTTCT  1095 
 
Query  887   TTGGCAACTTCTGTATTATGCACGTGAAGCCTTCCCGGAGCCAGCGAGCATATGCTGCAT  946 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  1096  TTGGCAACTTCTGTATTATGCACGTGAAGCCTTCCCGGAGCCAGCGAGCATATGCTGCAT  1155 
 
Query  947   GAGGACCTTTCTATCTTACATTATGGCTGGGAATCTTACTCTTTCATCTGATACCTTGTT  1006 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  1156  GAGGACCTTTCTATCTTACATTATGGCTGGGAATCTTACTCTTTCATCTGATACCTTGTT  1215 
 
Query  1007  CAGATTTCAAAATAGTTGTAGCCTTATCCTGGTTTTACAGATGTGAAACTTTCAAGAGAT  1066 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  1216  CAGATTTCAAAATAGTTGTAGCCTTATCCTGGTTTTACAGATGTGAAACTTTCAAGAGAT  1275 
 
Query  1067  TTACTGACTTTCCTAAAATAGTTTCTCTACTGGAAACCTGATGCTTTTATAAGCCATTGT  1126 
             ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
SDCBP  1276  TTACTGACTTTCCTAGAATAGTTTCTCTACTGGAAACCTGATGCTTTTATAAGCCATTGT  1335 
 
Query  1127  GATTAAGATGACTGTTACAGGCTTTACTTTTGTGGGAAAACCAGTCACCTTTTTCCTAAG  1186 
             ||||| ||||||||||||||||||  |||| ||| ||||||||||||||||| ||||| | 
SDCBP  1336  GATTAGGATGACTGTTACAGGCTTAGCTTT-GTGTGAAAACCAGTCACCTTTCTCCTAGG  1394 
 
Query  1187  GAATGAAGAAGGGCGGTCNAAATTACTTTAAGTTCTTAANCAAACTTGGATCTTTAACAN  1246 
              ||||| | || || ||  | ||||||||| |||||  | || ||||| ||||||||||  
SDCBP  1395  TAATGA-GTAGTGCTGTTCATATTACTTTA-GTTCTATAGCATACTTGCATCTTTAACAT  1452 
 
Query  1247  NGCTATCA-AGGACATTTAAAANGATTGCCTTTGAAtttttttt-AAATCTCGGGG-GTG  1303 
              ||||||| || ||||||| || |||||||||||| |||||||| |||| || | | ||| 
SDCBP  1453  -GCTATCATAGTACATTTAGAATGATTGCCTTTGATTTTTTTTTTAAAT-TCTGTGTGTG  1510 
 
Query  1304  GGTNGGGGGAAAANGCCANTaaaaaa-aCAGGGTTCTTTCCCTGGAGGC-TTAAACAAGG  1361 
95 
 
              || | |  |||| |||| | || || || || ||| |||| || | || |||||||  | 
SDCBP  1511  TGT-GTGT-AAAATGCCAATTAAGAACACTGGTTTCATTCCATGTAAGCATTAAACAGTG  1568 
 
Query  1362  GATTGGGGTTTCAAGAAATTG  1382 
              ||   |||||||||| |||| 
SDCBP  1569  TATGTAGGTTTCAAGAGATTG  1589 
Figure B.11 Alignment data for SDCBP mRNA. 
This insert sequence is homologous to nt 316-1589 of Homo sapiens syndecan 
binding protein (syntenin) (SDCBP), transcript variant 1, mRNA 
(NM_001007067.1). This partial cDNA sequence is fused in frame to the GAL4 
DNA-BD and codes for the last 246 amino acids of 298 amino acid SDCBP protein. 
Homo sapiens SEC31 homolog A (S. cerevisiae) (SEC31A), transcript variant 6, 
mRNA 
Score = 1892 bits(1024),Expect = 0.0,Identities = 1033/1037(99%) 
Gaps = 2/1037(0%),Strand = Plus/Plus 
     
Query  107   CAACCAGCCAAATATCATGCAGCTTCGTGACAGACTTTGTAGAGCACAAGGAGAGCCTGT  166 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2338  CAACCAGCCAAATATCATGCAGCTTCGTGACAGACTTTGTAGAGCACAAGGAGAGCCTGT  2397 
 
Query  167   AGCAGGACATGAATCACCTAAAATTCCGTACGAGAAACAGCAGCTCCCCAAGGGCAGGCC  226 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2398  AGCAGGACATGAATCACCTAAAATTCCGTACGAGAAACAGCAGCTCCCCAAGGGCAGGCC  2457 
 
Query  227   TGGACCAGTTGCTGGCCACCACCAGATGCCAAGAGTTCAAACTCAACAATATTATCCCCA  286 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2458  TGGACCAGTTGCTGGCCACCACCAGATGCCAAGAGTTCAAACTCAACAATATTATCCCCA  2517 
 
Query  287   TGGAGAAAATCCTCCACCTCCGGGTTTCATAATGCATGGAAATGTTAATCCAAATGCTGC  346 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2518  TGGAGAAAATCCTCCACCTCCGGGTTTCATAATGCATGGAAATGTTAATCCAAATGCTGC  2577 
 
Query  347   TGGTCAGCTTCCCACATCTCCAGGTCATATGCACACCCAGGTACCACCTTATCCACAGCC  406 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2578  TGGTCAGCTTCCCACATCTCCAGGTCATATGCACACCCAGGTACCACCTTATCCACAGCC  2637 
 
Query  407   ACAGCCTTATCAACCAGCCCAGCCGTATCCCTTCGGAACAGGGGGGTCAGCAATGTATCG  466 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2638  ACAGCCTTATCAACCAGCCCAGCCGTATCCCTTCGGAACAGGGGGGTCAGCAATGTATCG  2697 
 
Query  467   ACCTCAGCAGCCTGTTGCTCCTCCTACTTCAAACGCTTACCCTAACACCCCTTACATATC  526 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2698  ACCTCAGCAGCCTGTTGCTCCTCCTACTTCAAACGCTTACCCTAACACCCCTTACATATC  2757 
 
Query  527   TTCTGCTTCTTCCTATACTGGGCAGTCTCAGCTGTACGCAGCACAGCACCAGGCCTCTTC  586 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2758  TTCTGCTTCTTCCTATACTGGGCAGTCTCAGCTGTACGCAGCACAGCACCAGGCCTCTTC  2817 
 
Query  587   ACCTACCTCCAGCCCTGCTACTTCTTTCCCTCCTCCCCCTTCCTCTGGAGCATCCTTCCA  646 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2818  ACCTACCTCCAGCCCTGCTACTTCTTTCCCTCCTCCCCCTTCCTCTGGAGCATCCTTCCA  2877 
 
Query  647   GCATGGCGGACCAGGAGCTCCACCATCATCTTCAGCTTATGCACTGCCTCCTGGAACAAC  706 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2878  GCATGGCGGACCAGGAGCTCCACCATCATCTTCAGCTTATGCACTGCCTCCTGGAACAAC  2937 
 
Query  707   AGGTCCTCAGAATGGTTGGAATGACCCTCCAGCTTTGAACAGAGTACCCAAAAAGAAGAA  766 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2938  AGGTCCTCAGAATGGTTGGAATGACCCTCCAGCTTTGAACAGAGTACCCAAAAAGAAGAA  2997 
 
Query  767   GATGCCTGAAAACTTCATGCCTCCTGTTCCCATCACATCACCAATCATGAACCCGTTGGG  826 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 2998  GATGCCTGAAAACTTCATGCCTCCTGTTCCCATCACATCACCAATCATGAACCCGTTGGG  3057 
 
Query  827   TGACCCCCAGTCACAAATGCTGCAGCAACAGCCTTCAGCTCCAGTACCACTGTCAAGCCA  886 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query  887   GTCTTCATTCCCACAGCCACATCTTCCAGGTGGCCAGCCCTTCCATGGCGTACAGCAACC  946 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 3118  GTCTTCATTCCCACAGCCACATCTTCCAGGTGGCCAGCCCTTCCATGGCGTACAGCAACC  3177 
 
Query  947   TCTTGGTCAAACAGGCATGCCACCATCTTTTTCAAAGCCCAATATTGAAGGTGCCCCAGG  1006 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC31A 3178  TCTTGGTCAAACAGGCATGCCACCATCTTTTTCAAAGCCCAATATTGAAGGTGCCCCAGG  3237 
 
Query  1007  GGCTCCTATTGGAAATACCTTCCAGCATGTGCAGTCTTTGCCAACaaaaaaa-TTACCAA  1065 
             |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
SEC31A 3238  GGCTCCTATTGGAAATACCTTCCAGCATGTGCAGTCTTTGCCAACAAAAAAAATTACCAA  3297 
 
Query  1066  GAAACCTATTCCAGATGAGCACCTCATTCTAAAGACCCCTTTTGAGGATCTTATTCAGCG  1125 
             ||||||||||||||||||||||||||||||||||||| | |||||||||||||||||||| 
SEC31A 3298  GAAACCTATTCCAGATGAGCACCTCATTCTAAAGACCACATTTGAGGATCTTATTCAGCG  3357 
 
Query  1126  CTGCCTT-CTTCAGCAA  1141 
             ||||||| ||||||||| 
SEC31A 3358  CTGCCTTTCTTCAGCAA  3374 
Figure B.12 Alignment data for SEC31A mRNA. 
This insert sequence is homologous to nt 2338-3374 of Homo sapiens SEC31 
homolog A (S. cerevisiae) (SEC31A), transcript variant 6, mRNA 
(NM_001191049.1). This partial cDNA sequence is fused in frame to the GAL4 
DNA-BD and codes for an intermediate 330 amino acids of 1200 amino acid 
SEC31A protein. 
Homo sapiens chromodomain helicase DNA binding protein 3 (CHD3), transcript 
variant 1, mRNA 
 
Score = 1574 bits(852), Expect = 0.0, Identities = 857/859(99%)  
Gaps = 2/859(0%),Strand = Plus/Plus 
     
Query  104   GAGGTGGAGCCTCCCCAGCCGTTTCCCTGCAGAATCAGCTCTGTCTCATGTGGAAGTGGA  163 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6480  GAGGTGGAGCCTCCCCAGCCGTTTCCCTGCAGAATCAGCTCTGTCTCATGTGGAAGTGGA  6539 
 
Query  164   GAATCAGCCTTGCCTGGCCTTTAGGAACTTTTGTGGGGAAGAGAGCTTTGAagagaggag  223 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6540  GAATCAGCCTTGCCTGGCCTTTAGGAACTTTTGTGGGGAAGAGAGCTTTGAAGAGAGGAG  6599 
 
Query  224   ggggactttagagagggatgaaaatgagccctgggagggaggaagggacgaggaggggTG  283 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6600  GGGGACTTTAGAGAGGGATGAAAATGAGCCCTGGGAGGGAGGAAGGGACGAGGAGGGGTG  6659 
 
Query  284   GCTGCATGTTACCGTCCCCTACCTCTCCCCACGTGGAGGGTGGAGCAGTTATGAGGGAGG  343 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6660  GCTGCATGTTACCGTCCCCTACCTCTCCCCACGTGGAGGGTGGAGCAGTTATGAGGGAGG  6719 
 
Query  344   AAGTCAACTGCTGTTCAGCCTCAGAATAAAGGTGCCGTTCACTGGCTCAGTTACCTCCTG  403 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6720  AAGTCAACTGCTGTTCAGCCTCAGAATAAAGGTGCCGTTCACTGGCTCAGTTACCTCCTG  6779 
 
Query  404   TGTACCGGCATCTTGTGTTGGGAATGTTCCCCCCTCCCTAGGGACCAAGGACCACCCCTA  463 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6780  TGTACCGGCATCTTGTGTTGGGAATGTTCCCCCCTCCCTAGGGACCAAGGACCACCCCTA  6839 
 
Query  464   CAAAAAGAGTAATGGTTGGGTGATACTCCCTCAAGCCAAAGAGGAGCTCCCCAACCTGTT  523 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6840  CAAAAAGAGTAATGGTTGGGTGATACTCCCTCAAGCCAAAGAGGAGCTCCCCAACCTGTT  6899 
 
Query  524   CTAGGGACCCAGGTAACCTAGAAGGGTGGGAGAGAATACAATGGGCCAGATGTGGTGGAA  583 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6900  CTAGGGACCCAGGTAACCTAGAAGGGTGGGAGAGAATACAATGGGCCAGATGTGGTGGAA  6959 
 
Query  584   GCCCAGCTCTGGGGCTCAGGTTCCTGGAAGACTTCTACTACCCTCCCTCCTCAAGGCCTG  643 
97 
 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   6960  GCCCAGCTCTGGGGCTCAGGTTCCTGGAAGACTTCTACTACCCTCCCTCCTCAAGGCCTG  7019 
 
Query  644   GATACAGACTAAATTTGTATAAGTCAGGCAGGGGACCTAGTCAGGGTCTTGGGAGCTACC  703 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   7020  GATACAGACTAAATTTGTATAAGTCAGGCAGGGGACCTAGTCAGGGTCTTGGGAGCTACC  7079 
 
Query  704   TTGTCGTTGGGACCAGAGCAAAATAGTGGAGGGCAGGCTAGGGAAATGTGGGCACATCCC  763 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   7080  TTGTCGTTGGGACCAGAGCAAAATAGTGGAGGGCAGGCTAGGGAAATGTGGGCACATCCC  7139 
 
Query  764   CCCTCCCAGGAGGGGCCGGGGAGAGTGGCAGTTTGCATGGCGAACCCCCCACTTCCTCTT  823 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   7140  CCCTCCCAGGAGGGGCCGGGGAGAGTGGCAGTTTGCATGGCGAACCCCCCACTTCCTCTT  7199 
 
Query  824   TGCTGCCCCTTCACTTTCTTGCTGCCCCTTTCCCAGTCTCTCTTCACACCCACTCCTGGT  883 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CHD3   7200  TGCTGCCCCTTCACTTTCTTGCTGCCCCTTTCCCAGTCTCTCTTCACACCCACTCCTGGT  7259 
 
Query  884   CTGTCCTGATCCCCTCTTCTGTATCAGGGTTTATTGGTTGTACATATAAATTATACTttc  943 
             |||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||| 
CHD3   7260  CTGTCCTGATCCCCTCTTCTGTATCAGG-TTTATTGGTTGTACATATAAATTATACTTTC  7318 
 
Query  944   ctttct-aaaaaaaaaaaa  961 
             |||||| |||||||||||| 
CHD3   7319  CTTTCTGAAAAAAAAAAAA  7337 
Figure B.13 Alignment data for CHD3 mRNA. 
This insert sequence is homologous to nt 6480-7337 of Homo sapiens chromodomain 
helicase DNA binding protein 3 (CHD3), transcript variant 1, mRNA 
(NM_001005273.2). This partial cDNA sequence is fused in frame to the GAL4 
DNA-BD. The peptide sequence coded by this transcript does not correspond to a 
peptide inside CHD3 protein sequence.  
Homo sapiens major facilitator superfamily domain containing 2A (MFSD2A), 
transcript variant 1, mRNA  
Score = 1836 bits(994), Expect = 0.0,Identities = 1097/1145(96%) 
Gaps = 17/1145(1%),Strand = Plus/Plus 
     
Query  106   GGCTGGTCATGAGCCACGGCCCATACATCAAACTTATTACTGGCTTCCTCTTCACCTCCT  165 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1077  GGCTGGTCATGAGCCACGGCCCATACATCAAACTTATTACTGGCTTCCTCTTCACCTCCT  1136 
 
Query  166   TGGCTTTCATGCTGGTGGAGGGGAACTTTGTCTTGTTTTGCACCTACACCTTGGGCTTCC  225 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1137  TGGCTTTCATGCTGGTGGAGGGGAACTTTGTCTTGTTTTGCACCTACACCTTGGGCTTCC  1196 
 
Query  226   GCAATGAATTCCAGAATCTACTCCTGGCCATCATGCTCTCGGCCACTTTAACCATTCCCA  285 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1197  GCAATGAATTCCAGAATCTACTCCTGGCCATCATGCTCTCGGCCACTTTAACCATTCCCA  1256 
 
Query  286   TCTGGCAGTGGTTCTTGACCCGGTTTGGCAAGAAGACAGCTGTATATGTTGGGATCTCAT  345 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1257  TCTGGCAGTGGTTCTTGACCCGGTTTGGCAAGAAGACAGCTGTATATGTTGGGATCTCAT  1316 
 
Query  346   CAGCAGTGCCATTTCTCATCTTGGTGGCCCTCATGGAGAGTAACCTCATCATTACATATG  405 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1317  CAGCAGTGCCATTTCTCATCTTGGTGGCCCTCATGGAGAGTAACCTCATCATTACATATG  1376 
 
Query  406   CGGTAGCTGTGGCAGCTGGCATCAGTGTGGCAGCTGCCTTCTTACTACCCTGGTCCATGC  465 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1377  CGGTAGCTGTGGCAGCTGGCATCAGTGTGGCAGCTGCCTTCTTACTACCCTGGTCCATGC  1436 
 
Query  466   TGCCTGATGTCATTGACGACTTCCATCTGAAGCAGCCCCACTTCCATGGAACCGAGCCCA  525 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query  526   TCTTCTTCTCCTTCTATGTCTTCTTCACCAAGTTTGCCTCTGGAGTGTCACTGGGCATTT  585 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1497  TCTTCTTCTCCTTCTATGTCTTCTTCACCAAGTTTGCCTCTGGAGTGTCACTGGGCATTT  1556 
 
Query  586   CTACCCTCAGTCTGGACTTTGCAGGGTACCAGACCCGTGGCTGCTCGCAGCCGGAACGTG  645 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1557  CTACCCTCAGTCTGGACTTTGCAGGGTACCAGACCCGTGGCTGCTCGCAGCCGGAACGTG  1616 
 
Query  646   TCAAGTTTACACTGAACATGCTCGTGACCATGGCTCCCATAGTTCTCATCCTGCTGGGCC  705 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1617  TCAAGTTTACACTGAACATGCTCGTGACCATGGCTCCCATAGTTCTCATCCTGCTGGGCC  1676 
 
Query  706   TGCTGCTCTTCAAAATGTACCCCATTGATGAAGAGAGGCGGCGGCAGAATAAGAAGGCCC  765 
             ||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||| 
MFSD2A 1677  TGCTGCTCTTCAAAATGTACCCCATTGATGAGGAGAGGCGGCGGCAGAATAAGAAGGCCC  1736 
 
Query  766   TGCAGGCACTGAGGGACGAGGCCAGCAGCTCTGGCTGCTCAGAAACAGACTCCACAGAGC  825 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1737  TGCAGGCACTGAGGGACGAGGCCAGCAGCTCTGGCTGCTCAGAAACAGACTCCACAGAGC  1796 
 
Query  826   TGGCTAGCATCCTCTAGGGCCCGCCACGTTGCCCGAAGCCACCATGCAGAAGGCCACAGA  885 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1797  TGGCTAGCATCCTCTAGGGCCCGCCACGTTGCCCGAAGCCACCATGCAGAAGGCCACAGA  1856 
 
Query  886   AGGGATCAGGACCTGTCTGCCGGCTTGCTGAGCAGCTGGACTGCAGGTGCTAGGAAGGGA  945 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1857  AGGGATCAGGACCTGTCTGCCGGCTTGCTGAGCAGCTGGACTGCAGGTGCTAGGAAGGGA  1916 
 
Query  946   ACTGAAGACTCAAGGAGGTGGCCCAGGACACTTGCTGTGCTCActgtggggccggctgct  1005 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MFSD2A 1917  ACTGAAGACTCAAGGAGGTGGCCCAGGACACTTGCTGTGCTCACTGTGGGGCCGGCTGCT  1976 
 
Query  1006  ctggggcctcctgcctccc-tctgcctgcctggggggccaa-ccctggggctgccactgg  1063 
             ||| ||||||||||||||| |||||||||||| |||||||| |||||||||||||||||  
MFSD2A 1977  CTGTGGCCTCCTGCCTCCCCTCTGCCTGCCTGTGGGGCCAAGCCCTGGGGCTGCCACTGT  2036 
 
Query  1064  gAAAATGCCAAGGAATGATCGGGCCTACCCCGAAA-ACTAAAGGAAAAAACttttttttt  1122 
             ||| |||||||||| |||||||||||| |||| || ||||| | | ||| |||||||||| 
MFSD2A 2037  GAATATGCCAAGGACTGATCGGGCCTAGCCCGGAACACTAATGTAGAAACCTTTTTTTTT  2096 
 
Query  1123  ACAAAGCCCAATAAA-AACTTAAAGACTGGG-ACAANNCAAAGGGGGGTGTTGGTAAAT-  1179 
             ||| |||| ||| || ||||||| ||||| | |||   ||| | | | |||  ||| ||  
MFSD2A 2097  ACAGAGCCTAATTAATAACTTAATGACTGTGTACATAGCAATGTGTG-TGTATGTATATG  2155 
 
Query  1180  TCTGGGACGC-ATTAaagggtttaattttc-taaaa-----aaa--aaaaaaaaaaaaaa  1230 
             |||| || || ||||| |   ||||||||| |||||     |||  |||||||||||||| 
MFSD2A 2156  TCTGTGA-GCTATTAATGTTATTAATTTTCATAAAAGCTGGAAAGCAAAAAAAAAAAAAA  2214 
 
Query  1231  aaaaa  1235 
             |||||  
MFSD2A 2215  AAAAA  2219 
Figure B.14 Alignment data for MFSD2A  mRNA. 
This insert sequence is homologous to nt 1077-2219 of major facilitator superfamily 
domain-containing protein 2A (MFSD2A) mRNA (NM_001136493.1). This partial 
cDNA sequence is not fused in frame to the GAL4 DNA-BD and because of this, it 
does not code a part or full of MFSD2A protein. 
Homo sapiens guanine nucleotide binding protein (G protein), beta polypeptide 2-
like 1 (GNB2L1), mRNA      
Score = 1531 bits(829), Expect  = 0.0, Identities = 843/849(99%) 
Gaps = 3/849(0%), Strand = Plus/Plus 
 
Query  105   GGGATGAGACCAACTATGGAATTCCACAGCGTGGCTCTGCGGGGTCACTCCCACTTTGTT  164 
             |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||| 
GNB2L1 246   GGGATGAGACCAACTATGGAATTCCACAGCGT-GCTCTGCGGGGTCACTCCCACTTTGTT  304 
 
Query  165   AGTGATGTGGTTATCTCCTCAGATGGCCAGTTTGCCCTCTCAGGCTCCTGGGATGGAACC  224 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
99 
 
GNB2L1 305   AGTGATGTGGTTATCTCCTCAGATGGCCAGTTTGCCCTCTCAGGCTCCTGGGATGGAACC  364 
 
Query  225   CTGCGCCTCTGGGATCTCACAACGGGCACCACCACGAGGCGATTTGTGGGCCATACCAAG  284 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 365   CTGCGCCTCTGGGATCTCACAACGGGCACCACCACGAGGCGATTTGTGGGCCATACCAAG  424 
 
Query  285   GATGTGCTGAGTGTGGCCTTCTCCTCTGACAACCGGCAGATTGTCTCTGGATCTCGAGAT  344 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 425   GATGTGCTGAGTGTGGCCTTCTCCTCTGACAACCGGCAGATTGTCTCTGGATCTCGAGAT  484 
 
Query  345   AAAACCATCAAGCTATGGAATACCCTGGGTGTGTGCAAATACACTGTCCAGGATGAGAGC  404 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 485   AAAACCATCAAGCTATGGAATACCCTGGGTGTGTGCAAATACACTGTCCAGGATGAGAGC  544 
 
Query  405   CACTCAGAGTGGGTGTCTTGTGTCCGCTTCTCGCCCAACAGCAGCAACCCTATCATCGTC  464 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 545   CACTCAGAGTGGGTGTCTTGTGTCCGCTTCTCGCCCAACAGCAGCAACCCTATCATCGTC  604 
 
Query  465   TCCTGTGGCTGGGACAAGCTGGTCAAGGTATGGAACCTGGCTAACTGCAAGCTGAAGACC  524 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 605   TCCTGTGGCTGGGACAAGCTGGTCAAGGTATGGAACCTGGCTAACTGCAAGCTGAAGACC  664 
 
Query  525   AACCACATTGGCCACACAGGCTATCTGAACACGGTGACTGTCTCTCCGGATGGATCCCTC  584 
             ||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||| 
GNB2L1 665   AACCACATTGGCCACACAGGCTATCTGAACACGGTGACTGTCTCTCCAGATGGATCCCTC  724 
 
Query  585   TGTGCTTCTGGAGGCAAGGATGGCCAGGCCATGTTATGGGATCTCAACGAAGGCAAACAC  644 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 725   TGTGCTTCTGGAGGCAAGGATGGCCAGGCCATGTTATGGGATCTCAACGAAGGCAAACAC  784 
 
Query  645   CTTTACACGCTAGATGGTGGGGACATCATCAACGCCCTGTGCTTCAGCCCTAACCGCTAC  704 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 785   CTTTACACGCTAGATGGTGGGGACATCATCAACGCCCTGTGCTTCAGCCCTAACCGCTAC  844 
 
Query  705   TGGCTGTGTGCTGCCACAGGCCCCAGCATCAAGATCTGGGATTTAGAGGGAAAGATCATT  764 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 845   TGGCTGTGTGCTGCCACAGGCCCCAGCATCAAGATCTGGGATTTAGAGGGAAAGATCATT  904 
 
Query  765   GTAGATGAACTGAAGCGAGAAGTTATCAGTACCAGCAGCAAGGCAGAACCACCCCAGTGC  824 
             |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 905   GTAGATGAACTGAAGCAAGAAGTTATCAGTACCAGCAGCAAGGCAGAACCACCCCAGTGC  964 
 
Query  825   ACCTCCCTGGCCTGGTCTGCTGATGGCCAGACTCTGTTTGCTGGCTACACGGACAACCTG  884 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GNB2L1 965   ACCTCCCTGGCCTGGTCTGCTGATGGCCAGACTCTGTTTGCTGGCTACACGGACAACCTG  1024 
 
Query  885   GTGCGAGTGTGGCAGGTGACCATTGGCACACGCTAGAAGTTTATGGCAGAGCTTTTNCaa  944 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||  ||| 
GNB2L1 1025  GTGCGAGTGTGGCAGGTGACCATTGGCACACGCTAGAAGTTTATGGCAGAGCTTTA-CAA  1083 
 
Query  945   a-aaaaaaa  952 
             | ||||||| 
GNB2L1 1084  ATAAAAAAA  1092 
Figure B.15 Alignment data for GNB2L1 mRNA. 
This insert sequence is homologous to nt 246-1092 of Guanine nucleotide binding 
protein (G protein), beta polypeptide 2-like 1 (GNB2L1) mRNA (NM_006098.4).  
This partial cDNA sequence is not fused in frame to the GAL4 DNA-BD and 
because of this it does not code a part or full of GNB2L1 protein. 
Homo sapiens HCLS1 associated protein X-1 (HAX1), transcript variant 1, mRNA 
Score = 1999 bits(1082), Expect  = 0.0, Identities = 1100/1108(99%) 
Gaps = 3/1108(0%),Strand = Plus/Plus 
     
Query  110   AGGGCTGCGCAGGTTTCCCCCGTCTGCGAATGGACCACTGGAGGGGTTCAAAGGTTCGCG  169 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   89    AGGGCTGCGCAGGTTTCCCCCGTCTGCGAATGGACCACTGGAGGGGTTCAAAGGTTCGCG  148 
 
Query  170   TCCCAGTACGGGAATGAGCCTCTTTGATCTCTTCCGGGGCTTTTTCGGCTTTCCTGGACC  229 
100 
 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   149   TCCCAGTACGGGAATGAGCCTCTTTGATCTCTTCCGGGGCTTTTTCGGCTTTCCTGGACC  208 
 
Query  230   TCGGAGCCACAGAGATCCCTTTTTTGGAGGGATGACTCGAGATGAAGATGATGATGAGGA  289 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   209   TCGGAGCCACAGAGATCCCTTTTTTGGAGGGATGACTCGAGATGAAGATGATGATGAGGA  268 
 
Query  290   AGAAGAAGAAGAAGGGGGCTCATGGGGCCGTGGGAACCCAAGGTTCCATAGTCCTCAGCA  349 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   269   AGAAGAAGAAGAAGGGGGCTCATGGGGCCGTGGGAACCCAAGGTTCCATAGTCCTCAGCA  328 
 
Query  350   CCCCCCTGAGGAATTTGGCTTCGGCTTCAGCTTCAGCCCAGGAGGAGGGATACGTTTCCA  409 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   329   CCCCCCTGAGGAATTTGGCTTCGGCTTCAGCTTCAGCCCAGGAGGAGGGATACGTTTCCA  388 
 
Query  410   CGATAACTTCGGCTTTGATGACCTAGTACGAGATTTCAATAGCATCTTCAGCGATATGGG  469 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   389   CGATAACTTCGGCTTTGATGACCTAGTACGAGATTTCAATAGCATCTTCAGCGATATGGG  448 
 
Query  470   GGCCTGGACCTTGCCTTCCCATCCTCCTGAACTTCCAGGTCCTGAGTCAGAGACACCTGG  529 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   449   GGCCTGGACCTTGCCTTCCCATCCTCCTGAACTTCCAGGTCCTGAGTCAGAGACACCTGG  508 
 
Query  530   TGAGAGACTACGGGAGGGACAGACACTTCGGGACTCAATGCTTAAGTATCCAGATAGTCA  589 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   509   TGAGAGACTACGGGAGGGACAGACACTTCGGGACTCAATGCTTAAGTATCCAGATAGTCA  568 
 
Query  590   CCAGCCCAGGATCTTTgggggggTCTTGGAGAGTGATGCAAGAAGTGAATCCCCCCAACC  649 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   569   CCAGCCCAGGATCTTTGGGGGGGTCTTGGAGAGTGATGCAAGAAGTGAATCCCCCCAACC  628 
 
Query  650   AGCACCAGACTGGGGCTCCCAGAGGCCATTTCATAGGTTTGATGATGTATGGCCTATGGA  709 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   629   AGCACCAGACTGGGGCTCCCAGAGGCCATTTCATAGGTTTGATGATGTATGGCCTATGGA  688 
 
Query  710   CCCCCATCCTAGAACCAGAGAGGACAATGATCTTGATTCCCAGGTTTCCCAGGAGGGTCT  769 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   689   CCCCCATCCTAGAACCAGAGAGGACAATGATCTTGATTCCCAGGTTTCCCAGGAGGGTCT  748 
 
Query  770   TGGCCCGGTTCTACAGCCCCAGCCCAAATCCTATTTCAAGAGCATCTCTGTGACCAAGAT  829 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   749   TGGCCCGGTTCTACAGCCCCAGCCCAAATCCTATTTCAAGAGCATCTCTGTGACCAAGAT  808 
 
Query  830   CACTAAACCAGATGGGATAGTGGAGGAGCGCCGGACTGTGGTGGACAGTGAGGGCCGGAC  889 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   809   CACTAAACCAGATGGGATAGTGGAGGAGCGCCGGACTGTGGTGGACAGTGAGGGCCGGAC  868 
 
Query  890   AGAGACTACAGTAACCCGACACGAAGCAGATAGCAGTCCTAGGGGTGATCCAGAATCACC  949 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   869   AGAGACTACAGTAACCCGACACGAAGCAGATAGCAGTCCTAGGGGTGATCCAGAATCACC  928 
 
Query  950   AAGACCTCCAGCCCTGGATGATGCCTTTTCCATCCTGGACTTATTCCTGGGACGTTGGTT  1009 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   929   AAGACCTCCAGCCCTGGATGATGCCTTTTCCATCCTGGACTTATTCCTGGGACGTTGGTT  988 
 
Query  1010  CCGGTCCCGGTAGCCTTGTTAACCCTCAGAGGCCTTCAAGTCCTTTCCACCTCTCACCCA  1069 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAX1   989   CCGGTCCCGGTAGCCTTGTTAACCCTCAGAGGCCTTCAAGTCCTTTCCACCTCTCACCCA  1048 
 
Query  1070  TTGCCCTCCATTAATAAGCTTAGCTTCTCTTGCC-CCTCAGGGGCTTGGATATGTGGAAT  1128 
             |||||| ||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
HAX1   1049  TTGCCCACCATTAATAAGCTTAGCTTCTCTTGCCACCTCAGGGGCTTGGATATGTGGAAT  1108 
 
Query  1129  AATGAACTGGGGCCATGTCAGTTTGTCA-TCACC-AAACTGGCCAATAAAACCttttttt  1186 
             | |||||||||||||||||||||||||| ||||| |||||| |||||||||||||| ||| 
HAX1   1109  AGTGAACTGGGGCCATGTCAGTTTGTCACTCACCCAAACTGACCAATAAAACCTTTATTT  1168 
 
Query  1187  ttgctaaaaaaaaaaaaaaaaaaaaaaa  1214 
              ||||||||||||||||||||||||||| 
HAX1   1169  ATGCTAAAAAAAAAAAAAAAAAAAAAAA  1196 
Figure B.16 Alignment data for HAX1 mRNA. 
101 
 
This insert sequence is homologous to nt 89-1196 of Homo sapiens HCLS1 
associated protein X-1 (HAX1), transcript variant 1, mRNA (NM_006118.3). This 
partial cDNA sequence is not fused in frame to the GAL4 DNA-BD and because of 
this it does not code a part or full of HAX1 protein. 
Homo sapiens chromosome 1 genomic scaffold, alternate assembly HuRef 
SCAF_1103279188134:57697-13195817 
Score = 2111 bits(1143), Expect = 0.0, Identities = 1210/1242(97%) 
Gaps = 7/1242(0%), Strand = Plus/Minus 
 
Query  109      GGAGAGACAGGAAATCACACTTGGTATGACCTGTCTGTCACCTGGAGGTTTAGGTTTCCC  168 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3289031  GGAGAGACAGGAAATCACACTTGGTATGACCTGTCTGTCACCTGGAGGTTTAGGTTTCCC  3288972 
 
Query  169      CAGCTTTACCAAGATGAGTGGGTATCCTCTATCCCTGCCAACCCCCACCTTGTGCTGACC  228 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288971  CAGCTTTACCAAGATGAGTGGGTATCCTCTATCCCTGCCAACCCCCACCTTGTGCTGACC  3288912 
 
Query  229      CTTCCTTGGCCTGTCTTGGTTTTTTCCTTTCTTCCTTAAACAAAGCTACTCCAAATAGGA  288 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288911  CTTCCTTGGCCTGTCTTGGTTTTTTCCTTTCTTCCTTAAACAAAGCTACTCCAAATAGGA  3288852 
 
Query  289      ACTAGGGTCCAAGGAAATAAAGACAGTATCCTAAAATggatttctcaatttcggcactat  348 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288851  ACTAGGGTCCAAGGAAATAAAGACAGTATCCTAAAATGGATTTCTCAATTTCGGCACTAT  3288792 
 
Query  349      tgacattttTTGGGGGTGGGTGGGGAGGAAAGGGGCAGCCACTCACGCCACCACctctgc  408 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288791  TGACATTTTTTGGGGGTGGGTGGGGAGGAAAGGGGCAGCCACTCACGCCACCACCTCTGC  3288732 
 
Query  409      ctgccactatcaacattttggactggataattctttgttgtgagaagctgtcctgtgcat  468 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288731  CTGCCACTATCAACATTTTGGACTGGATAATTCTTTGTTGTGAGAAGCTGTCCTGTGCAT  3288672 
 
Query  469      tgtaggctgtttagcagcatttctgacctAGTAACTTCCCAGTTGTACAACTAAAAATGT  528 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288671  TGTAGGCTGTTTAGCAGCATTTCTGACCTAGTAACTTCCCAGTTGTACAACTAAAAATGT  3288612 
 
Query  529      CTCCCTGGAAGGCAGAATTACCCTCTGTTGAGAACTATAGCCCTGGAAGAAATTGCCACC  588 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288611  CTCCCTGGAAGGCAGAATTACCCTCTGTTGAGAACTATAGCCCTGGAAGAAATTGCCACC  3288552 
 
Query  589      TATACATGGGAAACTTAGAATTCAGGTGGAATAGGTTACTAGTTAAATATTTATGTAACA  648 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288551  TATACATGGGAAACTTAGAATTCAGGTGGAATAGGTTACTAGTTAAATATTTATGTAACA  3288492 
 
Query  649      AGCAGCCTTCTGATAATCTGATTATGACTGTGTGTAGTGGCAACAACCACTTCTAAGTCA  708 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288491  AGCAGCCTTCTGATAATCTGATTATGACTGTGTGTAGTGGCAACAACCACTTCTAAGTCA  3288432 
 
Query  709      GCTTTCCTTTAAGCCAGGCTCTGGATTCTTTATTTTTGCTGGCCTTAATCTGTGTCTGGC  768 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288431  GCTTTCCTTTAAGCCAGGCTCTGGATTCTTTATTTTTGCTGGCCTTAATCTGTGTCTGGC  3288372 
 
Query  769      TTAACACCTCCTGGTCACTTTCCCTGGCTGGAATTTACGTACAGTTGTCAGTTGTTGATG  828 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288371  TTAACACCTCCTGGTCACTTTCCCTGGCTGGAATTTACGTACAGTTGTCAGTTGTTGATG  3288312 
 
Query  829      CAGGTGTTTGGTTGATGATGCATTGCCAAAGAGAAGAGGAACTTCCTTTGTGGACATACT  888 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288311  CAGGTGTTTGGTTGATGATGCATTGCCAAAGAGAAGAGGAACTTCCTTTGTGGACATACT  3288252 
 
Query  889      TCAGGGAGCTTCCTTGTTCTGTGCCTTTAAGGGGAGACTACAGTCTCTCAGTTGTTCTCC  948 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288251  TCAGGGAGCTTCCTTGTTCTGTGCCTTTAAGGGGAGACTACAGTCTCTCAGTTGTTCTCC  3288192 
 
Query  949      ACAGCCAACCAAGAGTTTGGCTGCTGATATTTATAACCCTTATGTGACCACCCCCACCTG  1008 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  




Query  1009     CCCACCCCAGAAAGAATTCCAATGCTCTGTAATAATCCTCTCCACCCCCACCATAGCAAC  1068 
                ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288131  CCCACCCCACAAAGAATTCCAATGCTCTGTAATAATCCTCTCCACCCCCACCATAGCAAC  3288072 
 
Query  1069     TGGATGTGGAAAAGGTGAAGGAGCCTTTAAGGCCTTTAAGTTTGCTTCATGTTGAACCTT  1128 
                |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3288071  TGGATGTGGAGAAGGTGAAGGAGCCTTTAAGGCCTTTAAGTTTGCTTCATGTTGAACCTT  3288012 
 
Query  1129     TTCCAGCTCCCTTTTAAAATATTGCCAGTTGGATTTTCAATTTCGGGGTCACAAGCAAAA  1188 
                ||||||||||||||||||||||||||||||| ||||| ||| || | ||||||||||||| 
Sbjct  3288011  TTCCAGCTCCCTTTTAAAATATTGCCAGTTGTATTTTAAATATCAGTGTCACAAGCAAAA  3287952 
 
Query  1189     TCCCAGGCTTGCAGCCACTGCTTCATCTTAAAGGAGCCTCATGCCCCATTGAAGGTAGTT  1248 
                ||||||||||||||||||||| |||||||||||||||||||||||||| ||||||||||  
Sbjct  3287951  TCCCAGGCTTGCAGCCACTGCATCATCTTAAAGGAGCCTCATGCCCCAGTGAAGGTAGTA  3287892 
 
Query  1249     AATTTGA-TGGGAGGGTTTAAA-TCTTCNAGAAAGGATTGA-AGAATTTACCAAAA-CTG  1304 
                || |||| ||| |||   |||| || || |||||||||||| ||| ||||| |||| ||| 
Sbjct  3287891  AAATTGAATGGAAGGTAGTAAAATCATCAAGAAAGGATTGATAGATTTTACAAAAATCTG  3287832 
 
Query  1305     GCTGGGAATTTGA-AGGAAGGTGA-ATTTTAA-GCCACCAAC  1343 
                 |||| ||||||| || ||||||| ||||||| || || ||| 
Sbjct  3287831  TCTGGAAATTTGATAGCAAGGTGAGATTTTAAAGCAACAAAC  3287790 
Figure B.17 Alignment data for  HuRef SCAF_1103279188134:57697-13195817. 
This insert sequence is homologous to nt 3289031 – 3287790 of Homo sapiens 
chromosome 1 genomic scaffold, alternate assembly HuRef 
SCAF_1103279188134:57697-13195817 (NW_001838577.2). This sequence does 
not correspond to a transcript.  
Homo sapiens chromosome X genomic scaffold, alternate assembly CHM1_1.0 
Score = 1254 bits(679), Expect = 0.0, Identities = 679/679(100%) 
Gaps = 0/679(0%), Strand = Plus/Plus 
     
Query 109      TGAGTACACTGCTGGAAAGAGGGTAAACTGGGAGTTAGTGGATGGTCCCAATGCCCTGCC  168 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761409 TGAGTACACTGCTGGAAAGAGGGTAAACTGGGAGTTAGTGGATGGTCCCAATGCCCTGCC  48761468 
 
Query 169      TACAGCAGAGTGCCAACCAGCCCTGAGTGCAAAATTCAAGTTCAAtgtgtgtgcttgtgt  228 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761469 TACAGCAGAGTGCCAACCAGCCCTGAGTGCAAAATTCAAGTTCAATGTGTGTGCTTGTGT  48761528 
 
Query 229      gtggtgtgCTTTATGGACCCGCAAATACCATATTCATTATTGATGATAAGATCTTCACAG  288 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761529 GTGGTGTGCTTTATGGACCCGCAAATACCATATTCATTATTGATGATAAGATCTTCACAG  48761588 
 
Query 289      AATCCTGTAGCTACTAATGCATTGAGTTTTTAATCTCAGTACATCAGCCAGGAGGAGCCA  348 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761589 AATCCTGTAGCTACTAATGCATTGAGTTTTTAATCTCAGTACATCAGCCAGGAGGAGCCA  48761648 
 
Query 349      GATCACAGGGTAGTGATGTCTACTGGGATTATACTCATAACATCTACACAAAACAAGTTG  408 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761649 GATCACAGGGTAGTGATGTCTACTGGGATTATACTCATAACATCTACACAAAACAAGTTG  48761708 
 
Query 409      AGAAGGATCCACGTTTTCATTGTTTATCAGAATTGTATCTCATTTGGCTGAGCATTACTT  468 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761709 AGAAGGATCCACGTTTTCATTGTTTATCAGAATTGTATCTCATTTGGCTGAGCATTACTT  48761768 
 
Query 469      TTGTCAGAATGTGTTATCTGTAAACCATGTGTAGTGAAATTCTTCTGTAACTTTGGATTA  528 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761769 TTGTCAGAATGTGTTATCTGTAAACCATGTGTAGTGAAATTCTTCTGTAACTTTGGATTA  48761828 
 
Query 529      AAGGTATTTATGGTCTTTTTGTTTGTTTGATTTTTAAGTAAGTTATTTCTTTTGTAGACC  588 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761829 AAGGTATTTATGGTCTTTTTGTTTGTTTGATTTTTAAGTAAGTTATTTCTTTTGTAGACC  48761888 
 
Query 589      TGCTGATGGTATGGTTCCATCCTTCTGACCTCAGCATCCAATCTTTTTAAGGATTTTTGT  648 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query 649      TTTCAATATTGTTATTTTAAATTGTGGTTGAAGCAATAGAAAATTGAAATATGGATTGTG  708 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48761949 TTTCAATATTGTTATTTTAAATTGTGGTTGAAGCAATAGAAAATTGAAATATGGATTGTG  48762008 
 
Query 709      CATGACTGTGTCTTGAGTGTAAAAATATTGCAGTTTGAAACTTGGACCTAAAGTATTGCa  768 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 48762009 CATGACTGTGTCTTGAGTGTAAAAATATTGCAGTTTGAAACTTGGACCTAAAGTATTGCA  48762068 
 
Query 769      aataaaaatgacaaacatc  787 
               ||||||||||||||||||| 
Sbjct 48762069 AATAAAAATGACAAACATC  48762087 
Figure B.18 Alignment data for  Homo sapiens chromosome X genomic scaffold. 
This insert sequence is homologous to nt 48761409 – 48762087 of Homo sapiens 
chromosome X genomic scaffold, alternate assembly CHM1_1.0 
(NW_004078123.1). This sequence does not correspond to a transcript 
Homo sapiens chromosome 14 genomic scaffold, alternate assembly CHM1_1.0 
chr14 
Score = 1042 bits(564), Expect = 0.0, Identities = 725/801(91%) 
Gaps = 17/801(2%), Strand = Plus/Minus 
 
Query 425      gtggtggctcacgcctggtaatctcagcgctttgggaggccgaggcaggtggatcactag  484 
               |||||||||||||||| |||||| |||| |||||||||||| |||  ||  |||||  || 
Sbjct 39451876 GTGGTGGCTCACGCCT-GTAATCCCAGCACTTTGGGAGGCCAAGGTGGGCAGATCATGAG  39451818 
 
Query 485      gtcaggagttcgagaccagcctggccaacatggtgaaagcccatctctgctaaaaataac  544 
               |||||||| | || |||| |||||| |||||||||||| ||||||||| |||||||||   
Sbjct 39451817 GTCAGGAGATAGAAACCATCCTGGCTAACATGGTGAAACCCCATCTCTACTAAAAATACA  39451758 
 
Query 545      aaggatcggccagatatgttggcatgtgcctgtaatcccagctgctcgggaggctgaggc  604 
               ||  ||      |   || | ||  | ||||||| ||||| || |||||||||||||| | 
Sbjct 39451757 AAAAATTAATTGGGCCTGGTAGC--GCGCCTGTAGTCCCACCTACTCGGGAGGCTGAGTC  39451700 
 
Query 605      gggagagtcgcttgagcccgggaggcagaggttgcagtgagctaaggttgcaccactgca  664 
                ||||| |||||||| |||||||||  ||||||||  ||||| ||| |||| |||||||| 
Sbjct 39451699 AGGAGAATCGCTTGAACCCGGGAGGTGGAGGTTGCCATGAGCCAAGATTGCGCCACTGCA  39451640 
 
Query 665      ctccagcctggcgacaaagtgagactctgtctcaaaaacaaaaacaaaaacaaaaaacaa  724 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 39451639 CTCCAGCCTGGCGACAAAGTGAGACTCTGTCTCAAAAACAAAAACAAAAACAAAAAACAA  39451580 
 
Query 725      aacaaaacaaaaatttttgttaagagggtagatctcacattaaatgttcttaacacacac  784 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 39451579 AACAAAACAAAAATTTTTGTTAAGAGGGTAGATCTCACATTAAATGTTCTTAACACACAC  39451520 
 
Query 785      acacacacaaacacacacacacacacacacacacaca-aaa-gagacaaggagagcaGTC  842 
               ||||||| | ||||||||||||||||||||||||||| ||| |||||||||||||||||| 
Sbjct 39451519 ACACACAAACACACACACACACACACACACACACACACAAAAGAGACAAGGAGAGCAGTC  39451460 
 
Query 843      CCCTGTAGGAAGAGACACTTTCCCTGGTCATGCTATCCAATAAATCACACCTGCTGTgga  902 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 39451459 CCCTGTAGGAAGAGACACTTTCCCTGGTCATGCTATCCAATAAATCACACCTGCTGTGGA  39451400 
 
Query 903      gaaaggagaaaggaaaacaaggaaagagaaaaggatggaagctactagaaaaagaataga  962 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 39451399 GAAAGGAGAAAGGAAAACAAGGAAAGAGAAAAGGATGGAAGCTACTAGAAAAAGAATAGA  39451340 
 
Query 963      aggCTGGGATGGAGAGAAAAGGGTTTCTCCCATACCCCTGATGTCTTTTTCTCTAATTAG  1022 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 39451339 AGGCTGGGATGGAGAGAAAAGGGTTTCTCCCATACCCCTGATGTCTTTTTCTCTAATTAG  39451280 
 
Query 1023     AAA-GACAGTGCTTTTCTTTCCAACCTCTTTAGTTTTTTCTTTCCCATAAGCTGTTTCTT  1081 
               ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 39451279 AAAAGACAGTGCTTTTCTTTCCAACCTCTTTAGTTTTTTCTTTCCCATAAGCTGTTTCTT  39451220 
 
Query 1082     TCAGTAGCTGCTAGCTTTAATTATATGCAATAATTGGAAGTTAATTAAGTATCCCAAGGG  1141 
               ||||||||||||||||| | |||||||||||| ||||| |||||||| |||||||| ||| 
104 
 
Sbjct 39451219 TCAGTAGCTGCTAGCTTAATTTATATGCAATATTTGGA-GTTAATTA-GTATCCCA-GGG  39451163 
 
Query 1142     TAACCGAATTCCCTTACCGAAGCCCTTTAGCTGGGGCCTTCCGCTGGAAAAAATGCCCTC  1201 
               |||| || |||||||| ||| ||| || ||||| | ||||| |||| | ||| |||| || 
Sbjct 39451162 TAACAGA-TTCCCTTAGCGATGCC-TT-AGCTGTG-CCTTCAGCTG-ATAAACTGCC-TC  39451109 
 
Query 1202     AAATACAAAtttttccaaaaa  1222 
               |||||||| |||| ||| ||| 
Sbjct 39451108 AAATACAA-TTTT-CCAGAAA  39451090 
Figure B.19 Alignment data for  Homo sapiens chromosome 14 genomic scaffold. 
This insert sequence is homologous to nt 39451876 – 39451090 of Homo sapiens 
chromosome 14 genomic scaffold, alternate assembly CHM1_1.0 chr14 
(NW_004078079.1). This sequence does not correspond to a transcript. 
Homo sapiens chromosome 2 genomic scaffold, alternate assembly CHM1_1.0 
Score = 1495 bits(809), Expect = 0.0, Identities = 814/816(99%) 
Gaps = 1/816(0%), Strand = Plus/Minus 
 
Query  107     GGACCAATCAAAACCGTTACCTCTGATAACATTATATTGTGCCCAGTATAAAATAGATAT  166 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162824  GGACCAATCAAAACCGTTACCTCTGATAACATTATATTGTGCCCAGTATAAAATAGATAT  162765 
 
Query  167     AATAATACCTCAAACTTAAATCCGGGCATTGTCATTGAATATCTTAAGAATATGCAACAA  226 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162764  AATAATACCTCAAACTTAAATCCGGGCATTGTCATTGAATATCTTAAGAATATGCAACAA  162705 
 
Query  227     AGGTGCTTTTAAAAATACAAGCtagtgattgtaccaaatttgtaaatcacataggatagt  286 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162704  AGGTGCTTTTAAAAATACAAGCTAGTGATTGTACCAAATTTGTAAATCACATAGGATAGT  162645 
 
Query  287     gggtcattttaagaatattagttatttcaatctataaacgtggatgtctttccttttttg  346 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162644  GGGTCATTTTAAGAATATTAGTTATTTCAATCTATAAACGTGGATGTCTTTCCTTTTTTG  162585 
 
Query  347     tgttttctttaatttctttcattaatatttgtcatttttgttgtcgaaatcttttacttc  406 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162584  TGTTTTCTTTAATTTCTTTCATTAATATTTGTCATTTTTGTTGTCGAAATCTTTTACTTC  162525 
 
Query  407     cttggttaaatttatttctaagtacatttttgtagctattgtaaaaggaattgctttctt  466 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162524  CTTGGTTAAATTTATTTCTAAGTACATTTTTGTAGCTATTGTAAAAGGAATTGCTTTCTT  162465 
 
Query  467     aatttcttgtttcagctagtttactatcaatatatagaaatgctactgatttttgtatgt  526 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162464  AATTTCTTGTTTCAGCTAGTTTACTATCAATATATAGAAATGCTACTGATTTTTGTATGT  162405 
 
Query  527     tgatttatatcctgcaactttattaatttcatgtatcaccctaagaagcttttggtagag  586 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162404  TGATTTATATCCTGCAACTTTATTAATTTCATGTATCACCCTAAGAAGCTTTTGGTAGAG  162345 
 
Query  587     tcttatttttttccgtgtataagatcacattgtctttaaacagggacaatttgactgtct  646 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162344  TCTTATTTTTTTCCGTGTATAAGATCACATTGTCTTTAAACAGGGACAATTTGACTGTCT  162285 
 
Query  647     cctttccaattcagatgtcctttatttctttctctcacctaattgtcctggctaagactt  706 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162284  CCTTTCCAATTCAGATGTCCTTTATTTCTTTCTCTCACCTAATTGTCCTGGCTAAGACTT  162225 
 
Query  707     tcactatgtgaaatatgattggtgagaataggcatccttttcttgttccagtaaaatcct  766 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
Sbjct  162224  TCACTATGTGAAATATGATTGGTGAGAATAGGCATCCTTTTCTTGTTCCAGTAAAATCTT  162165 
 
Query  767     tttcttgttcacagtaaaatctttcaccttttccacactcagtatgatcttagttgtaga  826 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  162164  TTTCTTGTTCACAGTAAAATCTTTCACCTTTTCCACACTCAGTATGATCTTAGTTGTAGA  162105 
 
Query  827     tttgtcctttatgtccttctgttttaaggcatatattttctatactaaattgttgagagg  886 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query  887     ttttttgtcatgtaagaatatttaattttgccgaaa  922 
               |||||||||||||||||||||||||||||||| ||| 
Sbjct  162044  TTTTTTGTCATGTAAGAATATTTAATTTTGCC-AAA  162010 
Figure B.20 Alignment data for  Homo sapiens chromosome 2 genomic scaffold. 
This insert sequence is homologous to nt 162824 – 162010 of Homo sapiens 
chromosome 2 genomic scaffold, alternate assembly CHM1_1.0 
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